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1,2-oxazine natural products are a small closely related family of highly oxidized 
compounds. Herein, the development of a synthetic strategy toward gliovirin and the 
trichodermamides is described which enabled the synthesis of the western fragments of gliovirin 
and trichodermamide B. To that end, we developed two novel copper-catalyzed transformations: 
the asymmetric propargylation of an oxime and the diasteroeselective oxidative cyclization of 
hydroxamic acid with a diene.  
The challenge of working with tetrahydro-1,2-oxazines is their sensitivity to a variety of 
reaction conditions and purification methods. Extensive optimization of each transformation was 
accomplished, bringing to bear the state-of-the-art in oxidative modifications, including a 
palladium-catalyzed direct desaturation of an epoxy ketone. As well as this work led to the rare 
observation of a vinylogous Payne rearrangement.  
The successful synthesis of the fully functionalized western and eastern fragments of 
gliovirin are described toward a late-stage diketopiperazine formation and thiolation. Interrogation 
of our late-stage strategy with these fragments demonstrates that the coupling of the fully 
functionalized western and eastern fragments is not an effective strategy toward gliovirin proof-
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An Introduction to Total Synthesis, Polythiodiketopiperazines, and Related Natural Products 
 
1.1 INTRODUCTION TO TOTAL SYNTHESIS 
Natural product synthesis is the use of chemical methods to generate complex molecules 
structurally identical to materials isolated from natural sources. The study of natural product 
synthesis has served, and continues to serve, the development of fundamental synthetic organic 
chemistry. Initially, it was used as a tool to provide the strongest form of evidence toward the 
elucidation of complex chemical structures. With the advent of advanced analytical techniques, 
the principle role of natural product total synthesis has shifted. In more recent years, it has 
demonstrated value as a platform to expose gaps in current chemical knowledge, motivating the 
development of new chemical transformations to form these challenging structures. 
 Natural product total synthesis as a discipline is characterized by two intellectual pursuits: 
strategy and tactics. Strategy focuses on retrosynthetic analysis, a conceptual framework 
developed in the mid 20th century with contributions from many prominent chemists but 
championed most notably by Prof. E.J. Corey.1 This method of analysis identifies bond 
disconnections which simplify complex structures by recognizing embedded structural motifs. By 
recognizing these underlying motifs, one can redefine the problem of natural product synthesis to 
simpler target molecules to inform a forward route. Through iterative application of this approach, 
one can methodically unravel a complex natural product to readily available feedstock materials.  
In contrast to the aim of pattern recognition and structural simplification in retrosynthetic 
analysis; synthetic tactics are defined as the methods one uses to realize the forward synthesis. 
While there are no fundamental constraints on the disconnections made in a retrosynthesis, tactics 
are limited to transformations either previously known or novel methods based on a fundamental 
understanding of chemical reactivity. The efficiency of these transformations is of the utmost 
importance; to that end chemoselective methods are engaged to minimize side products with an 
emphasis on functional group tolerance to minimize substrate decomposition. Despite the 
development of high-yielding chemical transformations, reactive conditions often generate by-
products or minor impurities. These impurities in the crude material can interfere with later 
chemical manipulations and, therefore, are typically purged from the crude reaction mixture. There 
are four main approaches to accomplish this goal, exploiting the physical properties of different 
components in the mixture: distillation (boiling point), crystallization (solubility and physical 
morphology), solvent partitioning (hydrophobicity), or elution through polar solid media 
(polarity).2 When considering the value of a method therefore, it is not only important to consider 
the ability of the method to generate the desired species but also the ease with which it can be 
isolated from the crude mixture effectively. 
Through the use of strategic thinking, a viable retrosynthesis selects bond disconnections 
that take advantage of efficient chemical transformations that will generate the target molecule in 
fewest number of steps. A common strategy to improve the efficiency of a synthesis is the 
incorporation of a convergent step. By independently functionalizing two fragments and 
combining them at a later stage one can maximize the number of independent chemical 
transformations while minimizing the number of steps in the longest linear sequence (LLS) from 
commercially available materials. Overman’s synthesis3 of (–)-actinophyllic acid (7, Scheme 1.1) 
is an excellent example of a convergent synthesis. However, the implementation of novel chemical 
methods can facilitate the rapid generation of intermediates of similar complexity. For example, 
the functionalized indole 5 is generated in 6 steps LLS while indole 10 generated in Kwon’s 
synthesis4 of 7 is accessed in 2 steps. However it is important, not to hold step count as the sole 
metric to measure a total synthesis. Chen’s synthesis5 of 7 has the lowest LLS of the syntheses  
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shown, yet it has the lowest overall yield. This is due to several low-yielding steps which resulted 
either from a lack of chemoselectivity or instability of the intermediates. Each of these syntheses 
stage the formation of key bond connections differently (Scheme 1.1 as highlighted), this defines 
the tactics and limits possible conditions based upon the stability of the intermediates and their 
functionality. Thus, the best retrosynthetic analysis identifies key intermediates that can be married 
with efficient tactics to form the desired functionality. 
 An optimal synthesis provides the product with the minimum number of chemical 
manipulations, high purity, and excellent yield. As scale requirements increase engineering 
problems such as safety, replicability, and cost are also taken into account. These ancillary 
practical principles are a key concern for larger scale syntheses undertaken in industrial process 
chemistry. At its heart, the total synthesis of natural products is the confluence of creative thinking, 
pattern recognition, and methodology development.  
 
1.2 POLYTHIODIKETOPIPERAZINES  
Polythiodiketopiperazines (PTPs) are a diverse class of natural products characterized by 
a cyclized dipeptide bearing a sulfur bridging moiety. This sulfur bridge usually spans a 
diketopiperazine (DKP) core as a disulfide; this class of PTPs are commonly referred to as 3,6-
epipolythiodiketopiperazines(3,6-ETPs). While these isolated compounds are initially generated 
from a limited number of canonical amino acids, their structural is the result of extensive enzyme-
mediated oxidative modifications of the amino acid side chains. The first 3,6-ETP isolated was 
gliotoxin (16, Figure 1.1) in 1936;6 however, extensive studies7–18 were required before the native 
structure was proposed in 195819 with final confirmation of the structure by X-ray crystallography 
studies in 1967.20 It gained interest not only for its compact and highly functionalized structure but 
also for it intriguing biological activity. Since 1936, a variety of compounds have been isolated 
with this 3,6-ETP core motif from fungi and plants, and have been the subject of several reviews 
of their structures and properties.21,22  
3,6-ETPs can be categorized by the mother amino acids, elucidated through feeding studies 
with isotopically labelled amino acids.21 While 3,6-ETPs can be either symmetrical or 
unsymmetrical all known 3,6-ETPs incorporate an amino acid with an aromatic moiety: either 
phenylalanine, tyrosine and tryptophan, and demonstrate high structural diversity.  
Figure 1.1. 3,6-ETP natural products derived from phenyalanine  
 
Phenyalanine–derived 3,6-ETPs are the largest family of 3,6-ETPs, with a wide variety of 
oxidative patterns. Hyalodendrin (15), one of the simplest 3,6-ETPs isolated,23 is an unsymmetrical 
































R=H, R’=Ac, apoaranotin (19)





























































R=Ac, scabrosin diacetate (21)
R=COn-Pr, ambewelamide A (22)











R=COn-Pr, scabrosin dibutanoate (24)
R=COn-Pe, scabrosin butanoate

























X=OH, R=Me, MCP1001 (37) 
X=H, R=Me, MCP1001B (38)
X=OH, R=H, emestrin (39)
R=H, R’=Ac, aranotin (33) 
R=R’=Ac, acetylaranotin (34)
R=COCH(R-OH)Ph, R’=COBn, emethallicin A (35)
R=R’=                                , SCH64874 (36)         
R’=H, R=                                       , hirsutellomycin 


















R=H, phomazine C (31)





























































motif featured in 16 can also be observed in other 3,6-ETPs such as emethallicin E&F (18 & 20) 
and apoaranotin (19).24,25 Further oxidized 5-6 systems can be differentiated by their oxidative 
patterns shown in the epoxy allylic alcohol motifs of the scabrosins26 (21, 24, 25) and 
ambewelamides27 (22, 23); are contrasted by the g- hydroxy enone motif of the epicorazines28–30 
(26-28). Other ETP natural products featuring the 5-6 ring system include: rostratins31 (29-30, 40-
41), phomazine C32 (31), and epicoccin U33 (32) which show a striking analogy to the epicorazine 
core. Exemplified by aranotin (33), the incorporation of a dihydrooxepine heterocycle as fused a 
5-7 bicycle is an anomalous motif, observed in many phenylalanine-derived ETPs is.34–39  
Figure 1.2. 3,6-ETP natural products derived from tyrosine 
 
 Tyrosine–derived ETPs are the smallest family of ETPs. Prenylation of the tyrosinyl phenol 
on substrate derived from cyclization with glycine yields dithiosilvatin40 (36, Figure 1.2). The 
other ETPs of this family incorporate serine in analogy to 16 and demonstrate similar oxidative 
dearomatization as demonstrated by phomalirazine41 (37) with its fused 5-6-5 tricyclic sidechain 
and the epimeric spirocyclic structures of the sirodesmins42,43 (38-40).  
 Unlike the ETPs derived from phenylalanine, tryptophan-derived ETPs do not present the 
same variety of oxidative patterns. Instead they all contain a pyrroloindoline motif with 
substitution at the benzylic position. Structural variation in this family instead results from arene 
functionalization, as seen in the sporidesmins44,45 (41-43, Figure 1.3), and manifold substitution at 
C3 of the mother indole, including dimerization of the pyrroloindoline exemplified by chaetocin 














































R=Ac, sirodesmin G (39)
R=H, desacetyl-sirodesmin PL (40)
products distinguished exclusively by C3 substitution on the ETP core: symmetryical dimeric 
ETPs47–50 (49–53), unsymmetrical dimeric ETPs51–53 (48, 54–58) and indolinated substituted 
ETPs54–59 (46-47, 59–63). 
Figure 1.3. 3,6-ETP natural products derived from tryptophan 
 
3,6-ETPs, with their noted [2.2.2]-disulfide core, are the most plentiful group of PTP 
natural products; however, other sulfur-containing DKP motifs have also been isolated. Many of 
the 3,6-ETPs shown above have sulfur bridge analogs, typically the trisulfide (64, Figure 1.4) and 
tetrasulfide (65).60 Furthermore, 3,6-dithiomethylated analogs, including gliovictin61,62 (66) as an 
analog of 15, are also prevalent and have also been the subject of total synthesis efforts.63–71 The 
least common motifs observed are mono-thiolated, unsaturated DKPs,72 including emethacin A 
(67), and DKP natural products dimerized through two disulfides exclusively observed in the 
vertihemiptellides (68–69).73   
The polythio linkage in some PTPs can also extend out from the a-carbon of DKP to the 
sidechain. As a result, the geometry of these disulfides diverge from 3,6-ETPs affecting both redox 
potential and overall stability of the disulfide.74 Currently the mechanism by which these unusual 















R=Me, X=OH, sporidesmin A (41)
R=Me, X=H, sporidesmin B (42)


























































R=Me, verticillin A (49)
R=CH2OH, melinacidin IV (50)
R=CH(OH)Me, verticillin D (51)
R=COMe, verticillin E (52)




















R=H, bionectin A (59)
R=CH(OH)Me, bionectin B (60)
R=Me, gliocladine C (61)
R=CH2OH, T988 C (62)
























R=Me, R’=CH2OH, verticillin B (54)
R=COMe, R’=CH(OH)Me, verticillin F (55)
R=CH(OH)Me, R’=Me, Sch52900 (56)
R=Et, R’=Me, Sch52901 (57)












Figure 1.4: PTP natural products which feature unusual sulfur connectivity 
 
high degree of structural analogy with 26-28 (Figure 1.1) and also result from the functionalization 
of a Phe-Phe DKP; suggestively, however, the disulfide forms either at C7 or C8 where 
unsaturation observed in the epicorazines. Structural variation within the epicoccin family occurs 
in the variation of oxidation alpha to the side chain sulfur. Whether these products form through 
downstream enzymatic pathways from epicorazine biosynthesis or are generated through a 
disparate pathway that has not been identified through biochemical studies.  
 Finally, [2.2.3]-ETPs have been isolated exhibiting disulfide bridges with thiolation at an 













R=Me, vertihemiptellide A (68)
R=H, vertihemiptellide B (69)
X=1, epicoccin A (74)
























































































R=H, pretrichodermamide A (82)

































































a) sulfur isomers of diketopiperazine natural products















X=α-OH, epicoccin B (70)
X=H epicoccin R (71)
X=β-OH epicoccin S (72)
X=β-OEt epicoccin T (73)
X=H, epicoccin M (77)
















R=H, pretrichodermamide B (84)
R=Me, N-methylpretrichodermamide B (85)
have N-oxidation at an amide nitrogen, with many taking the form of an atypical heterocycle: a 
1,2-tetrahydrooxazine. Aspirochlorine (79, Figure 1.4) was the first of this class of natural 
product to be isolated, initially termed A30641, in 1976.75 As a result of its unusual connectivity 
the structure of 79 was not elucidated until semisynthetic studies were carried out by Sakata and 
Clardy in 1987.76  Gliovirin77 (80) and its N-methylated analog, FA-209778 (81), were isolated 
independently in 1982. While the structure of 80 was disclosed in the initial report, the structure 
of FA-2097 was not fully elucidated until 1984.79 For 24 years, these three natural products 
remained the sole known [2.2.3]-ETPs, until the pretichodermamides A-F(82-88) were isolated 
from related fungi.80–82 These newly isolated compounds had a high level of structural fidelity 
with 80 with only small variations occurring in the oxidation pattern of the western fragment and 
N-methylation of the amide nitrogen. 
 
1.2.2 KNOWN MODES OF 3,6-ETP BIOACTIVITY 
 Due to their low availability from natural sources, the study of ETPs in biological 
systems has been, by no means, exhaustive; however, initial studies have established that their 
diverse structures demonstrate wide–ranging activity as antifungal agents, cytotoxins, antibiotics, 
antimicrobials, and antitumor agents.83  
The bioactivity of ETPs is chiefly ascribed to the redox-active disulfide bond; the other 
functionality modifying the specificity of the protein–small molecule interactions. This disulfide 
moiety can interfere with biological processes through four distinct modes. ETPs can modulate 
the activity of proteins through interaction with cysteine residues by either directly forming 
protein-ETP conjugates84 (Figure 1.5A) or modifying the confirmation of the protein through 
formation of disulfide bonds not present within native protein85 (Figure 1.5B). ETPs can also  
Figure 1.5. Known modes of 3,6-ETP toxicity. 
 
chelate metal co-factors to deactivate proteins.86 Furthermore, these molecules can undergo a 
redox cycle to produce reactive oxygen species (ROS), such as superoxide radical anion or 
hydroxide radical, when in the presence of an appropriate reductant in the cellular environment 
(Figure 1.5C).87,88  An ETP natural product can have multiple modes of toxicity operative to 
provide a given phenotype; therfore considerable biological studies are required to fully 
characterize the origins of their bioactivity. 
 
1.2.3 BIOSYNTHESIS OF 3,6-ETPs 
3,6-ETP biosynthesis has been the subject of much study with the greater portion directed 
toward the enzyme-mediated formation of gliotoxin, 16. In the cell, gliotoxin synthesis begins with 



























































































a non-ribosomal peptide synthetase (NRPS).89,90 Thiolation of the resulting DKP is proceeds in 
two steps beginning with concombinant bishydrodroxylation at C3 and C6 of the DKP by a p450 
monooxygenase (GliC). This hemiaminal 89 can then undergo subsequent thiolation with 
glutathione facilitated by a S-transferase (GliG).91 An enzymatic cascade generates the dithiol (98, 
Scheme 1.3) from 90 through iterative degradation of the glutathione sidechains.92 First, the naked 
cysteine residue is unveiled through action of a g-cyclotransferase (GliK) and a dipetidase93 (GliJ). 
Then a pyridoxal 5’-phosphate (PLP, 96) dependent lyase (GliI) reveals the dithiol through the 
transient generation of a Schiff base 95, before expelling pyruvate (97) and regenerating PLP.94 
Oxidation of 98 to the disulfide 99 is then facilitated by a dedicated dithiol oxidase (GliT). With 
the core ETP 99 formed in Scharf’s studies. It has not been clearly established whether the 
biosynthetic pathway of 16 proceeds through dithiol or disulfide intermediates. However, given 
that as the disulfide moeity undergoes reversible reduction, and both 98 and the reduced form of 
16 are substrates for GliT, the oxidase may act as oxidative regulator during the final oxidative 
manipulations en route to 16. For simplicity, the pathway will be shown proceeding through 99. 











































































Phe-Ser (88) 89 90
91 92 93
Scheme 1.3. Conversion of a 3,6-dicysteinyl DKP to 3,6-ETP core and oxidation to gliotoxin 
 
To complete the biosynthesis of 16, the phenylalanine sidechain is proposed to be 
oxidatively dearomatized to the epoxy diene through the action of a p450 monooxygenase (GliF 
or GliC), which undergoes spontaneous ring closure via nucleophilic attack of the amide nitrogen 
to yield 100. Finally, N-methylation of the amide proceeds through a methyl transferase (GliN) to 
yield 16. 
 The biosyntheses of the other members are proposed to proceed in an analogy to 16 through 
a three-phase sequence: NRPS-mediated formation of the DKP from canonical amino acids; 
formation of ETP core via an enzymatic cascade; and oxidative modifications the ETP sidechains. 
ETPs are diverse family of natural products; however, their structures result from a small subset 
of canonical amino acids: Phe, Ser, Tyr, Trp, Ala, Val, Gly, Thr. Therefore, most of the variation 
in the biosynthetic pathway should reside in the enzyme-mediated modifications to the sidechains, 












































































































Aside from 15, all phenylalanine derived ETPs feature cyclization of the amide. While 
rigorous biochemical studies have not been undertaken for the formation of the epicorazines or 
scabrosins, it is proposed that these derivatives are formed through further modification of a 
gliotoxin subunit (102) formed by analogous p450 monooxygenase-mediated cyclization of the 
amide.27 To access the epicorazine motif (105) it is thought that the enone is formed through initial 
epoxidation of the more substituted alkene followed by a Meinwald rearrangement.95 This 
electrophilic enone can then undergo a Michael addition or conjugate addition to generate a 
rostratin unit (106). Conversely, the scabrosin motif is thought to diverge from the gliotoxin 
pathway, instead proceeding through an SN2’-type pathway to form dienol 108 facililated by some 
GliC or GliF mutant. The resulting intermediate (108) can then undergo epoxidation under the 
influence of a monooxygenase. 
Originally, the dihydrooxepine moeity observed in both symmetrical and unsymmetrical 
ETPs, exemplified by 33 and 37 (Figure 1.1), were proposed to form through a sigmatropic ring 
expansion of 107 to form 110, before undergoing a further oxidation and subsequent amide 





































































































a)  proposed biosynthetic pathway toward epicorazines and rostratin ETPs
cyclization (Scheme 1.5a).96 However, through genome-based deletion analysis, it has recently 
been shown that these 3,6-ETPs proceed through an analogous cyclization to other phenylalanine-
derived ETPs, proceeding through 114 as a key intermediate before undergoing a direct oxidative 
ring expansion to form 34 (Scheme 1.5b).97 
 Scheme 1.5. Sidechain modification in the biosynthesis of dihydrooxepine–containing 3,6-ETPs 
 
 The gene cluster responsible for the biosynthesis of tyrosine-derived ETPs has been the 
subject of biochemical study; however, unlike 34 and 16 the distinct roles and order of each coded 
gene have not been fully elucidated.98 A putative biosynthetic route has instead been proposed 
through labelling experiments and isolation of intermediates. In constrast to phenyalanine-derived 
ETPs, a prenyl transferase caps the phenolic oxygen prior to sulfenylation, either as the amino acid 
or after DKP formation.99 The prenylated DKP 116 undergoes sulfenylation in analogy to other 
3,6-ETPs to yield 117. Bis N-methylation of 117 would yield 36 (Figure 1.2); however, 117 can 
also undergo a Claisen rearrangement and subsequent cyclization to form 119.100  The 
dihydrobenzofuran 119 can then undergo a p450 monooxygenase-mediated amide cyclization to 
form 120, which can be further oxidation leading to the formation of phomalirazine (37). The 
sirodesmins can be generated from 37 through an oxidative rearrangement. Tetrasubstituted 
















































a) original oxepine biosynthetic proposal
b)  elucidated biosynthetic pathway for acetylaranotin



























Scheme 1.6. Proposed biosynthesis of sirodesmin family of ETPs 
 
quenched through 1,2-carbonyl migration.101,102 Based on the diasteroselectivity of the ring 
contraction epimeric spirocycles 123a and 123b are generated. Elaboration of these siprocyclic 
substrates via 1,2-reduction of the carbonyl, O-acylation, and N-methylation delivers sirodesmins 
38 and 39.  
 The gene cluster responsible for 45 biosynthesis has been sequenced and compared with 
those of 16 and 38. As previously proposed, the sequences coding for 3,6-ETP core synthesis 
demonstrated homology with previously identified sequences in other biochemical studies.103 The 
DKP 124 is formed through the action of a NRPS. Conversion of 124 to the 3,6-ETP core 125 
occurs through bis-hydroxylation with p450 monooxygenase, chaC, followed by an analogous 
glutathione thiolation and degradation. Formation of the pyrroloindoline motif 126 is characteristic  













































































































































































































of tryptophan–derived 3,6-ETPs and proceeds via oxidative cyclization of the amide which is  
initiated a cyctochrome p450, chaB. Dimerization of the 3,6-ETP to form desmethyl-chaetocin A 
127 is then facilitated by another cytochrome p450, claE. Finally, in analogy to 16 N-methylation 
of the remaining free amides would deliver the fully elaborated 45.   
 
1.2.3 BIOSYNTHESIS OF [2.2.3]-ETPs AND RELATED NATURAL PRODUCTS 
The gene clusters responsible biosynthesis of [2.2.3]-ETPs 79 and 80 have been sequenced 
and compared with known enzymes.104,105 Despite the structural dissimilarities of 79 and 80 both 
natural products are synthesized Phe-Phe DKPs. While the sequences responsible for [2.2.3]-ETP 
core synthesis were identified, their specific substrates and intermediates have not been fully 
elucidated. Hence, whether the origin of [2.2.3]-ETP specificity occurs due to rearrangement of 
3,6-ETP (130) or through direct benzylic functionalization (132) remains a mystery. Despite this,  
Scheme 1.8. Proposed biosynthetic pathways for the formation of [2.2.3]-ETPs 
 
b) Mukherjee’s proposed biosynthetic pathway for gliovirin



































































































































several key observations have been established. In the synthesis of 79, the first on-pathway 
intermediate in the biosynthesis of 79 is 133, with [2.2.3]-ETP core and extensive sidechain 
oxidation already incorporated. It is only after oxidative cleavage of the benzylic sidechain that N-
methoxylation occurs. This observation runs in contrasts to previous results in the gliotoxin 
biosynthetic pathway where N-oxidized DKPs were observed in glutathione transferase deletion 
mutants.106 Interestingly, to the characteristic aryl chloride of 79 is incorporated in the last step. In 
the biosynthesis of 80 Mukherjee proposes conversion from 129 to 131 prior to thiolation to install 
the [2.2.3]-ETP, however none of those intermediates were characterized in though their deletion 
studies. However, based upon Hertweck’s study of 79 it is likely that [2.2.3]-ETP core synthesis 
and oxidation to the triphenol precedes both N-oxidation and the oxidative dearomatization to form 
the 1,2-tetrahydroxazine.   
[2.2.3]-ETPs are densely functionalized natural products with reactive functionality, 


































































































































trichodermamide A (138) trichodermamide B (139)

























aspergillazines B & C
C-2 epimers (142ab)
aspergillazines D & E
C-2 epimers (143ab)
a) natural products with distinct structural homology to known [2.2.3]-ETPs
b) proposed mechanism for the spontaeneous decomposition of pretrichodermamides to form trichodermamides
therefore, it is unsurprising that related natural products resulting from shunt pathways or through 
core rearrangement occurring in the cell media. Thiomethylated derivatives, 136 and 137 (Figure 
1.6), were recently isolated in analogy to sulfur isomers 66 and 67 (Figure 1.4).107 Furthermore, 
the trichodermamides (138–140) which were originally isolated independently from endophytic 
fungi108,109 but are now proposed to be generated through spontaeneous decomposition of 83–85 
as 138 was formed from 83 under mild protic conditions expelling the disulfide as elemental 
sulfur.80 Other natural products appears to precipitate from N-O bond scission, as observed in the 
aspergillazines B-E (142ab, 143ab).110,111 
 
1.3 SYNTHETIC EFFORTS TOWARD EPIPOLYTHIODIKETOPIPERAZINES 
 The total synthesis of 3,6-ETPs has a rich history in organic chemistry motivated by their 
powerful bioactivity, their low availability from biological sources, and their diverse and highly 
functionalized structures. One the key area of study to enable this work is the development of 
methods toward the synthesis of the 3,6-ETP core. 
 Most methods for 3,6-ETP core synthesis proceed through an a-functionalized DKP 
substrate, reminiscent of the biological sulfenylation pathway. The 3,6-ETP core was first accessed 
by Trown through nucleophilic displacement of dibromide 146 (Scheme 1.9) with thioacetate 
followed by saponification to generate a dithiol, which is subsequently oxidized to the requisite 
disulfide 147.103 Method development accelerated in the 1970s through the sulfenylation of DKP 
substrates with varying a-functionalization. Schmidt demonstrated that dibromide 147 could be 
sulfenylated with a polydithiolate, subsequent reduction of the polythio bridge and re-oxidation 
generates the desired core.113 Kishi showed that under Lewis–acidic conditions unsaturated DKP 
148 could be thiolated by an aryltrithiolane, to form a thioacetal which can be unmasked generate  
Scheme 1.9. Selected methods for 3,6-ETP core synthesis from the a-functionalized substrates 
 
147 in two steps.114 As a major advance direct formation of the dithiol was attained by Matsunari, 
using hydrogen sulfide as a nucleophile in conjugation with zinc chloride to activate 
bismethoxylated 149, through the generation of an iminium intermediate.115 These methods 
remained the state of the art for almost 30 years until a tandem cyclization–sulfenylation presented 
itself as an orthogonal approach. While this method was concise, it was not adopted widely toward 
the synthesis of 3,6-ETPs.116 Instead synthetic groups revisited Matsunari’s approach using 
hydrogen sulfide through the optimization of Lewis acids and the a-oxidized DKP substrates.117–
119 These modified conditions were efficacious in a variety of applications; however, some 
substrates were unreactive. To generate the desired motif in these less reactive substrates, the 
Movassaghi lab found that integration of a polysulfide chain at a singular position on a DKP 
substrate could undergo subsequent Lewis acid-mediated cyclization to generate the 3,6-ETP 
core,120 as well other sulfur nucleophiles could be used.118 
 While the lion’s share of 3,6-ETP core synthesis resulted from the thiolation of a-

















































































































R'2. KI3 –or– I2
M=Hf(OTf)4,












































1. H2S, TFA; i-PrO2Cl












R'3. BF3•OEt2, TESH,    dtbmp
Scheme 1.10. Selected methods for 3,6-ETP core synthesis through direct sulfenylation of DKPs 
 
sodium amide in ammonia, results in generation of a dithiol which could then be oxidized to form 
the disulfide (147, Scheme 1.10a).121 These conditions were not amenable to more sensitive 
substrates; yet the substitution of bulky strong bases, the hexamethyldisilazides, in place of sodium 
amide gave improved results for the direct thiolation of DKPs, both with elemental sulfur122 and a 
protected sulfur chloride.123 Unlike Schmidt’s original conditions, these novel conditions yield 
polythiolated intermediates which are reduced to the dithiol prior to the final oxidation to yield the 
disulfide bridge.  
  Methods for 3,6-ETP core synthesis have been optimized under both Lewis acidic and 
strongly basic conditions, ensuring that the synthetic chemist has flexibility in the substrates that 
can be targeted as intermediates in the total synthesis of 3,6-ETP natural products.  
 
1.3.2 TOTAL SYNTHESES OF EPIPOLYTHIODIKETOPIPERAZINES 
 The earliest syntheses of 3,6-ETPs were accomplished in studies by Kishi and coworkers. 
Their first synthetic efforts were toward to sporidesmin A&B (41-42, Figure 1.3).114,124 
Strategically, Kishi targeted a protected 3,6-ETP core as a key intermediate (157) before 
incorporating the sidechain functionality. An unsaturated monothiolated DKP (156, Scheme 1.11) 
was generated in two steps, which was subsequently converted to the thioacetal 157 after 
deprotection of the thioacetate. Stoichiometric deprotonation of 157 occurs selectively alpha to the 





















































    DIPEA
4. O2
HS SO3Na,
Scheme 1.11. Kishi’s syntheses of sporidesmin A&B 
 
indole substrate accessed from commercially available starting materials in 4 steps and 51% 
cumulative yield. Coupled product 159 was converted to 160 in three steps, with installation of the 
hydroxyl group through diastereoselective reduction. Acetate 160 acts as a key intermediate for 
the divergent synthesis of 41 and 42. Direct oxidative cyclization 160 gave 161, which could be 
converted to 41 in three steps. To synthesize 42 the acetate was reduced to the methylene before 
being subjected modified oxidative cyclization conditions to generate 162 which could be 
advanced to 42 in two steps analogous to the final sequence of to access 41. Despite their reliance 
on some low yielding transformations, these syntheses were ground breaking. Furthermore, the 
use of an oxidative cyclization to install the key pyrroloindoline motif would be later revisited and 
extensively refined by other synthetic groups in the pursuit of other tryptophan-derived 3,6-ETP 
natural products. 























































































    THF/MeOH, 0 °C
2. mCPBA, 0 °C; 
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2. NBS, Bz2O;























162 (26%, 2 steps)






Scheme 1.12. Kishi’s racemic synthesis of gliotoxin 
 
3,6-ETP core generation followed by elaboration of the side-chains could be generally applied to 
the synthesis of other 3,6-ETPs. With that in mind, they turned their efforts toward the synthesis 
of 16125 (Scheme 1.12) and its aromatized analog 17 (Scheme 1.13).126 The protected 3,6-ETP 164 
is synthesized in six steps, using the Trown conditions to generate the dithiol (Scheme 1.9a), with 
the 3,6-ETP core in hand, base–mediated attack of epoxy diene 163b, in equilibrium with oxepin 
163a,127 generates 165 as the major diastereomer. A four-step sequence converts the ester to benzyl 
chloride 166. Upon exposure to excess strong base not only promotes cyclization to generate the 
desired pyrollidine, additional deprotonation at the bridgehead site on the opposite side can be 
quenched with a chloromethyl ether to install the serine side chain to generate 167; a further two 
steps unveil 16. 
 As 17 had less sensitive functionality than 16, Kishi took an alternative approach 
integrating the aryl moiety prior to formation of the protected 3,6-ETP core.126 While Kishi showed 
that copper–catalyzed N-arylation of DKP 169 generates their sulfenylation substrate 171, later 
work by Wood128 showed that direct DKP formation from the aniline 168b was a more scalable 
alternative. The rest of the synthesis proceed in analogy to 16, through tandem cyclization of a 

































2. TFA, ClCO2Et, NEt3;
    LiBH4, LiCl, MeOH
3. MsCl, NEt3; LiCl, DMF
4. MeONa, DCM/MeOH
PhLi, BOMCl











1. BCl3, 0 °C
2. mCPBA; 











Scheme 1.13. Kishi’s total synthesis and Wood’s formal synthesis of dehydrogliotoxin 
 
global deprotection and formation of the disulfide to yield the target 17. 
 The first synthesis of 15 by other chemists followed the an identical strategy to Kishi 
(Scheme 1.14a); through iterative alkylation of a symmetrical protected 3,6-ETP 175 to generate 
176, followed by similar deprotection and disulfide formation.129 The synthesis of  
16 was revisited by Williams, in 1980, with a novel strategy focused on side chain substitution 
prior to sulfenylation to form the 3,6-ETP core.130 The hydoxymethylene is incorporated through  















































































    –78 °C to rt
HClO4, 0 °C
(72% yield)





















1. LDA, –78 °C
2. BnBr
3. LDA, –78 °C













































(4 steps from 177)
175 176
177





(29%, 3 steps)(51%, 2 steps)
Scheme 1.15. Fukuyama’s novel synthesis to of hyalodendrin 
 
an aldol reaction, which subsequently protected as the silyl enol ether 178. Benzylation occurs 
through enolate alkylation, which is followed by monothiolation through a Schmidt reaction 
(Scheme 1.9b) to provide 179. The monothiol is capped as a disulfide before the thiolation of the 
enol proceeds with a sulfur chloride electrophile. The resulting bis-disulfide is then reduced to the 
dithiol before being re-oxidized to the disulfide 15. While, Williams synthesis has higher step 
count from DKP 177 when compared to the Strunz & Kakushima synthesis (14 steps versus nine 
steps) the overall yield is significantly improved.  
 Finally, Fukuyama demonstrated an orthogonal strategy to synthesizing 15 as a proof-of-
concept from a novel bicyclic intermediate 181, accessible in 6 steps from commercial materials.131 
The benzyl moiety is integrated through an aldol reaction. The benzylic alcohol activated with 
mesyl chloride prior to reduction. The reduced product is then exposed to strong base in the 
presence of a sulfur chloride which cleaves the bridging thioether to yield and unsaturated disulfide 
183. The synthesis is then completed through dihydroxylation of exocyclic olefin followed by 
activation of C6 under Lewis acidic conditions reminiscent of a Movassaghi sulfenylation 
strategies (Scheme 1.9h). While Fukuyama’s synthetic strategy has merit for its novel approach, it 
does not represent a significant increase in synthetic efficiency toward 15. 
 Synthetic studies towards oxidatively modified phenylalanine-derived 3,6-ETPs were 
initiated by the Diver group toward the scabrosins (21-25, Figure 1.1). In contrast to Kishi and 
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(43%, 3 steps) (49%, 2 steps)
non-canonical amino acids prior to DKP formation and sulfenylation. Tactically, synthesis of an 
enantioenriched propargyl glycine 185 proceeds smoothly through enantioselective alkylation 
followed by enyne metathesis to form a cyclohexadienyl amino acid. Unfortunately, the Backvall 
chloroacetoxylation was low yielding and featured no diastereoselectivity; however, the desired 
diastereomer could be isolated cleanly to provide 186. N-deprotection was followed by a base–
mediated cyclization to form the desired 6-5 bicyclic motif 187. This key intermediate 187 was 
advanced to the DKP 190 through the coupling N-boc amino acid 188 with amino ester 189 
followed by cyclization. While this strategy was able to form the pentacyclic core, 190 could not 
be further elabolated through further oxidation or sulfenylation toward the synthesis of 21.  
The synthesis of scabrosins was revisited by Carriera132, strategically in line with Williams 
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189 188, R=H, R’=Boc (75%, 2 steps)




























elaborating a DKP substrate before late-stage sulfenylation. Enabled by studies by Loughlin133 a 
bis-N-acylated DKP was directly converted to the unsaturated 193, formation of the requisite 6-5 
bicyclic sidechains proceeds efficiently through Lewis acidic activation of the bicylic ether. 
Directed epoxidation of bis-allylic alcohol led exclusively decomposition. To circumvent this  
deleterious reactivity, the allylic alcohol was oxidized to the enone which readily undergoes 
epoxidation under modified Weitz-Sheffer conditions. Unfortunately, 1,2-reduction generates the 
opposite diastereomer and further oxidative elaboration to the allylic epoxy alcohol was 
unsuccessful. 
 While efforts toward the scabrosins were unsuccessful, efforts toward tryptophan-derived 
3,6-ETPs were more fruitful. A concise synthesis of (+)-11,11'-dideoxyverticillin A (200, Scheme 
1.17) was accomplished by Movassaghi.118 Unlike the early syntheses of 3,6-ETPs their strategy 
focused upon late-stage dimerization and sulfenylation. Similar to Kishi’s oxidative cyclization in 
the syntheses of the sporidesmins, the DKP 197 can undergo a bromocyclization yielding an 
intermediate with a functional handle for a radical cobalt-mediated dimerization. Following 
dimerization, both DKPs were activated for sulfenylation through tetraoxidation prior to exposure 
to thiocarbonate as a nucleophilic sulfur source. The disulfide 200 was unveiled through two-step 
sequence. 
 This bromocyclization strategy was effectively used by Movassaghi in the synthesis of 
another dimeric 3,6-ETP chaetocin120 (45, Scheme 1.18) as well the indolinated 3,6-ETP  










































1. Na(Hg), NaH2PO4, MeOH
2. K2CS3, TFA
3. ethanolamine, acetone

















197 198 199(59%, 2 steps) (16%, 3 steps) (30%, 4 steps)
Scheme 1.18. Movassaghi’s syntheses of chaetocin and luteoalbusin 
 
luteoalbusin A134 (47). To synthesize 45, an analogous dimeric tetrahydroxylated DKP 203 was 
readily accessed; however, in contrast to their synthesis of 200 the intial sulfenylation of the 
activated 203 led only to monothiolation of each DKP subunit. However formation of an acyclic 
disulfide was successful, with the disulfide incorporated, further activation of the DKP under 
Lewis acidic conditions resulted in an intramolecular cyclization to yield the disulfide moiety of 
the natural product 45. This same sulfenylation tactic was successful in the later synthesis of 47 
which diverged from 45 only in the early incorporation of the indole through a silver-mediated 
coupling with key intermediate 202.  
 Movassagahi was also successful in the synthesis of bionectin A (59, Figure 1.3) an 
indolinated 3,6-ETP with an additional oxidation on the bicycle. Strategically, this synthesis 
focused on the initial synthesis of a DKP derived from non-canonical amino acids followed by 
incorporation of the indole and late stage sulfenylation.68 The additional oxidation was 
incorporated early through an aldol reaction with 208 and 209 with high diastereoselectivity 



































































(27%, 2 steps) 203
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(+)–chaetocin A (45)(63%, 4 steps)
1. N2H4; NaH, TrSCl
2. N2H4
2. hν, 1,2-DMN 3. BF3•OEt2, TESH,
    dtbmp
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2. H2S, TFA; 
    i-PrO2Cl
3. hν, 1,2-DMNSO2Ph
1. N2H4; NEt3, TrSCl
2. BF3•OEt2, TESH,
    dtbmp
3. Me3SnOH
(38%, 3 steps) (68%, 3 steps)
Scheme 1.19. Movassaghi’s Synthesis of (+)–bionectin A 
 
intramolecular cyclization provided the DKP substrate 211 primed for bromocylization. To 
incorporate the indole moiety in this synthesis they chose to bring it in with a silyl tether prior to 
the C-C bonding step. Protecting group exchange was important prior to bis-hydroxylation of the 
DKP which again activated the substrate for sulfenylation with a nucleophilic sulfur source, which 
could be converted to the dusilfude 59 in a one-pot procedure. 
 Concurrent with Movassaghi’s program, Overman developed a unified strategy toward 
C10-indolinated 3,6-ETPs. Favoring synthesis of the indolated sidechain through asymmetric 
carboxylation of C2-indolinated oxindole 219 (Scheme 1.20) prior to incorporating into an 
unsaturated DKP 223 through condensation. In contrast to Movassaghi’s work resulting 
unsaturated 244 could cyclize under Lewis-acid activation of a hemiaminal to form 225 as a key 
intermediate. Exposure to Grignard or a strong reductant led to mono-hydroxylated DKPs 226-
228. The unsaturaturation was then used as a handle to incorporate necessary oxidation 


















    NEt3
2. TBSOTf
































    EDCI•HCl, HOBt
3. TFA; AcOH, t-BuOH
























































208 209 (42%, 2 steps) 210 (77%, 3 steps) 211
(94% yield) 212 215(50%, 2 steps) (24%, 3 steps)
(45%, 2 steps) (81% yield)(62%, 2 steps) 216
213, DMAP
1.















Scheme 1.20. Overman’s Unified Strategy to Access C10-indole pyrroloindoline 3,6-ETPs 
 
could be expediently converted into three C10-indolinated 3,6-ETPs 59, 61, and 63. 
 Martin was later able to generate racemic formal syntheses of C10-indolinated 3,6-ETPs 
in a similar fashion to Overman’s approach while refining some of the tactics.135 Generating a bis–
enamide in situ prior to exposure to the highly electrophile isatin to generate 234. Unlike Overman, 
Martin then incorporates the requisite indole through Lewis acidic activation of the allylic alcohol. 
Cyclization was then accomplished under reducing Lewis acidic conditions to yield unsaturated 
DKP 236. This key intermediate could either be brought through Overman’s sequence to access 
62 in seven steps or radical hydroxylation and protecting group manipulations could generate 237 



































2. HC(OMe)3, PPTS 
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3. LiBH4, MeOH, 











1. Me–MgCl, –78 °C
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    K2OsO4•2H2O, (DHQ)2PHAL
    t-BuOH, H2O, acetone
2. Ac2O, DMAP
1. H2S, BF3•OEt2, –78 °C
2. I2, NEt3 –or– O2 MeOH









R=H, 38%, 3 steps
R=Me, 40–51%, 3 steps








    NEt3, DMF
R=H, 88%, 14:1 dr, 2 steps




R=H, 75%, 2 steps
R=Me, 70–76%, 2 steps
R=i-Pr, 79%, 1.2:1 dr, 2 steps
R=H, bionectin A (59)
R=Me, gliocladine C (61)
R=i-Pr, leptosin D (63)
R




221(68%, 2 steps) (88% yield) (54%, 4 steps)








































226 R=H, (227); R=Me, (228)
226–228
79%, 1.2:1 dr, 2 steps
Scheme 1.21. Martin’s formal syntheses of (+/–)-gliocladine C and (+/–)-T988C 
 
The synthesis dimeric trypophan-derived 3,6-ETPs was also revisited by Sodeoka taking 
Movassaghi’s synthetic strategy and refining the tactics, resulting in a more efficient synthesis of 
45 (Scheme 1.22). Paramount to this effort was the recognition that an efficient bis-hydroxylation 
could be carried out prior to cobalt-mediated dimerization. Furthermore, engaging the resulting  
tetrahydroxylated dimer with the sulfenylation conditions that had been refined by Overman in his 
synthesis of C-10 indolinated 3,6-ETPs directly formed the tetrathiol which could be directly 
oxidized to 45.  
 Since, Kishi’s landmark synthesis of 16 the further synthetic studies were not undertaken 
until Nicolaou. In contrast to Kishi’s building-out strategy, Nicolaou took a similar approach as 
other modern 3,6-ETP synthetic strategies, through the synthesis of fully functionalized non-
canonical amino acids and late stage sulfenylation.65 240, derived from tyrosine, could be  

























    AlH3•NEtMe2
2. Pd(PPh3)4, 











































































(41%, 2 steps) (24%, 2 steps)239
2. H2S, BF3•OEt2;
     then I2
converted to dienyl 241 in three steps through palladium mediated elimination of an allylic 
acetate. A successful [4+2] with singlet oxygen formed an endo peroxide which could reduced to 
the triol 242. The gliotoxin amino acid was finally generated through Corey-Winter olefination, 
forming 243.  
 This unnatural N-boc amino ester 243 was a versatile intermediate, coupling with a 
protected serine derivative to generate 16 or could be further elaborated to the symmetrical 3,6-
ETP 18. Direct sulfenylation was a novel procedure as a refinement of Schmidt’s early work.    
Furthermore, Nicolaou through the synthesis of an epimeric rostratin derivative (255) that early 
formation of the 6-5-6-5-6 pentacylic framework could set up the substrate for expedient oxidation  
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a) synthesis of non-canonical amino ester intermediate
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    dppb, Et2NH
1. 246, BOPCl








    then LiHMDS
2. BnCO2H, DCC, 
    DMAP
2. 1,3-propanedithiol;




d) synthesis of 8,8’–epi-ent-rostratin B
240
1. Ac2O, 










































1. Tf2O, NEt3, DMAP
2. Pd(PPh3)4, K2CO3
1. LiHMDS, S8;
    then LiHMDS

























 8,8’–epi-ent-rostratin B (255)
2. (H2N)2C=S
b) synthesis of gliotoxin
c) synthesis of emathallicin E
240 241(77%, 3 steps) (61%, 2 steps) 242 (69%, 4 steps) 243
243
244 245(87%, 2 steps) (63%, 2 steps) (23% yield)
246 247 248
249







(62%, 2 steps) (24%, 2 steps)
2. [CuH(PPh3)]6;
    then KI3
253 254 (45%, 2 steps)
of the side chains after disulfide formation. Unsaturated 3,6-ETP 254 was rapidly functionalized 
through a singlet oxygen [4+2] in analogy to 242; however, a Kornblum–DeLaMare rearrangement 
generated the keto-alcohol instead of the diol. Subsequent conjugate addition followed by 
oxidative work-up provides the highly functionalized 3,6-ETP 255.  
The first successful synthesis of dihydrooxipene ETP was accomplished by Reisman in 
2012, through the synthesis of a non-canonical amino acids and late-stage sulfenylation .136 In 
contrast to other 3,6-ETP syntheses the stereochemistry of the pyrollidine was set first through a 
dipolar cycloaddition of an azomethine ylide. Pyrollidine 257 could be elaborated to propargylated 
alcohol 260 in a further eight steps which underwent rhodium-mediated cyclization to generation  
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269 270 acetylapoaranotin (271)(8%, 3 steps)(39%, 3 steps)(63%, 2 steps)
(34%, 2 steps) (44%, 2 steps) (58%, 2 steps)
the desired seven-membered ring. Orthogonal protecting groups are removed to form 262 and 263 
which can undergo amide coupling and cyclization to generate a fully functionalized DKP 264. 
The natural product could be formed through the Nicolaou’s direct sulfenylation protocol. 
The pyrollindine-first strategy was further applied to the synthesis of the gliotoxin 
monomer 269 en route to the unsymmetrical aceylapoaranotin (271). Chiral pyrollidine could be 
allylated prior to undergoing ring closing metathesis. Elimination of a epoxide provides 
unsaturated 268. Which can then be converted the desired dienyl alcohol 269 through the reduction 
of a vinyl triflate. While plagued with competitive aromatization pathways the DKP formation and 
direct sulfenylation were accomplished to form 271 in analogy to 34.  
 Tokuyama was also successful in the synthesis of 34137 engaging a similar synthetic 
strategy, targeting fully functionalized non-canonical amino acid monomers prior to DKP 
formation and direct sulfenylation. Their approach toward the synthesis of the dihydrooxepine 
subunit was more in line with Nicolaou’s strategy in the synthesis of the gliotoxin intermediate 
243. As opposed to a cyclization strategy, the seven-membered ring was formed through a Baeyer-
Villiger oxidation of the enone 274 followed by reduction of the corresponding vinyl triflate. 
Following a similar two step amide coupling-cyclization to form the DKP the alcohols were easily 
inverted in a two-step sequence to form 264. A similar direct sulfenylation as seen in the Reisman 
synthesis provided their target natural product 34.  
Taking lessons from their synthesis of 34 they were also able to accomplish the synthesis 
of the macrocyclic 3,6-ETP 38. Coupling of the dihydroxepine 277 with sarcosine formed the DKP 
core of the natural product 279. The macrocycle was formed through esterification of the diaryl 
ether 281 followed by an aldol reaction under highly optimized conditions follow by oxidation to 
generate the macrocyclic ketone 282. A novel direct sulfenylation was then accomplished through 
Scheme 1.25. Tokuyama’s Syntheses of oxepine-containing 3,6-ETPs 
 
the iterative incorporation of trisulfides from protected sulfur chlorides. This bis-trisulfide was 
then reduced to the dithiol followed by oxidation to the disulfide to deliver 34.  
A wide variety of strategies have been used to access 3,6-ETP natural products. While early 
work pioneered by Kishi focused on the early formation of a masked 3,6-ETP core followed by 
decoration of the side chains, later work on more structurally complex 3,6-ETPs has taken a 
radically different approach through synthesis of fully functionalized monomers which can 
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1.3.2 APPROACHES TO ASPIROCHLORINE 
In constrast to the substantial amount of work found the synthesis of 3,6-ETPs, natural 
products incorporating the [2.2.3]-ETP core have arguably not been explored synthetically to any 
great extent. The only successful total synthesis of a [2.2.3]-ETP was William’s synthesis of 79. 
Strategically, this work focused upon a bromocyclization to generate the spirocyclic motif and 
provide benzylic functionalization which could be leveraged for later sulfenylation.138  
 The benzofuran 285 could be synthesized in three steps from bisphenol 284. Conversion 
the acid chloride facilitates coupling with a glycine equivalent, followed by incorporation 
methoxylamine to generate 286. Exposure to NBS leads to bromocyclization in good yield. In an 
additional 4 steps the bis-methoxylated 289 is primed for thiolation with thioacetate similar to 
Trown’s approach but with a substrate in analogy that pioneered by Matsuri (Scheme1.9ad) to 
yield 79.   
 While Williams’ work remains the exclusive total synthesis of [2.2.3]-ETP, Danishefsky 
proposed an alternative three step protocol to simultaneously generate a benzofuran-derived 
spirocyle and unusual disulfide linkage.139  This approach uses the Kishi strategy, stoichiometric  
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Scheme 1.27. Danishefsky’s Approach to the spirocyclic aspirochlorine core 
 
 
deprotonation of the masked ETP 175 is able to undergo 1,2-addition with an electron-rich 
benzaldehyde to generate 291. Exposure of this intermediate to strongly acidic conditions 
presumably leads to ionization of the benzylic alcohol to form ortho-quinone methide 293, a strong 
electrophile. This species can undergo subsequent 1,2-sulfur migration with concurrent cyclization 
to quench the developing positive charge on the DKP. While remarkable, whether this 
rearrangement is biologically relevant is remains unknown.       
 
1.4 SYNTHESES OF THE TRICHODERMAMIDES 
In contrast to their disulfide-containing cousins, the presumed decomposition products of 
[2.2.3]-ETPs, the trichodermamides, have been the subject of several synthetic efforts. The first 
successful synthesis was disclosed by Zakarian140 utilizing an 1,2-oxo-aza Cope rearrangement 
which they pioneered to generated the key bicyclic oxazine fragment.141 Unfortunately, the 
substrate for this rearrangement required extensive synthetic efforts. The bicyclic framework was 









































































Scheme 1.28. Zakarian’s synthesis of trichodermamides B 
 
the requisite bridgehead trans-diol along with some redox manipulations to generate 298 in 9 
steps from 296. The rearrangement proceeded smoothly and protecting group manipulations 
generated 299, the appropriate oxidation pattern was generated through Grieco transposition and 
subsequent saponification provided 300 which could be coupled with aminocoumarin 301 to 
generate 302. Chlorination occur through invertive displacement of an allylic mesylate to 
generate the target 139.   
Joullie successfully completed the enantiospecific syntheses of 138 and 139.142 Epoxy 
ketone 303 could be synthesized in 18 steps from the chiral pool. One-pot oxime formation and 
acid mediated cyclization generated the bicyclic oxazine fragment. Oxidative elaboration of 304 
was challenging for the authors, especially the low-yielding allylic oxidation to generate enone 
306. Furthermore 1,2-reduction of that moiety, while high yielding, was completely unselective 
provide inseparable products; however, conversion to 307a and 307b provided to a separable 
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Scheme 1.29. Jouillie’s syntheses of trichodermamides A&B 
	
while 307a could converted to 139 in four steps, with a chlorination analogous to that used by 
Zakarian.  
Recently, Larionov disclosed concise racemic syntheses of the trichodermamides A-C 
through the rapid synthesis of the bicylic oxazine core.143 This was accomplished in a one-pot 
procedure. Stoichiometric deprotonation of 308 formed a hard nucleophile which performed a 1,2-
addition on 1,4-benzoquinone (BQ) following unveiling of the oxime oxygen under acidic 
conditions an oxy-Michael generates 309. A three-step sequence featuring a palladium catalyzed 
elimination of a carbonate analogous to that observed in Nicolaou’s route to the gliotoxin 
subunit(241, Scheme 1.23) generates their key intermediate 310.  
A manganese-catalyzed epoxidation of the dienyl alcohol is selective for the distal olefin. 
To provide the desired trans diol, epoxide opening proceeds with phenylselenol to provide 312. 
This allylic selenide is then saponified under mild conditions prior to amide coupling with 301. 
The resulting allylic selenide 313 readily undergoes a [2,3]-rearrangement under mildly oxidizing 
conditions to yield 138. The direct formation of the core, lack of protecting groups manipulations,  
303
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Scheme 1.30. Larionov’s synthesis of trichodermamide A 
 
and rapid incorporation of the oxidation results in a swift, scalable synthesis. 
 Larionov was able to further leverage 310 in the synthesis of 139 and 140 (Scheme 1.31). 
Direct coupling of the dienyl substrate with 301 yields 314. This is followed by a highly efficient 
allylic epoxidation to yield 315. A double displacement at the allylic position provides an 
appropriately disposed allylic selenide for the [2,3]-rearrangement so effectively utilized toward 
138. Tosylation of the newly formed secondary alcohol prior to [2,3]-rearrangement prevents 
undesired decomposition pathways. Under mildly oxidizing conditions 316 undergoes allylic 
transposition followed by chlorination of the newly activated allylic tosylate to generate 139.  
 Finally, to synthesize 140, methylation of 314 provided a substrate for analogous 
epoxidation as that seen in 138, while expedient from a step-count standpoint the efficiency of the 
epoxidation was reduced. However, with the coupled allylic epoxide 317 in hand the two step 
selenation-transposition sequence proceeded in high yield to generate the natural product 140.    
Synthetic efforts towards the trichodermamides have demonstrated that rapid formation of the key 













































(94% yield, 2 steps)
a) synthesis of key dienyl intermediate
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Scheme 1.31. The Completion of Larinov’s syntheses of trichodermamides B&C 
 
diastereoselectivity of chemical transformations with these substrates can be non-trivial. While 
concise syntheses have now been realized an enantioselective synthesis of the trichodermamides 
has yet to been accomplished. 
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A Synthetic Strategy Toward the Oxazinyl Natural Products Gliovirin, the Pretrichodermamides 
and the Trichodermamides    
 
2.1 INTRODUCTION  
Tetrahydro-1,2-oxazines and Dihydro-1,2-oxazines are a motif rarely found in natural 
products. Yet, oxazine-containing natural products display a highly-conserved oxidation pattern 
and structure, suggestive of a common intermediate.1 These can be categorized into three main 
classes: non-classical ETPs such as gliovirin (80),2,3 rearrangement products including the 
peniciadametizines,4 and elimination products exemplified by the trichodermamides (Figure 
2.1).5,6  
We were drawn to 80 as a synthetic target as it was isolated in an undisclosed yield, 
suggesting low availability from biological sources, and its unusual structure imparts intriguing 
bioactivity. Along with the tetrahydro-1,2-oxazine contained within its densely-functionalize
  
Figure 2.1. Examples of oxazine–containing natural products  
 
structure it also features an anomalous [2.2.3]-ETP core, seven stereocenters and is replete with 
oxidation. Due to its restricted availability and structural complexity a full understanding of its 
biological activity has been limited. Despite these challenges, gliovirin has shown antimicrobial 
activity against prominent phytopathogens including Phytopthora sp. and Pythium ultimum.7 
More recently, 80 has also demonstrated activity as an inhibitor of inducible TNF-a expression 
in human T-cells and macrophages.8  
The proposed synthetic strategy to access 80 is to generate the DKP at a late stage and 
install the disulfide linker as the final step. This approach, therefore, relies upon the synthesis of 
two fully functionalized non-canonical amino acids: the eastern fragment, an oxidized 
phenylalanine derivative (315, Scheme 2.1), and the western fragment, a highly oxidized bicyclic 
tetrahydroxazine (314, Scheme 2.1).  
Based upon Williams’ and Danishefsky’s work (see Section 1.3.2, Chapter 1) on the 
aspirochlorine core there was good precedent for benzylic sulfenylation either through direct 
benzylic functionalization or a 1,2-sulfur migration.9,10 Furthermore, the opposing strategy, pre-
integration of the benzylic sulfur, provided additional challenges beyond the scope of the desired 
area of research. Synthetic tactics to install the benzylic sulfur earlier in the route, including sulfa–










































Scheme 2.1. Retrosynthetic analysis of gliovirin 
 
yields for the necessary electron-rich substrates. As shown in Scheme 2.1 synthesis of the eastern 
fragment would be enabled through the palladium-catalyzed Negishi cross-coupling of a 
iodoserine derivative 318 with an aryl iodide.11   
The western fragment, a highly oxidized bicyclic tetrahydroxazine, provides an enormous 
synthetic challenge. In our strategy, this highly functionalized intermediate 315 could be generated 
through oxidative manipulations of an enantioenriched biyclic oxazine 317. This critical 
intermediate 317 would be generated either through radical cyclization of a hydroxamate or 
through a hetero Diels–Alder reaction. 
In approaching the synthesis of 315 there are several considerations that place limitations 
on the synthetic tactics one is able to engage. An important consideration is the oxazine N-O bond 
which is prone to reduction under a variety of conditions to form 1,4-aminoalcohols (Scheme 
2.2a).12–18 This reactivity has exploited in a variety of syntheses (Scheme 2.2b).19–30 Furthermore, 
the acidic a-proton of the tetrahydro-1,2-oxazine can enolize readily which facilitates subsequent 
N-O bond cleavage and tetrahydrofuran formation (Scheme 2.2a). The reactivity could be 









































2.2c).31 The oxidized ring of the western fragment 315 is likely unstable to oxidation as it could 
readily form an aromatic system or undergo an electrocyclic rearrangement (Scheme 2.2d).32  
Scheme 2.2. Transformations associated with tetrahydro-1,2-oxazines and the western fragment 
 
 
2.2 HETERO DIELS-ALDER DERIVATIVES 
The use of a hetero Diels–Alder cyclization to form the bicylic oxazine was attractive to 
us as a direct way to form the desired bicyclic motif. A reactive nitroso-alkene is known to be 
generated in situ from oxime 326, which can react with electron-rich olefins including silyl enol 
ethers and dienes.33 To further evaluate the strategy, the reaction was carried out with 1,3-
cyclohexadiene to generate the bicyclic dihydro-1,2-oxazine 327 in excellent diastereoselectivity 
and tractable yield on scale (Scheme 2.3). It would be advantageous if one could directly integrate 
oxidation at C4 using the appropriate silyl enol ether; however, previous studies show a high 
selectivity for integration at C9. Therefore, elaboration 327 was attempted to access the desired 







































a) decomposition pathways of tetrahydro-1,2-oxazines






































326 327 328 329
modest diastereoselectivity for the desired syn–syn product 328. Optimization of the 1,2–reduction 
to improve the diastereoselectivity was untenable due to cross reactivity with the reduction-prone 
N-O bond. Further oxidative elaboration of the all-carbon ring was also met with challenges. While 
the C7-C8 olefin of 327 could be epoxidized diasteroselectively to form 329, the desired base–
mediated elimination to yield the allylic alcohol motif present in 80 did not proceed.34 Instead, 
only minor epimerization of the starting material was observed at the ring fusion.  
Therefore, while the [4+2] approach generated the bicyclic framework rapidly, it did not 
lend itself easily to oxidative elaboration. Furthermore, the preparation of enantioenriched 
cycloadducts would require substantial method development.35 The racemic intermediate 321 
generated by this study was later used to evaluate amide coupling of the eastern and western 
fragments in model studies.  
Scheme 2.3. Elaboration of hetero Diels–Alder product 
 
 
2.3 SYNTHESIS OF OXIDATIVE CYCLIZATION SUBSTRATES 
 The biosynthetically inspired cyclization of a modified N-oxy-phenylalanine derivative 
was identified as a valuable strategy. Using an N-oxy amino ester as a cyclization substrate one 






















326 (50% yield) 327



















The cyclization intermediates targeted for evaluation were N-hydroxy-3,4-dihydrophenylalanines, 
such as 333, as the product would retain two conjugated synthetic handles on the all-carbon ring. 
To access the desired enantioenriched diene motif several approaches were attempted. N-oxidation 
of the known amino acids resulted in no desired product formation (Scheme 2.4a).36 A Second 
approach employs protected hydroxylamines to engage with activated enals electrophiles to 
undergo asymmetric conjugate addition to form bis-protected N-hydroxy amino ester 337  
(Scheme 2.4b).37,38 Yet, when 337 was subjected to modified Seyferth–Gilbert39 conditions using 
the Ohira–Bestmann reagent 33840 to homologate to the desired alkyne 339, unproductive 
decomposition was observed. Control experiments showed that the substrate was not stable to the 
mildly basic conditions used in the transformation. 
Scheme 2.4. Failed approaches to an oxidative cyclization substrate 
 
In subsequent series of attempts the desired 342, a known a-hydroxy ester was activated 
as the triflate, 340 (Scheme 2.4c).41 Displacement with a hydroxylamine nucleophile and 












a) N-oxidation of known non-canonical amino acids






1. 2,6-lutidine (1.0 equiv), 
    BnONH2 (2.0 equiv)
2. AcCl (3 equiv), 















c) Displacement of triflate with hydroxylamine nucleophile
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Grubbs II (37.5 mol %)
CH2Cl2, 40°C
(20% yield) 342
Gratifyingly, the alkyne 341 could undergo an inefficient enyne metathesis reaction to generate 
the N-hydroxy-3,4-dihydrophenylalanine 342. Attempts to debenzylate 342 under Lewis acidic 
conditions led to unproductive decomposition of the starting material.43 Due to the presence of an 
electron-rich diene, debenzylation under reductive conditions could not be attempted without 
competitive alkene reduction. Substitution of an orthogonal protecting group, trimethylsilyl 
(TMS), in place of the benzyl group on the hydroxylamine nucleophile was unsuccessful. HPLC-
MS analysis of the reaction media suggested that displacement 330 with O-trimethylsilyl 
hydroxylamine had occurred; however, no desired product was ever recovered from the crude 
reaction. As a result of the low yielding transformations of the displacement strategy and a lack of 
flexibility in its protecting group strategy a more direct route was explored.   
Scheme 2.5. Racemic and asymmetric syntheses of  N-siloxy propargyl glycine 
 
 Finally, it was hypothesized that a direct homopropargylation of the oxime ester 332 could 
efficiently access N-siloxy propargyl glycine 333. While 332 was initially resistant to 
functionalization, two methods were discovered to provide the desired product. The addition of 
allenyl zinc bromide, generated in situ, provided the racemic alkyne as the major product with a 
minor allenyl impurity (Conditions A, Scheme 2.5).44 Furthermore, copper–catalyzed asymmetric 
alkylation developed in the Reisman group (See Chapter 3) was also implemented to provide the 
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impurity observed (Conditions B, Scheme 2.2d). To the best of our knowledge this is the first 
example of a catalytic asymmetric alkylation of an oxime. The N-siloxyamino ester 344, was 
benzoylated efficiently but 345 was unstable to standard silica purification; a plug of Florisilâ,45 
however, provided clean product in excellent yield.  
Our Early attempts to perform a methylene-free enyne metathesis based on the initial 
disclosure by Diver led to high conversions but low yields (entry 1, Table 2.1).46,47 Darkening of 
the solution was suggestive of catalyst decomposition.48 Regardless, the yields remained 
intractable whether using a higher catalyst loadings or portion-wise catalyst addition. Similarly, 
different catalysts and common additives had negligible effect on yield. 
Table 2.1. Enyne metathesis optimization studies  
 
The stability of a Hoveyda-Grubbs’ catalyst is dependent upon solvent. A screen of a series 
of solvents for this reaction demonstrated that the efficiency of the reaction improved in argon-
degassed benzene (entry 8, Table 2.1). Slow addition of a solution of 345 and careful control of 
the concentration of catalyst in the reaction mixture was essential for productive reactivity. To 































































































metathesis reactions were used as a guide. These studies demonstrate that the productive enyne 
pathway is first order in cyclooctadiene and catalyst, but zero order in the substrate.49 Therefore, 
decreasing the concentration of the substrate in the reaction medium, raising the catalyst 
concentration (19–5 mM), and extending the addition time of 345 results in an excellent yield of 
the desired diene 346 (entry 9, Table 2.1).   
 
2.4 OXIDATIVE CYCLIZATION OF AN N-HYDROXY AMINO ESTER 
To accomplish the proposed oxidative cyclization, we were motivated to build upon 
previous studies on radical cyclizations of hydroxamic acids with olefinic substrates. This class of 
reactivity was first observed by Perkins when aromatic 336 spontaneously cyclized in air to 
generate a hydroperoxide 337 (Scheme 2.3a). Alexanian later systematically explored this reaction 
on a variety of substrates converting the intermediate cyclized hydroperoxides to alcohols or 
ketones, we particularly by the encouraged by their ability to generate 6-6 bicyles (Scheme 2.3b) 
and highly diastereoenriched products (Scheme 2.3c) in good yields.50,51 Our investigations 
focused on analogous reactivity in novel substrates; unlike Alexanian’s work we identified a 
copper catalyst as an efficient catalyst to facilitate cyclization. Since our optimization studies, 
several disclosures of intermolecular radical additions in simplified systems were published 
utilizing copper sources as catalysts (Scheme 2.3d–f).52–54 
In contrast to previous work, where stereocenters were formed in close proximity to one 
another (Scheme 2.3ab), the goal of the present study was to form disparate stereocenters on 350 
at C7 and C10, with diastereocontrol relative to the C3 a-carbon. Prior to undertaking these 
studies, it was hoped that a reductive work-up of the intermediate allylic hydroperoxide would 
provide an a-disposed alcohol at the newly formed C7 allylic site which could be subsequently 
leveraged as a directing group to ensure facile installation of the desired tri-substituted epoxide 
Scheme 2.6. Oxidative radical additions of N-oxides to olefins 
 
present in the 80. Despite these aspirations, upon silyl deprotection and subsequent oxidative 
cyclization a complex mixture of allylic alcohols was observed in low yields with the major 
product being the syn-anti-b-OH 350 (Scheme 2.4). Along with the mixture of allylic alcohols, 
enone products were also formed despite the reductive work-up exhibiting with the desired C3-
C10 syn-diastereomer 351 as the major product.  
The selectivity at C7 for the undesired diastereomer can be rationalized through 
conformational analysis informed by previous computational studies by Houk in which it was 
shown that triplet oxygen and cyclic allylic combine through an antiperiplanar trajectory in the 
transition state.55 A qualitative comparision of the transition state conformers for axial (353axial, 
Scheme 2.5) and equatorial (353equatorial) oxygen capture, suggest that they are close in energy; 








































1. DLP (10 mol%)
2. Ac2O(1 equiv)





a) Perkins, 1990 b) Alexanian, 2010
(64% yield, 5.25:1 dr)
c) Alexanian, 2012





































(25 examples, 34–82%)356 357 358
the intermediate hydroperoxide 354axial which upon reduction forms the observed major 
diastereomer (350).    
 
Scheme 2.7. Initial studies and conformational analysis of an oxidative cycylization   
 
Guided by this analysis, it suggested that this diastereoselectivity would not be easily 
improved and therefore optimization toward the selective generation of the syn-enone 351 was 
undertaken. To that end, a Kornblum-DeLaMare56 work-up was employed in a similar fashion to 
that used previously by Alexanian (Scheme 2.3c). A solvent screen identified acetonitrile as a 
superior solvent for the transformation and while a fluoride-mediated deprotection was efficacious, 
an acidic deprotection using methanesulfonic acid could be substituted and simplified the work-
up. The addition of a copper salt appeared to facilitate the reaction at a lower temperature. A screen 


























































































a) oxidative cyclization of an N-hydroxy amino ester with a reductive workup
b) conformational analysis to rationalize diastereoselectivity in C7–oxygenation
identified tetramethylethylenediamine (TMEDA) as the optimal additive (entry 3, Table 2.2). Use 
of a non-coordinating counterion provides a small but consistent improvement to the yield (entry 
5, Table 2.2). The reaction required dilute conditions for good reactivity, as concentrations above 
0.1M provided only trace product (entry 6, Table 2.2). Finally, a base screen of the Kornblum-
DeLaMare work-up showed that the weak base pyridine out-performed other nitrogenous bases in 
a separate screen and had improved scalability.   
Table 2.2. Optimization of the oxidative cyclization of N-siloxy-dihydrophenyalanine 
 
Upon completion of this optimization we wished to vary the substrate 335 to improve the 
diastereoselectivity and yield of the reaction further. Interestingly, substitution of a bulkier ester 
had no effect on the diastereoselectivity of the cyclization (entry 2, Table 2.3). Acyl substitution 
at the acyl substituent was varied, however, a significant increase in the preference for the syn-
product was observed (entry 3, Table 2.3).. The overall yield of the transformation was not 
perturbed by this N–substitution, suggesting a negligible effect on the competitive decomposition 
pathways; yet, the shift in diastereoselectivity was a strongly indicative that the acyl substitutent 
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Previous studies have shown that cyclic amides have a preference for an equatorial 
disposition and will develop A1,3–type strain with a-substituents.59 Integrating these observations 
into conformational analysis of the initial cyclization step, one can rationalize the inherent syn- 
preference of the cyclization. To generate the observed major diastereomer, the reaction would 
proceed through a low-energy chair-like conformation with the C3 ester in an axial disposition 
(356chair, Scheme 2.6) to alleviate developing A1,3–type strain in the transition state. This 
conformational preference would be substantiated by crystal structure (See Table 2.6). 
Alternatively, the reaction could proceed through a transition state with a higher energy boat-like 
conformation (356boat) with A1,3 minimization or through another chair-like conformation 
(356chair*) with strain developing between the hydroxamate and the a-substitutent. Both of these 
higher energy conformations would lead to the minor diastereomer, though to discern their relative 
contributions to the reaction will require a more thorough computational analysis.  
Table 2.3. Structural effects on the oxidative cyclization of N-siloxy-dihydrophenyalanine 
 
 This novel copper-catalyzed cyclization inspired by Stack and Alexanian is a scalable 
method in hand to produce the key intermediate syn-351 as the major product. Furthermore, this 





2. Cu(TMEDA)2(BF4)2 (5 mol%), O2
3. Ac2O(3 equiv), pyridine (2 equiv)



























temperature. With the bicylic framework of the western fragment established the oxidative 
elaboration of the enone to the desired epoxy allylic alcohol was undertaken. 
Scheme 2.8. Conformational analysis to rationalize syn–diastereoselectivity in C10–cyclization 
 
 
2.5 EPOXIDATION STUDIES 
The copper–catalyzed cyclization provides an enone product with unsaturation at C5-C6 
which corresponds to the epoxide in gliovirin. Therefore, direct installation of the requisite 
oxidation was pursued using either the allylic alcohol or enone precursor. 
Initial studies were focused on the directed epoxidation of an a-disposed allylic alcohol 
(a-350, Scheme 2.7) as diastereoselectivity was a concern. Attempts to achieve a directed 
epoxidation of a-350 were mired by messy reaction profiles and, most prominently, competitive 
oxidation of the allylic alcohol to form the enone. Competitive C–H oxidation is a known side 
reaction of directed epoxidations and appeared unavoidable on this substrate. While a high-
yielding epoxidation of the allylic alcohol was unable to be achieved, the ratio of desired 357 to 














































































favored enone formation, while mCPBA favored epoxide formation. This reactivity is likely due 
to conformational effects. An equatorially–disposed alcohol accelerates the rate of epoxidation by 
mCPBA while vanadyl acetylacetonate prefers an axially-disposed alcohol in the transition state.60 
While the application of these reactions proved fruitless toward the synthesis of oxazine-
containing natural products it was appealing to see pronounced differential activity in these 
unusual substrates.   
Scheme 2.9. Directed epoxidation studies on the allylic alcohol 
 
Attention turned to epoxidation of 351. Standard Weitz-Scheffer conditions led to complete 
decomposition, with a small amount of desired product isolated only when a catalytic amount of 
base was used (entry 1, Table 2.4).61 To avoid strongly basic conditions, attempts to use enamine 
catalysis specifically designed for the epoxidation of cyclic enones gave no reaction.62 Similarly, 
other oxidants which epoxidize more electron-rich and less polarized olefins, such as DMDO, led 
to no reaction. 
 After an extensive survey of the literature, we were inspired by Magnus’ synthesis of (+)–
pancrastistatin.63 To avoid decomposition of their especially base–sensitive substrate the authors 
found that a mixture of H2O2 and NaHCO3 could generate a high yield of epoxide. To our delight, 
the first attempt of these conditions provided a 46% yield of the desired epoxide as a single 
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 369 : syn-363 
     1 : 2
     3 : 1
in variable yield (entry 2, Table 2.4). Encouraged by these promising results, however, reaction 
optimization studies began in earnest. 
Table 2.4. Selected entries from enone epoxidation optimization studies 
 
Epoxidations of isolated olefins mediated by H2O2/NaHCO3 were studied methodically by 
Burgess, noting that a low concentration of NaHCO3 was key to generating high yields of 
product.64,65 Lowering the concentration of NaHCO3 to 2.0M did not increase the yield of the 
reaction significantly (~50%) but the reaction time shortened and, importantly, scale-up of these 
conditions were replicable in contrast to Magnus’ conditions. Substitution of t-butanol for 
methanol led to an increase in yield (entry 3, Table 2.4). Finally, a screen of Lewis acid additives 
showed that catalytic CrCl3 consistently improved the yield of the epoxide to 70% isolated. Further 
experimentation showed that slow addition of a mixture of NaHCO3 and CrCl3 in t-BuOH and 
water to a cold solution of substrate and H2O2 in THF gave excellent yields on large scale. Despite 
this highly-involved optimization and mild conditions of the transformation when the epoxidation 
was attempted with a new bottle of H2O2 complete decomposition occurred. This was 
discouraging; however, it was found that sodium hypochlorite could be used in the place of H2O2 














































2.6 GENERATION OF EPOXY-ENE OXIDATION SUBSTRATE  
Several strategies for the oxidative elaboration of 363 to the desired epoxy allylic alcohol 
motif were explored. The first of which was a focus on the conversion of the carbonyl to the alkene 
followed by an allylic oxidation at C9. The dehydration substrate 371, while accessible through 
the inefficient epoxidation a-362 (Scheme 2.9) was more expeditiously generated through a 1,2-
reduction of 370 using Luche conditions (Scheme 2.10). Typical dehydration conditions  through 
activation of 371 as a sulfonate ester either returned the starting material or led to complete 
decomposition upon heating. Desired product 372 was formed when the Martin’s sulfurane was 
employed, yet again significant C-H oxidation was observed with competitive formation of 370.66 
Scheme 2.10. Inefficient elimination of epoxy alcohol through dehydration 
 
We wished to interrogate a palladium–mediated reduction of an epoxy vinyl triflate; 
however attempts to form the vinyl triflate did not produce an isolable intermediate. Further studies 
into this tactic were abandoned as a-epoxy vinyl triflates are prone to a myriad of decomposition 
and rearrangement pathways when subjected to palladium-catalyzed reductive conditions.67 
Finally, a three–step procedure was successful in generating the desired epoxy alkene 365. 
First, a modified Wharton protocol (for Method Development, see Section 2.10) generated a 
tertiary allylic alcohol 362 in high yield (Scheme 2.9).68 This intermediate could then be submitted 
to a light–mediated allylic bromination with N-bromosuccimide (NBS) to generate a 































 372 : 370
 5 : 2370
was not fully characterized but carried on crude through a silver–mediated halide elimination to 
form the desired epoxy alkene in excellent yield, two steps from 373.70 
Scheme 2.9. Efficient synthesis of the epoxy alkene from the epoxy ketone  
 
 
2.7 STUDIES ON C9-ALLYLIC FUNCTIONALIZATION 
 With 372 in hand the efficient introduction of oxidation at the C9 allylic methylene would 
complete the synthesis of the fully elaborated western fragment 315 (Scheme 2.1). Allylic 
oxidation has been the subject of much study in organic chemistry and applied to a number of total 
syntheses.71 These methods were brought to bear in the attempted oxidation of 361. The use of 
selenium dioxide as an oxidizing reagent under a variety of solvent mixtures and additives 
provided no desired reactivity.72 Use of a phosphate buffer or pyridine co-solvent prevented 
epoxide opening; however, no oxidation was observed. Increasing the reaction temperature to 
40 °C unfortunately led to complete decomposition of the materials. 
Scheme 2.10. Desired oxidative functionalization of epoxy alkene 
 
 The oxidation substrate, 372, was also unreactive to Kharasch-Sosnovsky oxidations73 
while metal-free oxidations, including NHPI–mediated oxidations,74,75 led to complete 
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oxidant, a mixture of an mixture of products was generated, yet evidence of desired product 
formation was observed by mass spectrometry. Unfortunately, repeated attempts to optimize, 
scale-up and isolated these potential oxidation products were unfruitful.76  
 With these negative results in mind, one’s attention inevitably returns to previously 
successful tactics: allylic bromination. Yet, the epoxy alkene 372 did not react when subjected to 
the previously optimized conditions for 373. Several trace bromide–containing products were 
detected, however no selectivity observed. Hoping to once again funnel the crude mixture to a 
single product, the crude was treated with silver(I) tetrafluoroborate and triethylsilanol resulting 
in the trace formation of an intractable mixture of silyl ether products.70 The low efficiency and 
selectivity this bromination–displacement approach led to its rejection. 
 While the outlook of the oxidation of the C9-deoxy substrate is poor, it would be of value 
to evaluate the ability of P450 mutants to facilitate this especially difficult C9 oxidation due to 
their ability to reverse the selectivity of known chemical methods and proceed at room 
temperature.77  
 
2.7 DESATURATION STUDIES 
 As the C9 allylic oxidation currently provides an inordinate challenge; therefore, 
alternative strategies were explored. A stereoretentive allylic transposition of a C7 oxidative 
handle to C9 was hoped to be thermodynamically favored. To interrogate this hypothesis, an allylic 
alcohol (377a, Table 2.6) must be accessed through the successful 1,2–reduction of a desaturated 
epoxy enone substrate (376, Table 2.5).  
Conversion of the 370 to 376 like many of these transformations in this series was 
challenging. Typically, a ketone is converted to the corresponding silyl enol ether which can then 
be subjected to a variety of conditions to form the desaturated product.78–80 There are two general 
approaches to silyl enol ether formation: kinetic deprotonation with a strong base and quenching 
with a silyl halide or milder thermodynamic conditions using an amine base in conjunction with 
sodium iodide and a silyl triflate. Unfortunately, under kinetic conditions the epoxy ketone 
decomposed while thermodynamic conditions returned starting material. Attempts to form the allyl 
enol carbonate also led to decomposition. 
Scheme 2.11. Revised retrosynthetic plan for a fully elaborated western fragment   
 
 Recently, several direct methods for ketone desaturation have been disclosed. Encouraged 
by these discoveries, a direct desaturation was explored. Use of hypervalent iodine reagent lead to 
either recovery of the starting material or decomposition (entry 1, Table 2.5).81 Alpha–selenation 
under thermal conditions gave a very messy reaction profile but appeared to have a small amount 
of a new enone–containing product (entry 3, Table 2.5). Isolation confirmed the formation of the 
desired 364 and while encouraged that the desired transformation could occur in one pot, the 
competitive decomposition observed suggested alternative approaches should be explored. 
Palladium catalysis has a rich history in ketone desaturation exemplified by the Saegusa–
Ito and Tsuji oxidations.78,82 New advances in the literature have avoided the stoichiometric  
generation of a functionalized enol, employing more Lewis acidic palladium sources, perhaps to 
encourage enolization and a-palladation.83 Submitting the epoxy ketone to these conditions (entry 
2, Table 2.5) provided trace amounts of the 364. Subjecting 360 to conditions derived from the 
























observed yield of 364 (entry 4, Table 2.5).84 Furthermore, the clean reaction profile and low 
reaction temperature made these conditions attractive for further optimization.   
Table 2.5. Selected entries in the optimization of the direct ketone desaturation 
 
A solvent screen indicated that DMSO was anomalous in its ability to foster productive 
reactivity, with acetonitrile being the only other solvent that provided a trace of product. By raising 
the temperature from 35 °C to 50 °C the yield increased from 30% yield (75% brsm) to 50% yield  
 (60% brsm) with a minimal decrease in the overall efficiency of the transformation. Improving 
conversion was critical as the product and starting material were difficult to separate 
chromatographically. This provided a challenge in reaction monitoring as 360 and 364 had 
identical retentions on reverse–phase HPLC and TLC. The reaction could, however, be monitored 
by NMR (Figure 2.2) suggesting that the majority of productive chemistry occurred in the first 50  
hours before non–productive decomposition became competitive. Raising the palladium catalyst 
loading, maintaining a slight excess of BQ provided improved and scalable yields of the epoxy 
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Figure 2.2 1H NMR Monitoring of the palladium-catalyzed desaturation in deuterated DMSO
 
 
2.9 ALLYLIC TRANSPOSITION  
To generate the desired allylic transposition substrate (365a, Table 2.6) the enone 364 was 
readily reduced under Luche conditions to give a separable mixture of allylic alcohols (entry 1, 
Table 2.6).85 Attempts to form the desired a-disposed 365a selectively were unsuccessful; as 
bulkier reductants provided lower yields and preferentially formed 365b (entries 2&3, Table 2.6).86 
Though NMR signals were inconclusive in the structural determination of these new products, an 











































chair-like conformation of the tetrahydro-1,2-oxazine ring and the axial disposition of the ester 
consistent with our previous conformational hypotheses.     
Table 2.6. 1,2-reduction to generate substrates for allylic transposition studies 
 
With clean samples of both diastereomers of the allylic alcohol in hand, their reactivity 
could be evaluated in rhenium-mediated conditions for allylic transposition. Initial test reactions 
with common rhenium additives, including methyl trioxorhenium (VII) (MTO), showed that 
both 377a & 377b were quite unstable.87,88 It was only through the use of freshly prepared 
Osborn catalyst (Ph3SiOReO3), known for its high activity and attenuated Lewis acidity, that 
trace new products were observed as minor constituents of the reaction mixture. While the yields 
of isomerized material were similar for both diastereomers; discouragingly, 377a had a greater 
degree of decomposition. THF and CH2Cl2 modulated the poor reactivity of the transformation; 
yet further screens did not appear generate a more tractable yield. Although the greater stability 
of 377b to the reaction conditions were initially attractive inversion of the hindered C9 
secondary alcohol appeared challenging. Efficient rhenium-mediated allylic transpositions often 
have a strong thermodynamic bias for the desired isomer or some method of trapping the desired 





































would be lower in energy than 377a due to hyperconjugative effects this is not reflected in our 
experimental observations.  
Table  2.7. Allylic transposition studies on the both allylic alcohol diastereomers 
 
 
2.10 OXIDATIVE FUNCTIONALIZATION OF THE EPOXY ENONE 
 The intransigence of the C9 oxidation of 372 and the poor reactivity observed in the allylic 
transposition of 377a led to a re-evaulation of the approach toward oxidative manipulation of the 
bicyclic oxazine 364. To circumvent these challenges, the strategic installation of a functional 
handle at C9 prior to formation of the inert epoxy alkene motif would provide facile access to the 
desired fully functionalized western fragment.  
To that end, oxidation of the epoxy enone 376 was attempted. Gratifyingly, both 
dihydroxylation and epoxidation proceeded diaseteroselectively with high crude yields. 
Importantly, these compounds while isolated with minimal impurities through aqueous work-ups 
but were completely unstable to further purification via column chromatography regardless of the 














































































Scheme 2.12. Efficient oxidative modifications of the epoxy enone 
 
 
2.11 DEOXYGENATIVE	REARRANGEMENTS OF C9-OXIDIZED SUBSTRATES 
 A Wharton rearrangement of these C9–oxidized substrates would generate an olefin–
containing product at the desired oxidation level. The bis-epoxy ketone was the substrate upon 
which the lion’s share of optimization was undertaken as it provided direct access to the epoxy 
allylic alcohol motif.  
The Wharton rearrangement is an interesting reaction which is proposed to proceed through 
disparate mechanisms differentiated by either a basic or acidic additive employed to facilitate the 
reaction. The base–mediated reaction is proposed to proceed through a polar mechanism 
culminating in the protonation of a vinyl anion while acidic conditions are proposed to proceed 
through a radical mechanism with the expulsion of nitrogen and recombination of a hydrogen atom 
with a vinyl radical.90  
There are four variants of the Wharton rearrangement known in the literature. The original 
conditions used by Wharton and Bohlen were excess hydrazine hydrate and catalytic acetic acid 
in methanol.68 Later application of conditions analogous to the Wolff-Kishner reduction showed 
that heating the substrate with a hydroxide base instead of acetic acid gave higher yields when 
applied to steroidal substrates.91 For many years, little systematic development of the Wharton 
rearrangement was undertaken until Luche, of the eponymous reduction, turned his attention to the 
transformation.92 A combination of hydrazine hydrochloride and triethylamine in anhydrous 
NMO (1.1 equiv)



















(93% yield) (~90% yield)379 380
acetonitrile afforded significant improvements to the transposition of more sensitive substrates and 
was later applied to several effective syntheses. Finally, conditions were developed by Wiemer 
using a mixture of hydrazine hydrate and trimethyl silyl chloride in DMF. These conditions were 
found to also improve the reaction in comparison to Wharton’s original conditions in some 
substrates.93  
 There are three examples of a Wharton rearrangement on bis–epoxy ketone substrate. The 
first two examples are found in Ichihara’s synthetic studies of (±)–senepoxyde and (±)–
crotepoxide.94 In these studies, the authors used neutral hydrazine in a mixed solvent system. 
Discouragingly, they do not disclose a yield for either transformation despite reporting yields on 
the other reactions in the paper. The final example was demonstrated in the Hoye’s studies of (+)–
scyphostatin, using canonical Wharton conditions.95 The authors note that the reaction is highly 
dependent on the hydrazine stoichiometry and reaction time affording the desired products in 
variable yield (30–40%). 
 As a result of the base sensitivity of the 1,2–tetrohydroazines, conditions involving strong 
base were not pursued during reaction development on the bis-epoxy ketone 379. Instead, the 
initial focus was held on conditions that were proposed to proceed through the radical mechanism. 
Canonical Wharton conditions lead to decomposition, a trace amount of product–like substance 
was observed in the crude mixture but lacked an epoxide moiety (entry 1, Table, 2.8). Applying 
the conditions developed by Wiemer and Luche the desired product was observed, without epoxide 
opening or reduction, albeit in low yield as a mixture of constitutional isomers (entries 3&4, Table, 
2.8). Stoichiometry studies indicated that excess hydrazine had a deleterious effect on the yield of 
the desired product. 
Integrating some of the lessons from Luche’s studies with the original conditions 
developed by Wharton, we conducted a solvent and additive screen and identified benzoic acid as 
a superior catalyst to acetic acid and dried ethyl acetate as an optimal solvent. Unfortunately, these 
conditions gave the two isomeric products in a 2:1 ratio, favoring the tertiary alcohol, in a 
cumulative 34% yield. This yield, while low, is consistent with the other bis-epoxy ketone 
substrates known in the literature. Further attempts to optimize this yield were unsuccessful and 
complicated by difficulties in replicability.  
Table 2.8. Selected entries in the optimization of Wharton rearrangement of the bis-epoxy ketone 
 
The undesired tertiary allylic alcohol isomer 381, is favored in the reaction but upon 
purification on triethylamine–neutralized fluorosil the isomeric ratio shifted toward 1:1 with 
negligible deviations between NMR yield and isolated yield. This shift in the isomeric ratio was 
suggestive that a background vinylogous Payne rearrangement is operative, analogous to that 
studied by Hoye and exploited by Myers.95,96 
Possible complications of the reaction could be the competitive formation of inert azines 


































































followed by dehydrative aromatization.97–99 Azine formation can be accelerated by under acidic 
conditions; however, if the acid catalyst is removed from the reaction of 367 the yield is 
unperturbed while the reaction time for full conversion of the starting material is elongated. In an 
alternative approach to alleviate possible deleterious side reactivity, The use of protected 
hydrazones were evaluated. Clean conversion to the desired silylated and carbamate capped 
hydrazones was observed by TLC and LCMS; however, when the hydrazone was unmasked no 
productive reactivity was observed. These results were confusing but given the sensitivity of the 
initial reaction it is possible that the added deprotection reagents causes critical interference with 
the productive reaction pathway. 
Scheme 2.12. Wharton transposition on dihydroxylated substrate 
 
 In contrast to the bis–epoxy ketone applying partially optimized conditions to the epoxy 
ketone diol 380 provided the desired allylic triol 383 in ~85% by quantitative 1H NMR. This could 
be indicative that the product of the bis-epoxide Wharton rearrangement is decomposing during 
the reaction. The resultant allylic epoxide is an excellent soft electrophile and hydrazine and 
hydrazones have soft nucleophilic character as a result of the alpha effect, similar to 
hydroxylamines.100  
Several alternatives to the Wharton rearrangement were interrogated. Initial reduction of 
379 formed the bis-epoxy alcohol 384 which was then exposed to modified Mitsonobu conditions 
with a sulfonyl hydrazide developed by Myers and Movassaghi, however 384 was unreactive to 





















in the synthesis of tripolide analogues and hindered polycylic substrates through the formation of 
an intermediate xanthate.102 While this strategy would increase the step count it could circumvent 
the sensitivity of the 382.103 In contrast to thioimidazolides and thiocarbonates in the literature, the 
intermediates generated from the 384 for radical decomposition were unstable to mild heating, 
work-up conditions, or direct column chromatography. However, if generated using DMAP to 
facilitate thioacylation the crude material could be cleanly converted to the desired activated 
substrates in situ (385 & 386, Scheme 2.13).  
Scheme 2.13. Studies on a photoredox catalyzed radical deoxygenation 
 
 In the literature, these activated thiocarbonyl compounds are typically reacted under 
heating in the presence of the AIBN and Bu3SnH; however, the thermal instability of the in situ 












































NBu3 (10 equiv) 
NBu3 (2 equiv)
NBu3 (10 equiv) 
NBu3 (10 equiv) 
NBu3 (10 equiv) 
NBu3 (10 equiv)
––
HCO2H (10 equiv) 
Hantzsch ester  (2 equiv)
Hantzsch ester  (2 equiv)
Hantzsch ester  (2 equiv)
Hantzsch ester  (2 equiv)




















































a) failed light–mediated reduction of bis-epoxythiocarbonate generated in situ
b) selected entries in the optimization studies on the light–mediated reduction of bis-epoxythioimidazolide generated in situ
(im)2C=S
(1.2 equiv)





classical O2/BEt3 radical initiation conditions were initially engaged instead. Disappointingly, no 
product was observed in the crude reaction.104 A photoredox–catalyzed reduction of thiocarbonyl 
derivatives had been disclosed, appreciating the ability of these conditions to facilitate reactivity 
in challenging substrates this tactic was applied to the reduction of 385 and 386.105 The 
thiocarbonate 385 merely decomposed unproductively (Scheme 2.12a) but the corresponding 
thioimidazolide 386 provided a low yield of the epoxy allylic alcohol exclusively as the desired 
isomer 382 (Scheme 2.12b). Despite this encouraging selectivity, variation in photocatalyst, 
hydrogen donor, and amine additive did not raise the yield of the reaction. To further probe the 
nature of the activating group on the reduction, a fluorinated electron-poor benzoate was generated 
however no desired product was observed.106 
 
2.12 REALIZATION OF THE SYNTHESIS OF THE WESTERN FRAGMENT 
 Inspired by apparent background vinylogous Payne rearrangements exchanging 381 and 
382 during purification of the bis-epoxy ketone Wharton transposition, the mixture of the isomeric 
epoxy allylic alcohols was exposed to TBSOTf/NEt3.96 To our delight, the secondary silyl ether 
387 as the exclusive product. Initially, the yield was quite low. Decreasing the temperature of the 
reaction and quenching excess silyl triflate with cold iso-propanol improved the reaction on a small 
scale. These results were challenging to maintain on scale, providing yields between 30–40%. 
When 381 is isolated and exposed to the reaction conditions, the yield does not improve suggesting 
an overall instability to the reaction conditions. Substitution of THF as a solvent generates 387 
while retaining 381 in the reaction mixture. Upon purification on neutralized fluorosil, recovered 
starting material is returned as a 1:1 mixture of 381 and 382 further substantiating the presence of 
the rarely observed vinylogous Payne rearrangement.  
Scheme 2.14. Final oxidative modifications to form the epoxy allylic alcohol  
 
As a result of the low yields observed in the conversion of 379 to 387  an alternative route 
proceeding through triol 383 was envisaged improve efficiency by functionalizing the C8 allylic 
alcohol as a leaving group and performing an SN2’ displacement to generate 382. Initial studies to 
selectively mesylate the C8 allylic alcohol were met with decomposition; however, dibutyl tin 
oxide was able to facilitate selective formation the allylic tosylate. Treating this intermediate with 
TBSOTf resulted in partial conversion to the silyl ether. Yet, despite the Lewis acidic conditions 
no epoxide formation was observed. Currently, the triol intermediate has not been successfully 
advanced to the desired motif. 
With 376 now successfully synthesized, a variety of deprotection conditions were 
attempted to cleave the N-benzoyl group. The transformation was intractable until use of 








































a) Silylation of a mixture of epoxy allylic alcohol isomers
























a382 reacted as a singular substrate
1, Scheme 2.15).107 Careful control of the stoichiometry of the reagent and study of the work-up 
conditions substantially improved the yield (entry 2, Scheme 2.15). With 388 in hand, the peptide 
coupling was now ready to be studied. Thermal instability and base sensitivity of the substrate 
were retained in this new substrate; any attempt to saponify the ester was met with 
decomposition.108,109 As a result, we were limited to coupling an eastern fragment amino acid with 
the oxazine nitrogen followed by cyclization to form the DKP. 
Scheme 2.15. N-deprotection of the fully elaborated western fragment 
 
 
2.13 SYNTHESIS OF THE EASTERN FRAGMENT 
With the fully elaborated Western fragment in hand, the eastern fragment needed to be 
synthesized. To that end a palladium catalyzed Negishi coupling between a protected iodoserine 
derivative 380 and an electron rich aryl iodide 381 provided the non-canonical Boc-protected 
amino ester 382.11 It is notable that the use of a coordinating protecting group (MOM) in place of 
a methyl ortho to the iodide dramatically improved the yield of the coupling. Saponification of the 
methyl ester proceeds unremarkably and affords good yield to provide a substrate for amide 
coupling. Foreseeing that the orthogonal and facile cleavage of the phenol and amine protecting 
groups may be necessary, Boc-protected 394b was expediently converted to Fmoc–protected 
derivative 396 in a three–step sequence now with a silyl protecting that could be unveiled in a final 






































Scheme 2.16. Synthesis of unnatural phenylalanine derivatives  
 
 
2.14 ATTEMPTED COUPLING OF EASTERN AND WESTERN FRAGMENTS 
While the peptide coupling substituted of isoxazolidine substrates is known using standard 
coupling reagents; the newly deprotected compound 389 was completely unreactive to any peptide 
coupling conditions. An exhaustive screen of reagents specifically designed for hindered or non-
nucleophilic amines (eg. BEP, HATU, TFFH) generated no desired product.110 To further evaluate 
the reactivity of tetrahydro-1,2-oxazines in coupling reaction model compounds 328 and 397 were 
also screened under a variety of peptide coupling conditions yet again a similar lack of reactivity 
was observed (Scheme 2.17). 
Exposing the deprotected material to pivaloyl chloride resulted in clean formation of an 
acylated acylated. Encouraged by this result, further study showed that Fmoc-Phe-Cl was also able 
to form a coupled product 399 (Scheme 2.18).111 Unfortunately, attempts couple the acid chloride 






















































a) Synthesis of a boc-protected non-canonical amino acid
b) Protecting group swap to generate orthogonally protected non-canonical amino acid
 
derived from the polyoxygenated eastern fragment 396 failed possibly due instability of the 
intermediate acid chloride under the conditions or a lowered reaction rate due to increased bulk. 
While further work may have resolved these incompatibilities, studies on the phenylalanine 
coupled 399 show that, despite facile Fmoc-deprotection, the resulting amine 400 would not 
undergo intramolecular cyclize to form the DKP 401. Attempts to drive the reaction thermally or 
the addition of stronger bases lead to decomposition.  
Scheme 2.18. Amide coupling of a model amino acid chloride with the Western fragment 
 
2.15 CONCLUSION OF STUDIES TOWARD GLIOVIRIN 
Cyclization to form DKPs can occur under mild conditions through ester saponification 
and the use of a peptide coupling reagent (See Chapter 1), direct DKP formation typically requires 



















































































untenable and the intermediate 400 demonstrates instability to base and mild heating it appears 
clear that this late stage DKP formation–sulfenylation strategy is not appropriate for the synthesis 
of gliovirin (80). To successfully generate this natural product, it behooves the synthetic chemist 
to reassess the synthetic route. Early stage amide coupling could generate a more robust substrate 
for DKP formation, however the transformations that have been successfully implemented in the 
N–benzoyl system in this work would require substantial re-optimization and the protecting group 
strategy would be non-trivial. Furthermore, early installation of the DKP would planarize the C3 
substituent upon cyclization which would destroy the key conformational element which imposes 
diastereocontrol during the oxidative modifications required to establish the epoxy allylic alcohol 
motif. Replacement of the ethyl group at the ester with an orthogonally cleavable subsitutent would 
be optimal however this would require further development as classic examples, including allyl 
and TMS-ethyl, would undergo undesirable cross reactivity in the current route. 
 
2.16 STUDIES TOWARD THE TRICHODERMAMIDES 
 With the deprotected oxazine 389 in hand, one could imagine a simple conversion to the 
trichodermamide family; indeed, upon exposure to lead tetraacetate the 1,2-dihydrooxazine 402 is 
formed cleanly (Scheme 2.18). With this compound in hand, epoxide opening provided the allylic 
chlorohydrin 403 to generate the western fragement of trichodermamide B. Attempts to generate 
trans-diol 394 only generated in trace yield.113 Disappointingly, attempts to saponify 392 were 
unsuccessful, prohibiting interrogation of the penultimate amide coupling to synthesize 
trichodermamide B. With these promising results in hand perhaps this synthetic route can lead to 
an enantioselective synthesis of the trichodermamides. However, the difficulty in handling these  
intermediates and the inefficient Wharton–silylation sequence provide challenges toward the 
successful realization of that end.   
 












2.17 EXPERIMENTAL SECTION 
2.17.1 MATERIALS AND METHODS 





































































freshly dried solvents. Tetrahydrofuran (THF), methylene chloride CH2Cl2), acetonitrile (MeCN), 
dimethylformamide (DMF), benzene (PhH), diethyl ether (Et2O) and toluene (PhMe) were dried 
by passing through activated alumina columns. Unless otherwise stated, chemicals and reagents 
were used as received. Triethylamine (Et3N) was distilled over calcium hydride prior to use. All 
reactions were monitored by thin-layer chromatography using EMD/Merck silica gel 60 F254 pre-
coated plates (0.25 mm) and were visualized by UV, p-anisaldehyde, vanillian, CAM or KMnO4 
staining. Flash column chromatography was performed either as described by Still et al.31 using 
silica gel (partical size 0.032-0.063) purchased from Silicycle. Optical rotations were measured on 
a Jasco P-2000 polarimeter using a 100 mm path-length cell at 589 nm. 1H and 13C NMR spectra 
were recorded on a Varian 400 MR (at 400 MHz and 101 MHz, respectively), or a Varian Inova 
500 (at 500 MHz and 126 MHz, respectively), and are reported relative to internal CHCl3 (1H, d = 
7.26), or DMSO (1H, d	= 2.50), and CDCl3 (13C, d = 77.0), or DMSO (13C, d =40.0). Data for 1H 
NMR spectra are reported as follows: chemical shift (d	ppm) (multiplicity, coupling constant (Hz), 
integration). Multiplicity and qualifier abbreviations are as follows: s =singlet, d = doublet, t = 
triplet, q = quartet, m = multiplet, br = broad, app = apparent. IR spectra were recorded on a 
Thermo Fisher Nicolet iS5 FTIR spectrometer and are reported in frequency of absorption (cm.–
1). HRMS were acquired using an Agilent 6200 Series TOF with an Agilent G1978A Multimode 
source in electrospray ionization (ESI), atmospheric pressure chemical ionization (APCI), or 
mixed (MM) ionization mode. Analytical chiral HPLC was performed with an Agilent 1100 Series 
HPLC utilizing Chiralpak AD or Chiralcel OD-H columns (4.6 mm x 25 S7 cm) obtained from 
Daicel Chemical Industries, Ltd with visualization at 254 nm. Low-temperature X-ray diffraction 
data (φ-and ω-scans) were collected on a Bruker AXS D8 VENTURE KAPPA diffractometer 
coupled to a PHOTON 100 CMOS detector with Cu-Kα radiation (λ = 1.54178 Å) from an IµS 
micro-source. 
 
2.17.3 PREPERATIVE PROCEDURES AND SPECTROSCOPIC DATA  
 
Cycloaddition of in situ–generated nitroso alkene and 1,3–cyclohexadiene 
 
Stir 1,3-cyclohexadiene (4.2g, 5.0 mL, 52.5 mmol, 5 equiv) and anhydrous NaHCO3 (6.121g, 57.8 
mmol, 5.5 equiv) in CH2Cl2 (40 mL) at 45 °C. Add a solution of ethyl bromopyruvate 2-oxime 
(2.204 g, 10.5 mmol, 1 equiv) in CH2Cl2 (40 mL) at a rate of 2 mL•h-1; after addition is complete 
stir overnight at 45 °C. Upon completion of the reaction, filter off salts and wash salts with CH2Cl2. 
Dry over Na2SO4, filter and concentrate in vacuo to yield crude product. Purify the by flash 
chromatography (silica, 4% EtOAc/CHCl3) to give dihydro-1,2-oxazine XX as a yellow oil (1.10g, 
5.26 mmol, 50% yield) 
1H NMR (400 MHz, CDCl3) δ 6.02 (dt, J = 9.7, 3.7 Hz, 1H), 5.85 (ddt, J = 9.9, 4.5, 2.3 Hz, 1H), 
4.37 – 4.28 (m, 2H), 4.25 (d, J = 3.8 Hz, 1H), 2.61 (dd, J = 19.6, 7.8 Hz, 1H), 2.29 (dd, J = 19.6, 
3.2 Hz, 1H), 2.25 – 2.06 (m, 3H), 1.62 (td, J = 7.8, 7.4, 5.3 Hz, 2H), 1.38 – 1.31 (m, 3H).  
13C NMR (101 MHz, CDCl3) δ 163.79, 149.09, 134.16, 123.97, 71.02, 61.84, 26.97, 25.07, 24.53, 
23.57, 14.13.  
FTIR (AT-IR) 2924.94, 2359.12, 2340.2, 1713.03, 1597.78, 1422.35, 1373.19, 1345.19, 1292.61, 
1261.43, 1225.74, 1172.33, 1152.55, 1109.52, 1078.81, 1037.42, 1004.62, 950.38, 913.42, 885.09, 













326 (50% yield) 327
HRMS (TOF, ES+) calc’d for C11H15NO3 [M+H]+ 210.1125, found 210.1123 (ppm=0.81) 
 
Diastereoselective 1,2-reduction of bicyclic dihydro-1,2-oxazine 
 
To a frozen solution of dihydro-1,2-oxazine (1.09 g, 5.21 mmol, 1.0 equiv) in AcOH (40 mL) in 
an ice bath add NaCNBH3 (687 mg, 10.94 mmol, 2.1 equiv) as a single portion. Stir to ambient 
temperature for 18h. Neutralize crude mixture 6M NaOH(aq) and adjust with pH=7 phosphate 
buffer. Extract reaction twice with EtOAc. Dry organic layer over Na2SO4, filter and concentrate 
in vacuo to yield crude product. Purification by flash chromatography (silica deactivated with 
NEt3, 5%EtOAc/50%CHCl3/Hexanes) provided a 2.3:1 diastereomeric mixture of tetrahydro-1,2-
oxazine (900 mg, 4.26 mmol, 82% yield) as a pale oil. A second separation of the mixture by flash 
chromatography (silica, 5%NEt3/5%EtOAc/50%CHCl3/Hexanes) provided a sample pure syn-
product (109 mg, 0.516 mmol) along with mixed fractions. 
1H NMR (500 MHz, CDCl3) δ 6.01 (dddt, J = 9.8, 4.8, 2.4, 0.9 Hz, 1H), 5.74 (dddd, J = 9.4, 4.4, 
2.5, 1.7 Hz, 1H), 5.65 (s, 1H), 4.19 (qd, J = 7.2, 1.3 Hz, 2H), 4.12 (s, 1H), 3.93 (dd, J = 10.9, 3.5 
Hz, 1H), 2.22 – 2.12 (m, 1H), 2.10 – 2.01 (m, 2H), 1.97 (dt, J = 13.5, 3.2 Hz, 1H), 1.90 (dt, J = 
10.1, 6.0 Hz, 2H), 1.53 – 1.44 (m, 1H), 1.28 (t, J = 7.1 Hz, 3H). 


















FTIR (AT-IR)	 3295.02, 3028.05, 2923.56, 2358.40, 1732.28, 1431.63, 1368.92, 1306.19, 
1261.56, 1203.94, 1179.62, 1134.70, 1098.47, 1066.71, 1022.02, 1005.65, 920.47, 879.26, 846.60, 
731.82, 685.99, 667.68, 623.57 cm-1 
HRMS (TOF, ES+) calc’d for C11H17NO3 [M+H]+ 212.1281, found 212.1291 (ppm=–4.62). 
 
Epoxidation of bicyclic dihydro-1,2-oxazine 
 
To a solution of dihydro-1,2-oxazine (10.9 mg 0.0521 mmol) in CH2Cl2 (0.2 mL) add a solution 
of freshly prepared DMDO114 (10 mL) stir at ambient temperature in air for 2h. Concentrate 
reaction mixture in vacuo to yield crude product. Purify the by flash chromatography (silica, 15% 
EtOAc/CHCl3) to give dihydro-1,2-oxazine as a clear oil (7.0 mg, 0.0311 mmol, 60% yield)  
1H NMR (600 MHz, CDCl3) δ 4.33 (qd, J = 7.1, 3.1 Hz, 2H), 4.28 (s, 1H), 3.41 (t, J = 3.0 Hz, 
1H), 3.26 (t, J = 4.3 Hz, 0H), 2.52 (dd, J = 19.5, 7.6 Hz, 0H), 2.27 (dd, J = 19.7, 2.1 Hz, 1H), 2.17 
– 2.10 (m, 1H), 2.08 – 2.02 (m, 2H), 2.00 – 1.89 (m, 1H), 1.37 (t, J = 7.1 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 163.58, 149.69, 72.49, 62.21, 52.46, 52.00, 25.97, 23.66, 22.23, 
21.15, 14.27. 
FTIR (AT-IR)	 2984.93, 2935.69, 1714.23, 1599.17, 1442.07, 1425.20, 1375.31, 1345.17, 
1291.72, 1264.12, 1229.17, 1172.76, 1120.80, 1105.88, 1070.87, 1037.02, 1006.52, 965.14, 
930.32, 861.13, 832.18, 810.22, 780.45, 746.53, 632.12 cm-1 
















Formation of propargylic triflate 
 
Stir Cu(MeCN)4ClO4 (205 mg, 0.626 mmol, 4 mol %) and R-T-BINAP (513 mg, 0.756 mmol, 5 
mol %) at ambient temperature for 30 minutes in Et2O (62.5 mL) and then chill to –30 °C. Add 
allenyl stannane (4.00 mL, 5.00g, 15.19 mmol, 1.0 equiv) and freshly distilled ethyl glyoxylate in 
toluene (13.51 mL, 68.18 mmol, 4.5 equiv). Stir reaction for 48h, then add 10% KF(aq) (60 mL) 
separate organic phase. The aqueous phase was washed with diethyl ether. Dry the combined 
organics over Na2SO4 and concentrate partially before flushing through a silica plug (50% Et2O/ 
pentanes). Concentrate the resulting solution partially to yield a solution of the crude intermediate 
alcohol. Stir the solution at 0 °C, add 2,6-lutidine (2.64 mL, 22.73 mmol, 1.5 equiv) and triflic 
anhydride (3.57mL, 21.21 mmol, 1.4 equiv). Allow reaction to warm to ambient temperature and 
continue stirring for 10h. Filter the crude reaction mixture through celite and wash with DI H2O 
(100 mL). Dry the organic over Na2SO4, filter and concentrate to yield a red oil. Purify by flash 
chromatography (silica, 15%EtOAc/Hexanes) to provide 340 (1.684 g, 6.14 mmol, 41% yield) as 
a clear oil. 
1H NMR (400 MHz, CDCl3) δ 5.19 (dd, J = 6.8, 5.0 Hz, 1H), 4.43 – 4.24 (m, 2H), 3.03 – 2.84 (m, 
2H), 2.16 (t, J = 2.7 Hz, 1H), 1.33 (td, J = 7.2, 1.0 Hz, 3H). 







1)ethyl glyoxylate (4.5 equiv),
   [Cu(MeCN)4]ClO4(4 mol %),  
   R-T-BINAP (5 mol %)
2)Tf2O (1.4 equiv), 2,6-lutidine (1.5 equiv)
Et2O, –30 °C–> rt
(41% yield over 2 steps)
SI2-1 340
FTIR (AT-IR)	 3302.74, 2988.13, 2359.29, 1751.07, 1417.39, 1375.39, 1349.38, 1282.85, 
1202.33, 1139.73, 1024.07, 998.37, 960.68, 920.94, 855.24, 793.29, 752.6, 735.62, 610.26 cm-1 
HRMS (TOF, ES+) calc’d for C8H9F3O5S [M+NH4]+ 292.0461, found 292.0459 (ppm=0.70) 
 
Nucleophilic displacement of triflate with O-benzyl hydroxylamine  
 
To a solution of triflate 331 (300 mg, 1.09mmol) in CH2Cl2 (24 mL) was added 2,6-lutidine 
(126.8 µL, 1.09 mmol). Cool solution was to 0 °C and add benzyloxylamine (256 µL,  2.18 mmol). 
Stir solution overnight to ambient temperature. Cool once again to 0 °C and add both Hunig’s base 
(572 µL, 3.27mmol) and acetyl chloride (234 µL, 3.27 mmol). Stir an additional 12h then quench 
with dilute citric acid and extract with CH2Cl2. Dry organic phase over Na2SO4, filter, and 
concentrate. Purify by flash chromatography (silica, 3%NEt3/15%EtOAc/Hexanes) to provide 341 
as a clear oil (89.0 mg, 0.308 mmol, 28% yield)  
1H NMR (400 MHz, CDCl3) δ 5.19 (dd, J = 6.8, 5.0 Hz, 1H), 4.43 – 4.24 (m, 2H), 3.03 – 2.84 
(m, 2H), 2.16 (t, J = 2.7 Hz, 1H), 1.33 (td, J = 7.2, 1.0 Hz, 3H).\ 
13C NMR (126 MHz, CDCl3) d ) δ 175.50, 168.70, 134.59, 129.28, 129.03, 128.79, 80.39, 78.45, 
71.08, 62.01, 60.67, 29.80, 20.89, 19.15, 14.21. 
FTIR (AT-IR) 3287.62, 2931.45, 2359.45, 2340.27, 1738.45, 1679.1, 1454.99, 1370.69, 1262.61, 
1228.39, 1190.09, 1081.39, 1019.76, 912.28, 845.00, 795.48, 755.58, 698.22, 667.93 cm–1 







1. 2,6-lutidine (1.0 equiv), 
    BnONH2 (2.0 equiv)
2. AcCl (3 equiv), 
    DIPEA (3 equiv)
(28%, 2 steps)340 341
Formation of protected rac-N-hydroxydihydrophenylalanine 
 
To a solution of 1,5-cyclooctadiene (74 µL, 0.603 mmol) in CH2Cl2 (1.1 mL) was added 
Grubbs II (4.2mg, 0.005 mmol). Stir two minutes. Attach reflux condenser and bring solution to 
40 °C. Slow addition of alkyne (19.4 mg, 0.0671 mmol) over 1.5h. Stir addition 16h. Incomplete 
conversion observed. Added additional Grubbs II (4.2 mg, 0.005 mmol). Stir 14h. Added 
additional Grubbs II (12.6 mg, 0.015 mmol) and 1,5-cyclooctadiene (74 µL, 0.603 mmol). Stir 16h 
at 40 °C. Allow to cool to room temperature. Concentrate and titurate three times with ice-cold 
methanol. Filter methanol solution through celite. Purification by flash chromatography (silica, 
20%EtOAc/Hexanes) provided 342 as a clear oil (4.6 mg, 0.0134mmol, 20% yield)  
1H NMR (400 MHz, CDCl3) δ 7.37 (s, 5H), 5.91 – 5.79 (m, 2H), 5.68 – 5.55 (m, 1H), 4.97 (d, J 
= 10.4 Hz, 2H), 4.86 (d, J = 10.5 Hz, 1H), 4.20 (qd, J = 7.1, 2.1 Hz, 2H), 2.75 (dd, J = 7.6, 1.4 Hz, 
2H), 2.15 – 2.04 (m, 7H), 1.27 (t, J = 7.1 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 174.55, 170.27, 134.78, 131.52, 128.95, 128.76, 128.63, 127.43, 
126.51, 123.62, 77.89, 61.52, 60.70, 34.17, 22.40, 22.15, 20.80, 14.17. 
FTIR (AT-IR) 3031.57, 2929.89, 2871.95, 2822.06, 2361.24, 2340.37, 1738.15, 1677.73, 
1497.43, 1454.30, 1425.97, 1368.64, 1293.30, 1265.01, 1213.72, 1184.55, 1087.66, 1028.46, 
971.50, 911.10, 845.33, 807.08, 735.32, 697.43, 667.87 cm–1 
HRMS (TOF, MM) calc’d for C20H25NO4 [M+H]+ 344.1856, found 344.1866 (ppm=2.91) 
 













Charge a round bottom flask with glyoxylic acid monohydrate (20.0 g, 217 mmol 1.00 equiv), 
hydroxylamine hydrochloride (15.3 g, 220 mmol, 1.01 equiv), pTSA•H2O (3.12 g, 16 mmol, 7.6 
mol%) and ethanol (260 mL). Fit with a Socklett extractor charged with activated 4Å molecular 
sieves and a reflux condenser. Heat the mixture at 120°C for 9 hours. Cool reaction to 
room temperature. Concentrate in vacuo then dilute oil in Et2O (400 mL) and NaHCO3(sat) (240 
mL). Separate organic layer and wash organics with NH4Cl(sat) (100mL) followed by pH=7 buffer 
(100 mL). Test aqueous layer for product and re-extract with Et2O(150 mL), if necessary. Wash 
combined organics with brine(100 mL). Dry over Na2SO4, filter, and concentrate in vacuo to give 
clean SI2-3 (20.9 g, 174 mmol, 82% yield) as a pale yellow oil. Physical and spectral properties 
were consistent with literature values.115  
 
Silylation of ethyl ester oxime 
 
Combine S2 (31.18g, 266 mmol), imidazole(55.76g, 819 mmol) and TBSCl (61.80g, 410 mmol) 
in DMF (). Stir at ambient temperature for 72h. Pour mixture into 6:1 DI:brine (2.1 L). Extract 
with Et2O (1.5L). Wash organic layer with brine(300 mL). Dry over Na2SO4 , filter and 
concentrate in vacuo to yield crude product. Purify by flash chromatography (silica, 3.5-4.5% 
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1H NMR (400 MHz, CDCl3) δ 7.59 (d, J = 1.5 Hz, 1H), 4.27 (qd, J = 7.1, 1.4 Hz, 2H), 1.31 (td, 
J = 7.1, 1.5 Hz, 3H), 0.92 (d, J = 1.9 Hz, 9H), 0.21 (d, J = 1.7 Hz, 6H). 
13C NMR (101 MHz, CDCl3) δ 162.41, 146.20, 61.42, 25.91, 18.18, 14.22, -5.23. 
FTIR (AT-IR)	 2931.13, 2858.75, 1748.31, 1724.71, 1596.54, 1472.39, 1370.02, 1315.12, 
1258.21, 1189.18, 1034.56, 967.56, 835.8, 785.55, 690.19, 667.95 cm–1 
HRMS (TOF, ES+) calc’d for C20H21NO3Si [M+H]+ 232.1363, found 232.1365 (ppm=-0.66) 
 
Formation of iso–propyl ester siloxime 
 
Charge a round bottom flask with glyoxylic acid monohydrate (10.00 g, 109 mmol 1.00 equiv), 
hydroxylamine hydrochloride (7.65 g, 110 mmol, 1.01 equiv), pTSA•H2O (1.56 g, 8.2 mmol, 7.5 
mol %), iso-propanol (108 mL), and benzene (12 mL). Fit with a Dean-Stark trap. Stir the mixture 
at 80°C until mixture is homogeneous. Raise reaction temperature to 115 °C and stir at reflux 19h.  
Cool reaction to room temperature. Concentrate in vacuo then dilute oil in Et2O (200 mL) and 
NaHCO3(sat) (120 mL). Separate organic layer and wash organics with NH4Cl(sat) (50mL) followed 
by pH=7 buffer (50 mL) and brine (50 mL). Dry over Na2SO4, filter, and concentrate in vacuo to 
give clean oxime (12.1 g, 92.2 mmol) as a white solid. Dissolve oxime in DMF (140 mL), cool to 
0 °C. Add TBSCl (20.9g, 138.5 mmol, 1.5 equiv) and imidazole (19.5g, 286.1 mmol, 3.1 equiv). 
Allow reaction to stir at ambient temperature for 24h. Dilute with 6:1 DI H2O:brine (740 mL). 
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2. TBSCl (1.5 equiv),
    imidazole
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(75% yield, 2 steps)
SI2-2 SI2-4
Na2SO4, filter and concentrate to yield crude product. Purification by flash chromatography (silica, 
5→7%EtOAc/Hexanes) provided SI2-4 as a clear oil (20.1g, 81.9 mmol, 75% yield over 2 steps). 
1H NMR (400 MHz, CDCl3) δ 7.54 (d, J = 1.4 Hz, 1H), 5.09 (pd, J = 6.3, 1.2 Hz, 1H), 1.24 (dd, 
J = 6.3, 1.4 Hz, 6H), 0.97 – 0.82 (m, 9H), 0.17 (t, J = 1.5 Hz, 6H). 
13C NMR (101 MHz, CDCl3) δ 161.75, 146.38, 69.02, 25.85, 21.72, 18.07, -5.32. 
FTIR (AT-IR) 2931.17, 2858.84, 1744.61, 1719.90, 1596.43, 1472.16, 1362.77, 1311.40, 
1252.73, 1193.62, 1145.34, 1107.77, 1003.84, 967.44, 836.79, 785.92, 686.88 cm–1 
HRMS (TOF, ES+) calc’d for C21H23NO3Si [M+H]+ 246.1520, found 246.1523 (ppm=-1.23) 
 
Organozinc 1,2-addition into glyoxalate-derived oxime 
 
Suspend dry Zn0 (14.13 g, 224.74 mmol, 2.6 equiv) in THF (400 mL). Add 1,2-dibromoethane 
(0.37 mL, 812 mg, 4.32 mmol, 5 mol %) and TMSCl (0.55 mL, 469 mg, 4.32 mmol, 5 mol %), 
stir at room temperature for 45 min. Add a solution of propargyl bromide, 80%wt in PhMe, (0.20 
mL, 1.80 mmol, 2 mol %). Heat gently until initiation is observed. Add the remainder of propargyl 
bromide, 80 wt% in PhMe, (23.9 mL, 214.57 mmol, 2.58 equiv) dropwise. With addition complete, 
stir 30 min at ambient temperature vigorously, until zinc is no longer consumed. Cannulate fresh 
organozinc into a solution of ethyl 2-(((t-butyldimethylsilyl)oxy)imino)acetate (20.00 g, 86.44 
mmol, 1.0 equiv) in THF (400 mL) chilled to 0 °C, over a three hour period. Upon disappearance 




















salts Et2O(3×200 mL). Wash combined organics with 1:1 DI H2O:brine then brine. Dry over 
Na2SO4, filter and concentrate in vacuo to yield crude product. Purification by flash 
chromatography (silica 500g, 5% EtOAc/Hexanes) yields XX (15.1g, 55.6 mmol, 64% yield) as a 
pale yellow oil. Trace allene S1 was also isolated for characterization. 
1H NMR (400 MHz, CDCl3) δ 5.60 (d, J = 9.5 Hz, 1H), 4.24 (q, J = 7.1 Hz, 
2H), 3.79 – 3.46 (m, 1H), 2.57 (dt, J = 6.4, 2.8 Hz, 2H), 2.02 (t, J = 2.7 Hz, 
1H), 1.29 (t, J = 7.1 Hz, 3H), 0.89 (s, 9H), 0.11 (d, J = 1.2 Hz, 6H). 
13C NMR (101 MHz, CDCl3) δ 171.77, 79.37, 70.86, 63.89, 61.25, 26.21, 19.37, 18.01, 14.34, -
5.43, -5.49. 
FTIR (AT-IR)	 3313.49, 2929.08, 2856.83, 2361.12, 2340.34, 1738.61, 1472.12, 1370.05, 
1342.99, 1248.41, 1215.41, 1186.14, 1054.34, 904.00, 834.61, 780.54, 667.96 cm–1 
HRMS (TOF, ES+) calc’d for C13H26NO3 [M+H]+ 272.1676, found 272.1673(ppm=-1.28) 
[a]D
23 –18.0° (c = 1.0, CHCl3).  
1H NMR (400 MHz, CDCl3) δ 5.48 (d, J = 10.6 Hz, 1H), 5.12 (q, J = 6.8 Hz, 
1H), 4.80 (dd, J = 6.7, 2.5 Hz, 2H), 4.18 (qd, J = 7.1, 0.9 Hz, 2H), 3.98 (ddt, J 
= 9.8, 7.0, 2.3 Hz, 1H), 1.23 (t, J = 7.1 Hz, 3H), 0.84 (d, J = 1.1 Hz, 9H), 0.05 
(d, J = 1.0 Hz, 6H). 
13C NMR (101 MHz, CDCl3) δ 209.30, 171.64, 85.51, 77.47, 64.67, 64.64, 61.08, 26.19, 26.15, 
26.13, 17.96, 14.34, 14.30, -5.49, -5.53, -5.57. 
 FTIR (AT-IR) 2929.12, 2856.96, 1957.66, 1741.62, 1472.28, 1390.00, 1368.67, 1301.88, 
1247.48, 1183.61, 1043.73, 832.33, 779.68, 666.29 cm-1 
HRMS (TOF, ES+) calc’d for C11H25NO3Si [M+H]+ 272.1676, found 272.1686 (ppm=3.67) 










Suspend Zn0 (3.47 g, 52.99 mmol, 2.6 equiv) in THF (100 mL). Add TMSCl (0.13 mL, 111 mg, 
1.02 mmol, 5 mol %) followed by 1,2-dibromoethane (0.9 mL, 192 mg, 1.02 mmol, 5 mol %) and 
stir at ambient temperature for 10 minutes. Add propargyl bromide, 80 wt% in PhMe, (0.2 mL, 
1.80 mmol, 9 mol %) and heat mixture slightly to initiate organozinc formation. Add the remainder 
of propargyl bromide, 80 wt% in PhMe, (5.47 mL, 49.11 mmol, 2.41 equiv) dropwise. After 
addition is complete stir an additional 25 minutes. Chill a solution of siloxime (5.00g, 20.38 mmol, 
1.0 equiv) in THF (100 mL) to 0 °C. Cannulate the previously prepared organozinc solution 
dropwise over one hour. Quench reaction with NaHCO3(aq) (47 mL). Filter off precipitate through 
sand. Rinse retained salts with Et2O (3×50 mL). Wash combined organic layer with NaHCO3(aq) 
(3×150 mL) then brine (50 mL). Dry organic phase over Na2SO4, filter and concentrate. Purify by 
flash chromatography (silica, 5	→20% Et2O/Hexanes) to yield SI2-6 (4.49g, 15.7 mmol, 77% 
yield) as a clear oil. 
1H NMR (400 MHz, CDCl3) δ 5.60 (s, 1H), 5.12 (p, J = 6.3 Hz, 1H), 3.59 (d, J = 6.4 Hz, 1H), 
2.72 – 2.38 (m, 2H), 2.01 (t, J = 2.7 Hz, 1H), 1.27 (dd, J = 6.3, 2.7 Hz, 6H), 0.88 (s, 9H), 0.11 (d, 
J = 0.6 Hz, 6H). 
13C NMR (101 MHz, CDCl3) δ 171.39, 79.44, 70.76, 68.86, 64.01, 26.20, 21.90, 19.32, 17.98,       
-5.42, -5.51. 
FTIR (AT-IR)	 3314.32, 2956.64, 2929.43, 2885.87, 2857.05, 1732.83, 1472.12, 1387.98, 
1374.66, 1361.80, 1325.04, 1248.31, 1221.75, 1190.63, 1145.40, 1106.94, 1054.85, 1006.08, 















HRMS (TOF, ES+) calc’d for C14H27NO3Si [M+H]+ 286.1833, found 286.1830 (ppm=1.04) 
 
Benzoylation of N-siloxyamino ethyl ester 
 
To a solution of substrate (3.99 g, 14.70 mmol, 1.0 equiv) in MeCN (14.7 mL) add DIPEA (5.13 
mL, 3.80 g, 29.40 mmol, 2.0 equiv) and benzoyl chloride (2.99 mL, 3.62 g, 25.73 mmol, 1.75 
equiv) at ambient temperature and stir 30 minutes. Heat mixture to 40 °C stirring vigorously for 7 
hours. Dilute in Et2O (140 mL) and wash organics with with pH=7 phosphate buffer (30 mL), then 
brine (30 mL). Dry organic layer with Na2SO4, filter through celite, and concentrate. Purify by 
flash chromatography (florisil, 20% Et2O/Hexanes) to yield 345 (5.5g, 14.65 mmol, >95% yield) 
as pale white crystals. 
SFC analysis (IC, 5% i-PrOH in CO2) peak 1(major): 6.748 min; peak 2(minor): 8.324 min; 94% 
ee 
1H NMR (400 MHz, CDCl3) δ 7.76 – 7.65 (m, 2H), 7.53 – 7.35 (m, 3H), 4.65 (dd, J = 10.5, 4.5 
Hz, 1H), 4.21 (qdd, J = 10.7, 7.0, 3.6 Hz, 2H), 2.97 (ddd, J = 17.4, 10.6, 2.7 Hz, 1H), 2.89 – 2.70 
(m, 1H), 2.14 (t, J = 2.7 Hz, 1H), 1.30 (t, J = 7.1 Hz, 3H), 0.95 (s, 9H), 0.30 (s, 3H), 0.21 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ 173.13, 168.28, 134.61, 131.05, 128.59, 128.48, 80.35, 71.70, 
63.97, 62.11, 26.18, 18.58, 14.31, -4.31, -4.51. 
FTIR (AT-IR)	 3310.03, 2929.56, 2857.22, 2359.18, 1744.02, 1694.62, 1472.02, 1446.93, 
1390.26, 1362.25, 1289.85, 1250.00, 1226.16, 1186.10, 1072.43, 1017.66, 964.62, 920.36, 831.69, 













DMAP (10 mol %)
MeCN, 40 °C
(>95% yield)
HRMS (TOF, ES+) calc’d for C20H30NO4Si [M+H]+ 376.1939, found 376.1934 
[a]D
23 –89.9° (c=1.0, CHCl3) 
 
Benzoylation of N-siloxyamino iso-propyl ester 
 
Dissolve SI2-6 (4.49g, 15.71 mmol, 1.0 equiv) in THF (60 mL). Add pyridine (6.40 mL, 6.21 g, 
78.55 mmol, 5 equiv) followed by benzoyl chloride (4.60 mL, 5.52 g, 39.28 mmol, 2.5 equiv) and 
DMAP (1.92 g, 15.71 mmol, 1.0 equiv). Wash the sides of flask with THF (90 mL). Heat mixture 
to reflux and stir 27h. Cool reaction to ambient temperature and dilute in Et2O (200 mL). Wash 
crude mixture with dilute citric acid (150 mL), pH=7 phosphate buffer (150 mL), and brine (150 
mL). Dry organic layer with Na2SO4, filter, and concentrate to yield crude product. A two stage 
purification by flash chromatography (silica, 5→12% EtOAc/Hexanes; then, fluorosil, 5→100% 
Et2O/Hexanes) yields SI2-7 (3.55g, 9.11 mmol, 58% yield) as a white solid. 
1H NMR (500 MHz, CDCl3) δ 5.60 (d, J = 9.6 Hz, 1H), 5.12 (p, J = 6.2 Hz, 1H), 3.59 (dt, J = 
9.6, 6.4 Hz, 1H), 2.65 – 2.46 (m, 2H), 2.01 (t, J = 2.7 Hz, 1H), 1.27 (dd, J = 6.3, 3.5 Hz, 6H), 
0.88 (s, 9H), 0.10 (d, J = 0.9 Hz, 6H). 
13C NMR (101 MHz, CDCl3) δ 173.54, 167.71, 134.70, 130.99, 128.52, 128.43, 80.57, 71.61, 
70.05, 64.08, 26.15, 21.89, 21.83, 18.77, 18.53, -4.45, -4.46. 
FTIR (AT-IR)	2930.02, 2857.32, 1739.8, 1698.57, 1471.80, 1447.34, 1375.01, 1361.30, 1288.72, 













HRMS (TOF, ES+) calc’d for C21H31NO4Si [M+H]+ 390.2095, found 390.2090 (ppm=1.31) 
 
Acylation of N-siloxyamino ethyl ester 
 
Add pyridine (1.48 mL, 1.46 g, 18.42 mmol, 5.0 equiv) and DMAP (450 mg, 3.83 mmol, 0.96 
equiv) to solution of 344 (1.04 g, 3.83 mmol, 1.0 equiv) in THF (60 mL). Add acetyl chloride (1.31 
mL, 1.45 g, 18.42 mmol, 5.0 equiv) and stir vigorously at ambient temperature for 18h. Dilute in 
Et2O (50 mL) and wash with pH=7 phosphate buffer (50mL) then brine (50 mL). Dry organic 
phase over Na2SO4, filter and concentrate gave SI2-8 (1.18 g, 3.76 mmol, 98% yield) as a pale-
yellow oil with no further purification necessary. 
1H NMR (400 MHz, CDCl3) δ 4.56 (t, J = 7.5 Hz, 1H), 4.21 (q, J = 7.1 Hz, 2H), 3.01 – 2.83 (m, 
2H), 2.16 (s, 3H), 2.02 (t, J = 2.7 Hz, 1H), 1.27 (t, J = 7.1 Hz, 3H), 0.96 (s, 9H), 0.29 (s, 3H), 
0.24 (s, 3H). 
13C NMR (126 MHz, CDCl3) δ 176.42, 168.14, 80.35, 70.42, 63.61, 61.72, 25.80, 21.52, 18.68, 
17.93, 14.08, -4.51, -4.76. 
FTIR (AT-IR)	 3282.17, 2930.95, 2858.52, 2361.30, 1742.64, 1674.63, 1472.78, 1463.68, 
1367.92, 1253.56, 1185.00, 1080.68, 1018.10, 983.77, 965.14, 938.25, 833.87, 784.10, 667.99 cm–
1 
HRMS (TOF, ES+)  calc’d for C15H27NO4Si [M+H]+ 314.1782, found 314.1780 (ppm=0.67) 
 











Add pyridine (0.45mL, 439 mg, 5.55 mmol, 5.0 equiv) and DMAP (27.1mg, 0.22 mmol, 0.20 
equiv) to solution substrate (300mg, 1.11mmol, 1.0 equiv) in THF (15mL). Add chloroacetyl 
chloride (0.13 mL, 188.6 mg, 1.67 mmol, 1.5 equiv) and stir vigorously at ambient temperature 
for 5h. Dilute in Et2O (50 mL) and wash with pH=7 phosphate buffer (50mL) then brine (50 mL). 
Dry organic phase over Na2SO4, filter and concentrate. Purification by flash chromatography 
(florisil, 20% EtOAc/Hexanes) provided SI2-9 as a pale oil (347 mg, 0.0XXmmol, 90% yield). 
1H NMR (400 MHz, CDCl3) δ 4.56 – 4.42 (m, 1H), 4.36 – 4.24 (m, 2H), 4.21 (q, J = 7.1 Hz, 2H), 
3.13 – 2.79 (m, 2H), 2.03 (t, J = 2.6 Hz, 1H), 1.26 (td, J = 7.1, 0.9 Hz, 3H), 0.95 (s, 9H), 0.30 (s, 
3H), 0.26 (s, 3H).  
13C NMR (101 MHz, CDCl3) δ 170.71, 166.64, 79.03, 70.06, 63.97, 61.21, 41.63, 24.81, 18.02, 
17.08, 13.17, -5.42, -5.75. 
FTIR (AT-IR)	 3303.84, 2931.44, 2859.45, 2361.24, 1742.56, 1683.23, 1472.71, 1367.63, 
1318.42, 1254.23, 1187.67, 1016.74, 959.4, 938.47, 835.12, 784.06, 667.94 cm–1 


















Solvate Mes-HG-II (692 mg, 1.103 mmol, 7.5 mol%) stored in the glovebox in benzene (55 mL). 
Maintain an Ar atmosphere. Add distilled and degassed 1,5-cyclooctadiene (18.0 mL, 15.90 g, 
147.0 mmol, 10 equiv), stir five minutes. Concurrently, both a solution of 336 (5.50 g, 14.70 mmol, 
1.0 equiv) in benzene (360 mL) and a solution of Mes-HG-II (461 mg, 0.735 mmol, 5 mol%) in 
benzene (10.6 mL) were added by syringe pumps over 12h. Stir at room temperature for 2h. 
Concentrate the crude reaction onto celite (50 g) overnight. Purify by flash chromatography (silica 
150 g, 10→20% Et2O/Hexanes). Concentrate to an oil and dilute in cold MeCN (50 mL). Filter 
off precipitate with celite and wash the celite pad twice with cold MeCN (50 mL). Concentrate to 
yield 346a (6.09 g, 14.2 mmol, 96% yield) a beige oil. 
1H NMR (400 MHz, CDCl3) δ 7.56 (dt, J = 6.8, 1.5 Hz, 2H), 7.45 – 7.37 (m, 1H), 7.37 (s, 2H), 
5.79 (dd, J = 9.5, 4.3 Hz, 1H), 5.70 – 5.54 (m, 2H), 4.45 (dd, J = 10.1, 4.4 Hz, 1H), 4.32 – 4.13 
(m, 3H), 2.85 (dd, J = 14.2, 10.1 Hz, 1H), 2.60 (d, J = 14.1 Hz, 1H), 2.15 – 2.09 (m, 4H), 1.33 (t, 
J = 7.1 Hz, 4H), 0.92 (s, 10H), 0.29 (s, 3H), 0.13 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ 170.80, 169.47, 134.72, 131.16, 130.60, 129.83, 128.26, 127.25, 
126.70, 124.77, 64.74, 61.74, 33.61, 26.19, 22.55, 22.19, 18.87, 14.29, -3.86, -4.52. 
FTIR (AT-IR) 2929.77, 2857.11, 2359.5, 2340.28, 1742.71, 1653.06, 1471.97, 1447.06, 1249.13, 
1183.09, 1019.33, 969.71, 919.13, 826.95, 783.52, 735.42, 700.25, 667.9 cm-1 
HRMS (TOF, ES+) calc’d for C24H35NO4Si [M+H]+ 430.2408, found 430.2395 (ppm=3.05) 
 
 














Solvate Mes-HG-II (60.2 mg, 0.096 mmol, 7.5 mol%) stored in the glovebox in benzene(5 mL). 
Maintain an Ar atmosphere. Add distilled and degassed 1,5-cyclooctadiene (1.57 mL, 1.38 g, 12.80 
mmol, 10 equiv). Concurrently, both a solution of SI2-7 (500 mg, 1.28 mmol, 1 equiv) in benzene 
(25 mL) and a solution of Mes-HG-II (45 mg, 0.072 mmol, 5 mol%) in benzene (2 mL) were added 
by syringe pumps over 7h50m. Stir at room temperature for 2h. Concentrate the crude reaction 
onto celite overnight. Purify by flash chromatography (silica, 5→27.5% Et2O/Hexanes) 
concentrate to product with trace impurities. Filter off precipitate with celite pad, wash with 
CH2Cl2 and concentrate to yield pure 346b (546.8 mg, 1.23 mmol, 96% yield) as a pale oil. 
1H NMR (500 MHz, CDCl3) δ 7.60 – 7.49 (m, 2H), 7.43 – 7.37 (m, 1H), 7.36 – 7.30 (m, 2H), 5.80 
(dd, J = 9.4, 4.4 Hz, 1H), 5.68 (s, 1H), 5.62 (h, J = 1.7 Hz, 1H), 5.05 (p, J = 6.3 Hz, 1H), 4.36 (dd, 
J = 9.9, 4.6 Hz, 1H), 2.81 (dd, J = 14.2, 9.9 Hz, 1H), 2.62 (dd, J = 14.4, 4.5 Hz, 1H), 2.12 (dtd, J = 
5.4, 3.8, 1.6 Hz, 4H), 1.29 (d, J = 6.2 Hz, 3H), 1.27 (d, J = 6.3 Hz, 3H), 0.97 – 0.86 (m, 9H), 0.21 
(d, J = 61.6 Hz, 6H). 
13C NMR (126 MHz, CDCl3) δ 171.19, 168.82, 134.81, 131.41, 130.56, 128.23, 127.24, 126.82, 
124.54, 69.52, 64.97, 33.70, 26.24, 22.54, 22.24, 21.96, 21.94, 18.89, -3.94, -4.24.  
FTIR (AT-IR) 2929.39, 2856.62, 2359.77, 2340.47, 1739.64, 1661.23, 1579.37, 1471.53, 
1447.32, 1386.82, 1374.19, 1360.95, 1248.97, 1179.95, 1144.34, 1106.04, 990.36, 960.89, 918.86, 
827.13, 783.07, 733.48, 700.54, 667.71 cm-1 
HRMS (TOF, ES+) calc’d for C25H37NO4Si [M+H]+ 444.2565, found 444.2565 (ppm=0.00) 
 













Solvate Mes-HG-II (176.7 mg, 0.282 mmol, 7.5 mol%) stored in the glovebox in benzene(14 mL). 
Maintain an Ar atmosphere. Add distilled and degassed 1,5-cyclooctadiene (4.62 mL, 4.07g, 37.64 
mmol, 10 equiv), stirring vigorously (700 rpm). Concurrently, both a solution of SI2-8 (1.18g, 
3.76mmol, 1 equiv) in benzene (90 mL) and a solution of Mes-HG-II (117.8 mg, 0.188 mmol, 5 
mol%) in benzene (3.5 mL) were added by syringe pumps over 10h. Stir at room temperature for 
3h. Concentrate the crude reaction onto celite overnight. Purify by flash chromatography (silica, 
7.5→10% EtOAc/Hexanes). Add P(CH2CH2OH)3 (1.16g, 20 equiv) to product-contained fractions 
along with silica and was sonicate until the combined solution is clear. Filter the solution was then 
and concentrate to yield 346c (991mg, 2.70 mmol, 72% yield) a clear oil. 
1H NMR (500 MHz, CDCl3) δ 5.81 (d, J = 1.3 Hz, 2H), 5.58 (d, J = 4.5 Hz, 1H), 4.47 (s, 1H), 4.26 
– 4.08 (m, 2H), 2.78 (ddd, J = 14.2, 10.3, 0.9 Hz, 1H), 2.65 (dd, J = 14.4, 4.8 Hz, 1H), 2.10 – 2.04 
(m, 7H), 1.27 (t, J = 7.1 Hz, 3H), 0.94 (s, 9H), 0.26 (s, 3H), 0.18 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ 175.10, 169.64, 131.84, 127.11, 126.84, 123.88, 64.01, 61.53, 
33.64, 25.97, 22.52, 22.24, 21.62, 18.07, 14.22, -4.53. 
FTIR (AT-IR) 2930.65, 2857.62, 2359.56, 2340.27, 1742.48, 1667.8, 1367.59, 1252.92, 1031.68, 
832.83, 783.93, 667.92 cm-1 
HRMS (TOF, ES+) calc’d for C19H33NO4Si [M+H]+ 368.2252, found 368.2253 (ppm=–0.38) 
 
 














Solvate Mes-HG-II(47.0 mg, 0.075 mmol, 0.075 equiv) stored in the glovebox in argon–degassed 
benzene (3.5 mL). Maintain an Ar atmosphere. Add distilled and degassed 1,5-cyclooctadiene 
(1.22 mL, 1.08g, 9.98 mmol, 10 equiv), stirring vigorously (700 rpm). Concurrently, both a 
solution of alkyne (347.1 mg, 0.998mmol, 1 equiv) in benzene (24 mL) and a solution of Mes-
HG-II (31.3 mg, 0.050 mmol, 0.05 equiv) in benzene (1.0mL) were added by syringe pumps over 
10h. Stir at room temperature for 3h. Concentrate the crude reaction onto celite overnight. Purify 
by flash chromatography (silica, 7.5→10% EtOAc/Hexanes). Yields SI2-9 (296 mg, 74% yield) 
as a pale oil. 
1H NMR (500 MHz, CDCl3) δ 5.86 – 5.76 (m, 2H), 5.58 (d, J = 4.5 Hz, 1H), 4.39 (dd, J = 10.6, 
4.7 Hz, 1H), 4.30 – 4.11 (m, 4H), 2.85 (dd, J = 14.2, 10.6 Hz, 1H), 2.72 – 2.60 (m, 1H), 2.13 – 
2.01 (m, 4H), 1.26 (t, J = 7.1 Hz, 3H), 0.92 (s, 9H), 0.25 (s, 3H), 0.19 (s, 3H).  
13C NMR (126 MHz, CDCl3) δ 170.52, 169.01, 131.54, 127.46, 126.63, 124.35, 65.63, 61.83, 
42.77, 33.83, 25.82, 22.47, 22.21, 17.97, 14.20, -4.68. 
FTIR (AT-IR) 2931.1, 2859.38, 2361.15, 2340.18, 1742.03, 1673.54, 1472.41, 1463.48, 1391.13, 
1364.3, 1318.5, 1251.92, 1213.32, 1184.41, 1083.27, 1017.52, 912.03, 836.04, 783.58, 731.43, 
668.09, 646.92 cm-1 
HRMS (TOF, ES+) calc’d for C19H32ClNO4Si [M+H]+ 402.1862, found 402.1862 (ppm=-0.03) 
 
 

















Add MeSO3H (0.23mL, 325mg, 3.49 mmol, 0.5 equiv) to substrate () under argon in wet MeCN 
(350 mL) and begin cool to –35 °C. Sparge reaction with O2 and add Cu(TMEDA)2(BF4)2 (0.0349 
mmol, 0.05 equiv) as a solution in MeCN (1 mL).  Note: Cu(TMEDA)2(BF4)2 made by dissolving 
Cu(BF4)2•xH2O (20 wt% Cu) (111 mg, 0.349 mmol, 0.05 equiv) and TMEDA (0.10 mL, 81 mg, 
0.10 equiv) in MeCN(1 mL). Continue cooling to –45 °C. Stop O2 sparge after 10 minutes at –45 
°C. Slowly allow reaction return to room temperature. Add acetic anhydride (3.84 mL, 4.16 g, 
40.48 mmol, 6.0 equiv), stir 1 minute then add pyridine (0.54 mL, 534 mg, 6.75 mmol, 1 equiv) 
allow to stir under air overnight. Dilute with EtOAc (350 mL) wash with an aqueous solution (357 
mL) composed of EDTA pH=9 buffer (7 mL), DI H2O (175mL) and brine (175mL). Wash organic 
with additional brine (50 mL). Extract combined aqueous layer with EtOAc (2x100mL). Dry 
combined organic layers over Na2SO4, filter and concentrate. Separate crude material on silica 
(215 g) with 40% EtOAc in Hexanes. 1.512g total product isolated (4.59 mmol, 69% yield)  
351a-syn: 1H NMR (400 MHz, CDCl3) δ 7.78 (d, J = 7.6 Hz, 2H), 7.57 – 
7.49 (m, 1H), 7.45 (ddt, J = 8.3, 6.6, 1.3 Hz, 2H), 6.02 (d, J = 2.3 Hz, 1H), 
5.54 (s, 1H), 4.62 (s, 1H), 4.26 (q, J = 7.2 Hz, 2H), 3.16 (d, J = 15.7 Hz, 
1H), 2.96 (dd, J = 15.8, 7.0 Hz, 1H), 2.51 (d, J = 16.7 Hz, 1H), 2.30 (td, J = 16.5, 15.9, 5.0 Hz, 
1H), 2.13 (d, J = 23.1 Hz, 1H), 1.97 – 1.80 (m, 1H), 1.29 (t, J = 7.2 Hz, 4H). 
13C NMR (101 MHz, CDCl3) δ 196.87, 170.20, 168.39, 153.52, 132.54, 131.83, 128.94, 128.27, 





2. Cu(TMEDA)2(BF4)2 (5 mol%), O2
3. Ac2O(3 equiv), pyridine (2 equiv)












FTIR (AT-IR)	 2979.74, 2359.59, 1738.00, 1667.46, 1600.60, 1578.10, 1447.41, 1387.71, 
1364.39, 1316.29, 1254.3, 1197.39, 1139.88, 1077.16, 1027.25, 975.89, 899.81, 871.89, 789.33, 
758.51, 706.03, 617.25 cm-1 
HRMS (TOF, ES+) calc’d for C18H19NO5 [M+H]+ 330.1336, found 330.1337 (ppm=-0.31) 
351a-anti: 
1H NMR (400 MHz, CDCl3) δ 7.80 (dt, J = 8.5, 1.6 Hz, 2H), 7.53 – 7.46 
(m, 1H), 7.46 – 7.38 (m, 2H), 6.02 – 5.93 (m, 1H), 4.99 (dd, J = 9.6, 7.6 
Hz, 1H), 4.76 (t, J = 8.3 Hz, 1H), 4.36 – 4.22 (m, 2H), 3.14 – 2.96 (m, 2H), 2.53 – 2.44 (m, 1H), 
2.33 – 2.14 (m, 1H), 1.89 (ddd, J = 9.7, 8.0, 5.0 Hz, 2H), 1.35 – 1.29 (m, 3H). 
1H NMR (500 MHz, CDCl3) δ 7.82 – 7.77 (m, 2H), 7.52 – 7.46 (m, 1H), 7.45 – 7.39 (m, 2H), 
6.01 – 5.96 (m, 1H), 4.98 (dd, J = 9.6, 7.5 Hz, 1H), 4.81 – 4.68 (m, 1H), 4.28 (q, J = 7.1 Hz, 2H), 
3.10 – 2.95 (m, 2H), 2.49 (dddd, J = 17.2, 4.4, 2.9, 1.2 Hz, 1H), 2.31 – 2.19 (m, 1H), 1.97 – 1.80 
(m, 2H), 1.31 (t, J = 7.1 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 196.64, 170.15, 168.93, 157.09, 132.65, 131.60, 129.22, 128.10, 
127.77, 80.96, 62.26, 58.14, 35.41, 30.86, 27.55, 14.28. 
FTIR (AT-IR) 2359.53, 2340.23, 1729.8, 1637.97, 1577.29, 1448.88, 1394.9, 1300.99, 1245.96, 
1199.42, 1098.44, 1008.47, 981.15, 962.42, 904.15, 844.43, 790.7, 736.73, 707.82, 667.97, 635.45 
cm-1 










Copper–catalyzed oxidative cyclization of benzoylated diene iso-propyl ester 
 
Add MeSO3H (24 µL, 35.6 mg, 3.49 mmol, 0.5 equiv) to 346b (329 mg, 0.741 mmol) under argon 
in wet MeCN (35 mL) and begin cool to –35 °C. Sparge reaction with O2 and add 
Cu(TMEDA)2(BF4)2 (0.0349 mmol, 0.05 equiv) as a solution in MeCN (1 mL).  Note: 
Cu(TMEDA)2(BF4)2 made by dissolving Cu(BF4)2•xH2O (20 wt% Cu) (12 mg, 0.0.0371 mmol, 
0.05 equiv) and TMEDA (11 µL, 8.6 mg, 0.0742 mmol, 0.10 equiv) in MeCN (2 mL). Continue 
cooling to –45 °C. Stop O2 sparge after 10 minutes but continue stirring at –45 °C for 2h. Slowly 
allow reaction return to room temperature. Add acetic anhydride (0.21 mL, 229 mg, 40.48 mmol, 
3.0 equiv), stir 1 minute then add pyridine (60 µL, 58.6 mg, 6.75 mmol, 2 equiv) allow to stir under 
air overnight. Dilute with EtOAc (35 mL) wash with an aqueous solution (35 mL) composed of 
EDTA pH=9 buffer (0.7 mL), DI H2O (17.5mL) and brine (17.5mL). Wash organic with additional 
brine (5 mL). Extract combined aqueous layer with EtOAc (2x100mL). Dry combined organic 
layers over Na2SO4, filter and concentrate. Separate crude material on silica with 40% EtOAc in 
Hexanes. 156.7 mg total product isolated (0.456 mmol, 62% yield, 5:1 dr)  
1H NMR (500 MHz, CDCl3) δ 7.75 (d, J = 7.7 Hz, 2H), 7.53 – 7.47 (m, 1H), 7.46 – 7.39 (m, 2H), 
5.99 (dt, J = 2.2, 1.2 Hz, 1H), 5.51 (d, J = 20.8 Hz, 1H), 5.07 (p, J = 6.3 Hz, 1H), 4.60 (s, 1H), 3.12 
(d, J = 15.7 Hz, 1H), 3.00 – 2.81 (m, 1H), 2.55 – 2.40 (m, 1H), 2.28 (td, J = 16.4, 15.9, 4.9 Hz, 
1H), 2.21 – 2.04 (m, 1H), 1.86 (t, J = 13.9 Hz, 1H), 1.24 (d, J = 6.1 Hz, 6H). 
13C NMR (126 MHz, CDCl3) δ 196.87, 170.15, 167.72, 153.70, 132.56, 131.68, 128.81, 128.16, 














2. Cu(TMEDA)2(BF4)2 (5 mol%), O2
3. Ac2O(3 equiv), pyridine (2 equiv)
FTIR (AT-IR)	 2980.74, 2250.35, 1733.31, 1668.08, 1600.87, 1578.34, 1447.99, 1386.42, 
1374.01, 1312.85, 1253.98, 1200.97, 1143.54, 1103.75, 1018.30, 976.54, 899.45, 823.75, 788.51, 
728.2, 706.22, 646.73 cm-1 
HRMS (TOF, ES+) calc’d for C19H21NO5 [M+H]+ 344.1492, found 344.1494 (ppm=-0.44)  
 
Copper–catalyzed oxidative cyclization of acylated diene ethyl ester 
 
Add MeSO3H (18 µL, 26.1 mg, 0.272 mmol, 0.5 equiv) in MeCN (0.5 mL) to 346c (200 mg, 0.544 
mmol, 1.0 equiv) under argon in wet MeCN (26 mL) and begin cool to –35 °C. Sparge reaction 
with O2 and add Cu(TMEDA)2(BF4)2 (0.00.136 mmol, 0.05 equiv) as a solution in MeCN (0.5 
mL).  Note: Cu(TMEDA)2(BF4)2 made by dissolving Cu(BF4)2•xH2O (20 wt% Cu) (4.3 mg, 
0.0.0136 mmol, 0.05 equiv) and TMEDA (4 µL, 3.2 mg, 0.0272 mmol, 0.10 equiv) in MeCN (0.5 
mL). Continue cooling to –45 °C. Stop O2 sparge after 10 minutes but continue stirring at –45 °C 
for 2h. Slowly allow reaction return to room temperature. Add acetic anhydride (0.16 mL, 168 mg, 
1.632 mmol, 3.0 equiv), stir 1 minute then add pyridine (44 µL, 43 mg, 0.544 mmol, 1 equiv) allow 
to stir under air overnight. Dilute with EtOAc (20 mL) wash with an aqueous solution (35 mL) 
composed of EDTA pH=9 buffer (10 mL), DI H2O (5mL) and brine (5 mL). Extract combined 
aqueous with EOAc (10 mL) Wash combined organics with additional brine (20 mL). Dry 
combined organic layers over Na2SO4, filter and concentrate. Purify crude material by flash 
chromatography on silica with 100% Et2O then 75% to 100%EtOAc/Hexanes. 90 mg total product 










MeSO3H (0.5 equiv), Ar; then
Cu(TMEDA)2(BF4)2 (2.5 mol%), O2;
then Ac2O (3 equiv)
pyridine (1 equiv)
MeCN, –45 to 23 °C
62%, 13:1 dr
346c 363c
1H NMR (600 MHz, CDCl3) δ 6.01 (q, J = 1.5 Hz, 1H), 5.41 (dd, J = 7.2, 1.4 Hz, 1H), 4.68 (dd, 
J = 10.7, 5.1 Hz, 1H), 4.27 – 4.15 (m, 2H), 3.11 (ddt, J = 15.7, 1.5, 0.7 Hz, 1H), 2.84 (dddd, J = 
15.7, 7.2, 2.5, 1.6 Hz, 1H), 2.63 – 2.55 (m, 1H), 2.41 – 2.33 (m, 2H), 2.25 (s, 3H), 1.98 (dddd, J = 
16.2, 14.1, 9.0, 3.3 Hz, 1H), 1.26 (td, J = 7.1, 1.0 Hz, 4H). 
13C NMR (126 MHz, CDCl3) δ 196.79, 171.44, 168.28, 153.41, 127.93, 78.79, 62.19, 53.60, 
35.02, 31.50, 26.38, 20.30, 14.26. 
FTIR (AT-IR)	 2931.38, 2360.54, 1737.83, 1668.55, 1402.03, 1368.95, 1314.81, 1256.65, 
1198.38, 1026.43, 975.46, 945.41, 900.55, 725.65 cm-1 
HRMS (TOF, ES+) calc’d for C13H17NO5 [M+H]+ 268.1179, found 268.1180 (ppm=-0.19)  
 
Copper–catalyzed oxidative cyclization of chloroacylated diene ethyl ester 
 
Add MeSO3H (0.99 mL, 1.47 g, 15.25 mmol, 0.75 equiv) in MeCN (5 mL) to 346c (8.11 g, 20.17 
mmol, 1.0 equiv) under argon in wet MeCN (1.0 L) and begin cool to –35 °C. Sparge reaction with 
O2 and add Cu(TMEDA)2(BF4)2 (1.01 mmol, 0.05 equiv) as a solution in MeCN (5 mL).  Note: 
Cu(TMEDA)2(BF4)2 made by dissolving Cu(BF4)2•xH2O (20 wt% Cu) (320.9 mg, 0.101 mmol, 
0.05 equiv) and TMEDA (0.30 mL, 235 mg, 2.02 mmol, 0.10 equiv) in MeCN (5 mL). Continue 
cooling to –45 °C. Stop O2 sparge after 10 minutes but continue stirring at –45 °C for 2h. Slowly 
allow reaction return to room temperature overnight. Add acetic anhydride (5.75 mL, 6.23 g, 60.51 
mmol, 3.0 equiv), stir 1 minute then add pyridine (2.97  mL, 2.91 g, 36.87 mmol, 1.8 equiv) allow 
to stir under air overnight. Dilute with EtOAc (700 mL) wash twice with EDTA pH=9 buffer (100 
N
CO2i-Pr










2. Cu(TMEDA)2(BF4)2 (5 mol%), O2





mL), then brine (500 mL). Dry combined organic layers over Na2SO4, filter and concentrate. Purify 
crude material by flash chromatography on silica with 75% to 100%EtOAc/Hexanes. Syn-
diastereomer recover exclusively (3.6 g, 11.9 mmol, 59% yield, >13:1 dr)  
1H NMR (500 MHz, CDCl3) δ 6.00 (q, J = 1.4 Hz, 1H), 5.33 (dd, J = 7.3, 1.4 Hz, 1H), 4.83 – 4.78 
(m, 1H), 4.42 (d, J = 13.3 Hz, 1H), 4.21 (tt, J = 7.1, 3.7 Hz, 2H), 4.17 (d, J = 13.3 Hz, 1H), 3.13 
(ddt, J = 15.7, 1.5, 0.8 Hz, 1H), 2.88 (dddd, J = 15.7, 7.2, 2.5, 1.6 Hz, 1H), 2.61 – 2.52 (m, 1H), 
2.43 – 2.33 (m, 2H), 2.02 – 1.89 (m, 1H), 1.24 (t, J = 7.1 Hz, 3H). 
13C NMR (126 MHz, CDCl3) δ 196.61, 167.61, 167.13, 152.49, 128.11, 79.24, 62.44, 54.24, 
40.77, 34.93, 31.25, 26.14, 14.22. 
FTIR (AT-IR) 2960.8 0, 2358.75, 1738.21, 1669.87, 1414.36, 1367.74, 1329.02, 1239.72, 
1189.30, 1094.68, 1024.45, 976.25, 955.89, 902.07, 858.34, 790.90, 767.92, 727.65, 667.80, 
646.77 cm-1 
HRMS (TOF, ES+) calc’d for C13H16ClNO5 [M+H]+ 302.0790, found 302.0789 (ppm=0.25) 
 
Deprotection of chloroacylated bicyclic tetrahydro-1,2-oxazine  
 
Add KHCO3 (49.8mg, 0.497 mmol, 1.0 equiv) and XX (150 mg, 0.497 mmol, 1 equiv) to dried 
EtOH (5mL). Add N-piperidyl thiocarboxamide (86 mg, 0.597 mmol, 1.0 equiv) to) and sparge 




















phosphate buffer:brine (1:1), Extract with EtOAc then four times with 10% i-PrOH CH2Cl2. Dry 
organic layer over Na2SO4, filter, and concentrate in vacuo to yield crude product. Purification by 
filtering through a florisil plug (75% EtOAc/Hexanes) followed by flash chromatography (silica, 
2%NEt3/5%EtOAc/50%CH2Cl2/Hexanes) provided 397 as a pale brown oil with an intractable 
impurity (31 mg, 0.138mmol, ~53% yield). 
1H NMR (400 MHz, CDCl3) δ 6.70 – 6.07 (m, 1H), 5.88 (dd, J = 2.7, 1.4 Hz, 1H), 5.83 (s, 1H), 
4.59 (dt, J = 10.8, 3.4 Hz, 1H), 4.21 (dddd, J = 17.9, 10.7, 7.2, 3.6 Hz, 2H), 3.81 (dd, J = 6.2, 1.9 
Hz, 1H), 3.74 (s, 2H), 3.03 – 2.86 (m, 2H), 2.47 (dddd, J = 16.7, 4.3, 2.8, 1.2 Hz, 1H), 2.31 (ddd, 
J = 16.7, 14.8, 5.0 Hz, 1H), 2.20 (dtt, J = 12.9, 5.1, 2.5 Hz, 1H), 1.77 (dddd, J = 15.4, 12.6, 10.8, 
4.6 Hz, 1H), 1.25 (td, J = 7.0, 2.3 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 197.81, 171.20, 156.80, 126.16, 76.32, 61.73, 59.30, 35.42, 31.42, 
26.80, 14.21. 
FTIR (AT-IR)	3291.5, 2978.95, 2360.16, 1704.04, 1667.76, 1564.22, 1417.99, 1367.73, 1327.17, 
1289.66, 1254.9, 1193.24, 1094.39, 1057.29, 1021.77, 981.68, 942.38, 888.76, 842.06, 772.03 cm-
1 
HRMS (TOF, ES+) calc’d for C11H15NO4 [M+H]+ 226.1074, found 226.1073 (ppm=0.37) 
Luche reduction of benzoylated bicyclic tetrahydro-1,2-oxazine 
 
Cool solution of XX (50 mg, 0.152 mmol, 1.00 equiv) and CeCl3•7H2O (84.8 mg, 0.228 mmol, 
1.50 equiv) in MeOH (5.0 mL) to –78 °C. Add a solution of NaBH4 (11.5 mg, 0.304 mg, 2.00 
equiv) in MeOH (2.5 mL) dropwise. After addition allow reaction to warm to ambient temperature 















MeOH, –78 °C to rt
(>95% yield)
phase over Na2SO4, filter, and concentrate in vacuo to yield  XX (51 mg, 0.152 mmol, >95% yield) 
as a white solid. 
1H NMR (400 MHz, CDCl3) δ 7.76 (d, J = 7.5 Hz, 2H), 7.54 – 7.45 (m, 1H), 7.45 – 7.35 (m, 
2H), 5.74 (t, J = 1.8 Hz, 1H), 5.52 (s, 1H), 4.36 – 4.20 (m, 3H), 2.94 (d, J = 14.5 Hz, 1H), 2.75 
(s, 1H), 2.06 (dd, J = 11.0, 5.0 Hz, 1H), 1.90 (s, 1H), 1.54 (d, J = 6.2 Hz, 1H), 1.41 – 1.31 (m, 
1H), 1.28 (t, J = 7.1 Hz, 3H). 
13C NMR (101 MHz, CDCl3) 169.75, 168.75, 132.91, 132.12, 131.20, 130.52, 128.84, 127.84, 
79.78, 66.61, 64.17, 61.74, 55.12, 31.28, 30.14, 24.79, 14.20 
FTIR (AT-IR): 3420.19, 2948.51, 2359.38, 2340.25, 1739.06, 1652.65, 1600.91, 1576.59, 
1447.96, 1405.11, 1367.49, 1331.48, 1267.29, 1193.98, 1147.61, 1029.11, 917.95, 866.62, 788.7, 
706.33, 667.96, 617.29 cm-1 
HRMS (TOF, ES+) calc’d for C18H21NO5 [M+H]+ 332.1492, found 332.1493 (ppm=-0.15) 
 
Diastereoselective epoxidation of benzoylated bicyclic tetrahydro-1,2-oxazine 
 
Substrate 363 (726.8mg, 2.207 mmol, 1 equiv) was dissolved in THF (37 mL) and pH=7 phosphate 
buffer (11 mL), reaction is kept dark, cooled to 0 °C. Cannulate suspension of CrCl3•3THF (33mg, 
0.088 mmol, 0.04 equiv) and NaHCO3 (556 mg, 6.620 mmol, 3.0 equiv) in THF (74 mL) and H2O 
(33 mL) dropwise. After 75 minutes, reaction is complete. Add 0.20M sodium thiosulfate and 
pH=7 phosphate buffer, Extract with CH2Cl2 3x (note: an emulsion forms, allow to settle). Wash 





















on florisil (35g) with a gradient 20–50% EtOAc in Hexanes to provide 370 (540.7 mg, 1.56 mmol, 
71% yield) as a white solid 
1H NMR (500 MHz, CDCl3) δ 7.74 (d, J = 7.6 Hz, 2H), 7.55 – 7.49 (m, 1H), 7.48 – 7.40 (m, 
2H), 5.68 (s, 1H), 4.36 (s, 1H), 3.30 (s, 1H), 2.62 (dd, J = 13.5, 6.1 Hz, 1H), 2.36 (dt, J = 17.3, 
5.2 Hz, 1H), 2.22 (dd, J = 20.4, 15.0 Hz, 2H), 2.11 (d, J = 15.4 Hz, 1H), 1.79 (s, 1H), 1.28 (t, J = 
7.2 Hz, 3H). 
13C NMR (126 MHz, CDCl3) δ 202.53, 170.07, 168.33, 131.70, 128.81, 128.17, 78.81, 62.40, 
60.80, 60.30, 55.39, 31.71, 30.86, 22.01, 14.29. 
FTIR(AT-IR) 2979.80, 2359.60, 1716.02, 1656.84, 1578.52, 1447.13, 1389.33, 1366.88, 1309.09, 
1257.56, 1178.77, 1092.65, 1026.42, 974.69, 920.18, 870.32, 788.06, 748.64, 707.41 cm-1 
HRMS (TOF, ES+) calc’d for C18H19NO6 [M+H]+ 346.1285, found 346.1291 (ppm=–1.69) 
Ref NC-VI-225 
 
Diastereoselective 1,2-reduction of tetrahydro-1,2-oxazine epoxy ketone 
 
To a solution of 370 (4.1 mg, 0.0119 mmol, 1.0 equiv) and CeCl3•7H2O (10.5 mg, 0.028 mmol, 
2.0 equiv) in MeOH (0.8 mL) was brought to –25 °C, stir 5 minutes. Add NaBH4 (6.9 mg, 0.182 
mmol, 15.0 equiv) in MeOH (0.4 mL) and allow mixture to slowly warm. Reaction complete at –
20 °C, quench with DI H2O (0.8 mL). Extract three times with Et2O (3×2.0 mL). Wash combined 
















73% yield (5.7:1)370 371
flash chromatography (silica, 50%EtOAc/Hexanes) to yield 371 (3.0 mg, 0.0086 mmol, 73% yield) 
as a white solid.  
1H NMR (400 MHz, CDCl3) δ 7.75 (d, J = 7.6 Hz, 2H), 7.55 – 7.46 (m, 1H), 7.46 – 7.38 (m, 2H), 
5.54 (s, 1H), 4.38 – 4.23 (m, 2H), 4.14 – 4.05 (m, 1H), 3.94 (dt, J = 8.7, 5.7 Hz, 1H), 3.20 (s, 1H), 
2.51 (dd, J = 13.5, 6.2 Hz, 1H), 2.12 (dd, J = 13.5, 2.3 Hz, 1H), 1.86 (d, J = 6.3 Hz, 1H), 1.72 – 
1.63 (m, 1H), 1.49 (s, 1H), 1.46 – 1.36 (m, 1H), 1.33 (t, J = 7.1 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 169.86, 169.01, 132.70, 131.52, 128.90, 128.09, 78.98, 65.86, 
65.00, 62.27, 56.12, 55.46, 31.01, 25.09, 20.81, 14.36. 
FTIR (AT-IR)	3433.47, 2932.85, 1736.83, 1644.41, 1577.8, 1447.82, 1391.49, 1367.35, 1310.52, 
1234.61, 1193.83, 1082.95, 1018.30, 918.35, 893.00, 871.28, 788.07, 707.48 cm-1 
HRMS (TOF, ES+) calc’d for C18H21NO6 [M+H]+ 348.1442, found 348.1438 (ppm=1.05) 
 
Wharton rearrangement of tetrahydro-1,2-oxazine epoxy ketone 
 
To a solution 370 (20 mg,  0.0579 mmol, 1 equiv) and benzoic acid (1.4 mg, 0.116 mmol, 0.20 
equiv) in MeCN(0.75 mL) add a solution of NH2NH2 (2.0 mg, 0.0608 mmol, 1.05 equiv) in 
MeCN(0.35 mL) stir at ambient temperature for 3h. Dilute in eluent solution (5% 
NEt3/45%EtOAc/50% Hexanes). Purification by elution through a NEt3-neutralized florisil plug 
to yield the 373 (17.5 mg, 0.0528 mmol, 91% yield) 
1H NMR (500 MHz, CDCl3) δ 7.73 (s, 2H), 7.50 – 7.44 (m, 1H), 7.43 – 7.37 (m, 2H), 5.91 (ddd, 















370 (91% yield) 373
3.93 (s, 1H), 2.62 (d, J = 13.5 Hz, 1H), 2.19 (dd, J = 13.2, 6.5 Hz, 1H), 2.08 (d, J = 18.9 Hz, 1H), 
1.94 (d, J = 3.0 Hz, 1H), 1.89 (d, J = 14.7 Hz, 2H), 1.71 (s, 1H), 1.26 (t, J = 7.1 Hz, 3H). 
13C NMR (126 MHz, CDCl3) δ 169.89, 168.76, 133.17, 132.90, 131.18, 128.86, 128.40, 127.91, 
82.54, 64.29, 61.68, 53.74, 36.88, 21.64, 20.46, 14.26. 
FTIR (AT-IR)	 3408.37, 2932.03, 1732.70, 1633.99, 1577.31, 1447.64, 1402.33, 1367.67, 
1316.25, 1228.24, 1188.30, 1082.79, 1030.05, 995.14, 921.35, 871.17, 780.89, 732.50, 707.45, 
667.99 cm-1 
HRMS (TOF, ES+) calc’d for C18H21NO5 [M+H]+ 332.1492, found 332.1487 (ppm=1.65) 
 
Allylic bromination and halide displacement of tertiary allylic alcohol  
 
Suspend 373 (127.1 mg, 0.383 mmol, 1.0 equiv), NBS (75.1 mg, 0.422 mmol, 1.10 equiv), and 
lauroyl peroxide (3.0 mg, 0.0077 mmol, 0.02 equiv) in CCl4 (9.6 mL). Wash down sides of flask 
with hexanes (3 mL). Stir under mercury floodlamp illumination with fan cooling for one hour. 
Dilute mixture with 10% EtOAc/Hexanes (20 mL) and filter through celite. Vacuum transfer 
solvent mixture then azeotrope the resulting crude mixture from toluene to yield a mixture of 
allylic bromination products and trace starting material as a pale yellow foam. Suspend the crude 
mixture in MeCN (15 mL). Add DIPEA (0.27 mL, 198 mg, 1.53 mmol, 4.0 equiv) then AgBF4 
(112 mg, 0.421 equiv, 1.10 equiv) as a solution in MeCN (0.7 mL). Add 4 beads of activated 4Å 
MS. Stir in the dark at ambient temperature for 9 hours. Add additional AgBF4 (14.9 mg, 0.077 






1. NBS (1.10 equiv)
    lauroyl peroxide (2.5 mol%)






2. AgBF4 (1.7 equiv)
    DIPEA (6 equiv)
    MeCN, 4Å MS
(70%, 2 steps)373 372
continue stirring 9h30m. Dilute in 20% EtOAc/Hexanes (20 mL) and filter through celite. Add 
NEt3 (1 mL) and concentrate crude on celite. Purify by flash chromatography (fluorosil, 0→60% 
EtOAc/Hexanes) to yield 372 (88.1 mg, 0.268 mmol, 70% yield) as a white solid. 
1H NMR (400 MHz, CDCl3) δ 7.72 (d, J = 7.6 Hz, 2H), 7.49 (ddt, J = 8.4, 6.6, 1.4 Hz, 1H), 7.45 
– 7.37 (m, 2H), 5.93 (dt, J = 9.9, 3.7 Hz, 1H), 5.78 – 5.59 (m, 2H), 4.33 – 4.28 (m, 1H), 4.25 (q, J 
= 7.1 Hz, 2H), 3.36 – 3.27 (m, 1H), 2.61 (dd, J = 13.3, 6.2 Hz, 1H), 2.43 – 2.30 (m, 1H), 2.26 (d, 
J = 13.3 Hz, 1H), 2.17 – 2.01 (m, 1H), 1.28 (t, J = 7.1 Hz, 3H). 
13C NMR (126 MHz, CDCl3) δ 170.03, 168.86, 132.72, 131.43, 129.10, 128.85, 127.98, 122.17, 
79.33, 62.12, 57.05, 55.25, 54.63, 31.66, 27.13, 14.32. 
FTIR (AT-IR) 2981.11, 2361.34, 1736.53, 1655.94, 1578.36, 1447.47, 1388.17, 1317.21, 
1274.26, 1227.59, 1185.7, 1030.03, 926.32, 882.31, 787.32, 742.03, 708.43, 667.92  cm-1 
HRMS (TOF, ES+) calc’d for C18H19NO5 [M+H]+ 330.1336, found 330.1339 (ppm=–0.91) 
 
Desaturation of tetrahydro-1,2-oxazine epoxy ketone 
 
To a solution of substrate 370 (1.688 g, 4.89 mmol, 1.0 equiv) in DMSO(0.15M, 32.5 mL) add 
1,4-benzoquinone (660 mg, 6.11 mmol, 1.25 equiv), Pd(MeCN)4(BF)4 (325.7 mg, 0.733 mmol, 
0.15 equiv), and PIDA(394 mg, 1.22 mmol, 0.25 equiv). Heat to 50 °C, stir 96h. Cool to ambient 
temperature. Add 75 mL NaHCO3(aq), extract 4x175 mL EtOAc. Wash organic layer with 40 mL 
brine. Dry organic layer with Na2SO4, filter, and concentrate. Purify by flash chromatography 















370 (67% yield) 376
1H NMR (400 MHz, CDCl3) δ 7.79 – 7.69 (m, 2H), 7.58 – 7.50 (m, 1H), 7.49 – 7.41 (m, 2H), 6.30 
(s, 1H), 6.08 (dt, J = 10.6, 1.4 Hz, 1H), 5.65 (s, 1H), 4.72 (s, 1H), 4.34 – 4.12 (m, 3H), 3.53 (t, J = 
1.6 Hz, 1H), 2.70 (dd, J = 13.9, 6.2 Hz, 1H), 2.28 (d, J = 14.0 Hz, 1H), 1.27 (t, J = 7.1 Hz, 4H). 
13C NMR (101 MHz, CDCl3) δ 192.45, 170.22, 168.04, 136.07, 132.22, 131.90, 130.64, 128.71, 
128.27, 76.11, 62.50, 60.42, 59.24, 55.60, 29.61, 14.19. 
FTIR (AT-IR) 2982.21, 1737.29, 1690.76, 1661.42, 1600.80, 1579.13, 1447.34, 1390.80, 
1365.58, 1334.93, 1306.37, 1266.83, 1226.57, 1187.35, 1026.36, 947.14, 910.44, 859.39, 826.78, 
780.45, 729.61, 708.37, 647.95 cm-1 
HRMS (TOF, ES+) calc’d for C18H17NO6 [M+H]+ 344.1129, found 344.1127 (ppm=0.48) 
Ref NC-V-003, NC-V-211 
 
Unselective Luche reduction of tetrahydro-1,2-oxazine epoxy enone 
 
Cool 368 (140 mg, 0.408mg, 1.0 equiv) and CeCl3•7H2O (304mg, 0.816 mmol, 2.0 equiv) in 
MeOH (6.7 mL) to –20 °C. Add a solution of NaBH4 (30.9 mg, 0.816 mmol, 2.0 equiv) and stir 
for 30 minutes before raising the temperature to 0 °C. Add NaHCO3(aq) (9 mL). Extract with EtOAc 
four times. Wash combined organics with brine. Dry over Na2SO4, filter, and concentrate. 
Purification by flash chromatography (fine silica, 20% PhMe/40% Acetone/Hexanes) provided 
369a (63.3 mg, 0.183 mmol, 45% yield) and some mixed fractions which were subsequently 
purified on normal phase prep-HPLC (45% EtOAc/Hexanes) to provide additional 369a (27.0mg, 





















369a(f2): 1H NMR (500 MHz, CDCl3) δ 7.74 (d, J = 7.6 Hz, 2H), 7.54 
– 7.48 (m, 1H), 7.46 – 7.39 (m, 2H), 5.79 (d, J = 10.3 Hz, 1H), 5.66 (s, 
1H), 5.38 (s, 1H), 4.47 (s, 1H), 4.40 (s, 1H), 4.32 – 4.18 (m, 2H), 3.59 
(t, J = 2.0 Hz, 1H), 2.66 – 2.53 (m, 1H), 2.24 (d, J = 13.7 Hz, 1H), 2.08 (s, 1H), 1.64 (s, 1H), 
1.29 (t, J = 7.1 Hz, 3H). 
13C NMR (126 MHz, CDCl3) δ 170.09, 168.74, 133.50, 131.72, 128.88, 128.16, 119.84, 76.90, 
65.00, 62.29, 62.01, 56.89, 55.35, 30.65, 14.31. 
FTIR (AT-IR)	 3515.22, 2359.36, 2340.32, 1713.29, 1651.27, 1448.14, 1400.82, 1371.84, 
1300.75, 1271.34, 1237.79, 1198.4, 1086.26, 1044.77, 1015.91, 974.42, 917.96, 850.56, 808.77, 
791.48, 707.66, 668.00, 627.70 cm-1 
HRMS (TOF, ES+) calc’d for C18H19NO6 [M+H]+ 346.1285, found 346.1281 (ppm=1.20) 
369b(f1): 1H NMR (500 MHz, CDCl3) δ 7.74 (d, J = 7.6 Hz, 2H), 7.55 
– 7.47 (m, 1H), 7.46 – 7.40 (m, 2H), 5.96 (ddd, J = 9.6, 4.6, 2.0 Hz, 
1H), 5.55 (d, J = 74.0 Hz, 2H), 4.50 (s, 1H), 4.41 (s, 1H), 4.34 – 4.19 
(m, 2H), 3.37 (q, J = 1.6 Hz, 1H), 2.60 (dd, J = 13.6, 6.1 Hz, 1H), 2.16 (dd, J = 13.7, 1.9 Hz, 
1H), 1.93 (s, 1H), 1.31 (td, J = 7.1, 0.9 Hz, 3H). 
13C NMR (126 MHz, CDCl3) δ 170.24, 168.80, 131.97, 131.75, 128.90, 128.18, 120.92, 76.79, 
63.26, 62.39, 60.50, 55.64, 53.93, 30.96, 14.32. 
FTIR (AT-IR)	3506.46, 2925.60, 2359.53, 2340.3, 1733.94, 1653.54, 1578.26, 1447.05, 1367.84, 
1298.39, 1233.21, 1189.33, 1025.82, 905.79, 867.34, 831.29, 790.72, 768.16, 730.21, 706.66, 
667.91 cm-1 














Diastereoselective epoxidation of tetrahydro-1,2-oxazine epoxy enone 
 
To chill a solution of substrate (1.1207g, 3.26 mmol, 1 equiv) in wet dioxane (13 mL dioxane, 
0.1mL DI H2O) to 0 °C. Add NaOCl (12.5 wt% in H2O) (3.62mL, 4.37g (243 mg NaOCl), 2.25 
equiv) Stir 5h at 0 °C. Dilute in 1:1 brine/DI H2O (65 mL). Extract with EtOAc 3x75mL. Dry 
organics over Na2SO4. Filter and concentrate. Take up crude in benzene, concentrate; take up 
again in hexanes and re-concentrate. Yields 371 (1.09g, 93% yield) as a white foam. Note: 371 
was not amenable to chromatographic purification due to instability and was used with no further 
purification. 
1H NMR (400 MHz, CDCl3) δ 7.78 – 7.69 (m, 2H), 7.56 – 7.49 (m, 1H), 7.49 – 7.40 (m, 2H), 5.53 
(s, 0H), 4.74 (s, 1H), 3.43 (d, J = 1.8 Hz, 1H), 3.40 (s, 1H), 3.39 – 3.33 (m, 1H), 2.63 (dd, J = 14.0, 
6.1 Hz, 1H), 2.11 (dd, J = 14.1, 1.8 Hz, 1H), 1.28 (t, J = 7.1 Hz, 4H). 
13C NMR (101 MHz, CDCl3) δ 197.03, 170.44, 167.70, 132.10, 131.96, 128.50, 128.32, 75.09, 
63.75, 62.60, 61.63, 56.77, 55.37, 54.25, 31.10, 14.14. 
FTIR (AT-IR) 1736.36, 1707.34, 1666.01, 1447.25, 1368.08, 1303.87, 1226.04, 1185.33, 
1022.17, 947.87, 912.99, 868.45, 788.53, 708.45 cm-1 





















Diastereoselective dihydroxylation of tetrahydro-1,2-oxazine epoxy enone 
 
Dissolve K2OsO2(OH)4 (1.5 mg, 0.00407 mmol, 0.05 equiv), NMO (14.1 mg, 0.120 mmol, 1.5 
equiv), and citric acid monohydrate (33.0 mg, 0.157 mmol, 1.95 equiv) in DI H2O (1.5 mL). Add 
t-BuOH (1.5 mL) to the aqueous solution to generate a pale a pale yellow solution. Add the 
osmium solution to 368 (27.6 mg, 0.0804 mmol, 1.0 equiv) in THF (0.9 mL). Sparge reaction 
mixture for 10 minutes and continue stirring under argon at ambient temperature for 2h20m. Add 
pH=7 phosphate buffer (1 mL) and brine (2 mL) and extract six times with EtOAc (6×3 mL). 
Dry combined organics over Na2SO4, filter, and concentrate to yield crude product. Take up 
crude material in MeCN (3 mL) and wash twice with pentanes (2×4 mL). Concentrate to yield 
372 with trace impurities (27.6 mg, 0.0731 mmol, ~90% yield) as a pale yellow oil. Note: 372 
was not amenable to chromatographic purification due to instability and was used with no further 
purification. 
1H NMR (400 MHz, CDCl3) δ 7.77 – 7.66 (m, 2H), 7.59 – 7.50 (m, 1H), 7.49 – 7.43 (m, 2H), 5.93 
– 5.30 (m, 1H), 4.51 (s, 1H), 4.29 – 4.19 (m, 2H), 4.12 (d, J = 3.7 Hz, 1H), 4.04 (s, 1H), 3.51 (d, J 
= 1.2 Hz, 1H), 2.63 (dd, J = 13.6, 6.0 Hz, 1H), 2.19 (dd, J = 13.7, 2.0 Hz, 1H), 1.28 (t, J = 7.1 Hz, 
3H). 
13C NMR (101 MHz, CDCl3) δ 170.29, 168.41, 132.16, 132.00, 128.78, 128.42, 79.78, 74.77, 
69.03, 69.01, 62.57, 58.35, 32.02, 30.19, 29.16, 22.83, 22.02, 14.35, 14.31, 14.27. 
NMO (1.50 equiv)


















FTIR (AT-IR) 3447.39, 2981.48, 2361.33, 2341.29, 1734.63, 1653.82, 1600.95, 1578.07, 
1447.91, 1390.57, 1368.42, 1308.69, 1227.00, 1191.68, 1121.21, 1060.54, 1025.05, 954.00, 
910.67, 881.89, 861.12, 787.53, 728.04, 709.00, 667.94, 647.54 cm-1 
HRMS (TOF, ES+) calc’d for C18H19NO8 [M+H]+ 378.1183, found 377.1174 (ppm=2.49) 
 
Wharton rearrangement of tetrahydro-1,2-oxazine bis-epoxy ketone 
 
Cool to solution of benzoic acid (6.8 mg, 0.057 mmol, 0.20 equiv) in EtOAc (2mL) to 10 °C. 
Concurrently, add solutions of NH2NH2 (8.9 mg, 8.7µL, 0.278 mmol) in EtOAc (5 mL) and 379 
(100 mg, 0.278 mmol) in EtOAc (5 mL) dropwise via syringes to the cooled reaction flask over 
30 minutes. Rinse substrate syringe with EtOAc (1 mL). Bring reaction to ambient temperature 
and stir five minutes before adding triethylamine (1 mL). Filter through a neutralized florisil plug 
and rinse plug with (5% NEt3/EtOAc). Purification of that crude mixture by flash chromatography 
(florisil 5.0g, 5% NEt3/50%EtOAc/Hexanes) to yield a 3:2 mixture of 381 and 382 (31.4mg, 
0.091mmol, 33% yield) which were carried forward as a mixture. 382 could be isolated cleanly 
for characterization by flash chromatography (40%EtOAc/Hexanes). 
382: 1H NMR (400 MHz, CDCl3) δ 7.72 (d, J = 7.7 Hz, 2H), 7.56 – 7.47 (m, 1H), 7.46 – 7.36 (m, 
2H), 6.19 (dd, J = 9.8, 4.0 Hz, 1H), 6.13 – 6.02 (m, 1H), 5.66 (s, 1H), 4.30 (s, 1H), 4.24 (q, J = 7.1 
Hz, 2H), 3.92 (s, 1H), 3.41 (dt, J = 4.1, 1.3 Hz, 1H), 2.69 (dd, J = 13.3, 6.2 Hz, 1H), 2.39 – 2.22 
























379 (33% yield, ~3:2)
EtOAc
13C NMR (101 MHz, CDCl3) δ 170.16, 168.79, 136.71, 133.28, 131.70, 128.76, 128.19, 126.98, 
81.68, 64.57, 62.28, 59.83, 55.26, 54.45, 31.04, 14.34. 
FTIR (AT-IR) 3457.65, 2981.45, 2359.53, 2340.24, 1739.24, 1652.54, 1576.29, 1447.92, 
1394.23, 1317.61, 1274.82, 1267.49, 1230.14, 1189.56, 1028.04, 954.06, 867.43, 809.44, 788.73, 
763.78, 749.59, 708.28, 667.92 cm-1 
HRMS (TOF, ES+) alc’d for C18H19NO6 [M+H]+ 346.1285, found 346.1282 (ppm=0.91) 
 
Wharton rearrangement of tetrahydro-1,2-oxazine epoxy keto-diol 
 
Add 380 (39 mg, 0.103 mmol, 1.0 equiv) and BzOH (2.5 mg, 0.021 mmol, 0.20 equiv) in MeCN 
(4.2 mL). NH2NH2 (3.5 mg, 3.4 µL, 0.109 mmol, 1.05 equiv) in MeCN (1.0 mL). Stir 20 minutes 
at ambient temperature and then add pH=7 phosphate buffer. Extract three with EtOAc. Wash 
organic phase with brine. Dry over Na2SO4, filter, and concentrate to yield product (33 mg, 0.090 
mmol, ~85% yield). 
1H NMR (400 MHz, CDCl3) δ 7.68 (s, 2H), 7.54 – 7.46 (m, 1H), 7.42 (ddt, J = 8.4, 6.8, 1.2 Hz, 
2H), 5.64 (s, 2H), 5.33 (d, J = 23.4 Hz, 1H), 4.27 (s, 1H), 4.19 (qd, J = 7.1, 4.2 Hz, 2H), 4.02 (s, 
1H), 3.56 (s, 1H), 3.24 (d, J = 83.5 Hz, 1H), 2.59 (s, 1H), 2.24 (dd, J = 13.6, 6.7 Hz, 1H), 1.27 (t, 
J = 7.1 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 170.32, 168.57, 132.88, 131.56, 131.38, 129.24, 128.51, 128.26, 





















FTIR (AT-IR)	 3387.29, 2930.19, 1735.10, 1636.40, 1576.98, 1448.32, 1400.27, 1368.76, 
1323.20, 1226.31, 1193.94, 1129.64, 1066.18, 1022.40, 917.90, 833.76, 787.43, 707.14, 678.99, 
645.09 cm-1 
HRMS (TOF, ES+) calc’d for C18H21NO7 [M+H]+ 364.1391, found 364.1390 (ppm=0.22) 
 
Convergent silylation of Wharton rearrangement products 
 
Cool solution of 373 and 374 (31.6 mg, 0.0915 mmol) to –5 °C. Add triethylamine (93mg, 128 
µL, 0.915 mmol, 10 equiv) followed by TBSOTf (48.4 mg, 42 µL, 0.183 mmol, 2.0 equiv). Warm 
to 10 °C and stir 25 minutes. Add additional triethylamine (44 mg, 60 µL, 0.430 mmol,  4.7 equiv) 
followed by TBSOTf (23 mg, 20 µL, 0.087 mmol, 0.95 equiv). Quench excess TBSOTf with i-
PrOH (25 µL) and stir at ambient temperature for 5 minutes. Concentrate crude reaction and purify 
by flash chromatography (florisil 3.6g, 2% NEt3/5→15%EtOAc/Hexanes) provides XX (9.6mg, 
38% yield) 
1H NMR (400 MHz, CDCl3) δ 7.78 – 7.68 (m, 2H), 7.48 (d, J = 1.6 Hz, 1H), 7.44 – 7.38 (m, 2H), 
6.04 (ddd, J = 10.0, 3.6, 1.3 Hz, 1H), 5.77 (ddd, J = 10.0, 4.1, 1.1 Hz, 1H), 5.46 (s, 1H), 4.23 (d, J 
= 5.7 Hz, 2H), 4.16 (s, 1H), 4.08 (d, J = 3.8 Hz, 1H), 3.24 (dt, J = 3.6, 1.0 Hz, 1H), 2.45 (dd, J = 
13.8, 5.1 Hz, 2H), 1.29 (t, J = 7.1 Hz, 3H), 0.78 (s, 9H), -0.10 (d, J = 34.0 Hz, 6H).  
13C NMR (101 MHz, CDCl3) δ 169.81, 169.07, 134.70, 132.72, 131.30, 128.61, 128.04, 124.94, 



























FTIR (AT-IR)	 2954.10, 2928.42, 2856.26, 2361.06, 2340.36, 1739.52, 1652.91, 1471.97, 
1447.94, 1389.33, 1315.95, 1253.02, 1226.52, 1188.91, 1094.5, 1027.62, 915.93, 878.84, 837.35, 
814.81, 778.37, 746.41, 706.37, 668.03, 654.57, 648.90, 632.41, 617.5, 608.61 cm-1 
HRMS (TOF, ES+) calc’d for C24H33NO6Si [M+H]+ 460.2150, found 460.2146 (ppm=0.85)  
 
1,2-reduction of tetrahydro-1,2-oxazine bis-epoxy ketone 
 
Chill a solution of XX (74 mg, 0.206 mmol, 1.0 equiv) in EtOH (0.3M, 6.9 ml) to 0 °C. Add 
CeCl3•7H2O (76.7 mg, 0.206 mmol, 1.0 equiv), stir two minutes. Add NaBH4 (11.7 mg, ) as a 
single portion stir at 0 °C for 30 minutes. Add EtOAc (5 mL) and brine (5mL), stir five minutes. 
Extract the crude mixture with EtOAc (3×5 mL). Dry over Na2SO4 and concentrate. Reconcentrate 
crude residue with benzene. Purify on by flash chromatography (florisil, 20–100% 
EtOAc/Hexanes) provides 377 as a white solid (57.5mg, 0.159 mmol, 77% yield).   
1H NMR (400 MHz, CDCl3) δ 7.75 (dt, J = 7.0, 1.4 Hz, 2H), 7.58 – 7.50 (m, 1H), 7.49 – 7.42 (m, 
2H), 5.52 (s, 1H), 4.55 (d, J = 10.1 Hz, 2H), 4.28 (qq, J = 7.3, 3.6 Hz, 2H), 3.22 (q, J = 1.6, 1.0 
Hz, 1H), 3.21 – 3.15 (m, 1H), 2.98 (s, 1H), 2.54 (dd, J = 13.8, 6.0 Hz, 1H), 2.41 (d, J = 9.3 Hz, 
1H), 1.99 (dd, J = 13.8, 1.9 Hz, 1H), 1.33 (t, J = 7.1 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 170.51, 168.84, 132.27, 131.96, 128.69, 128.31, 75.25, 62.54, 
61.54, 60.48, 55.63(br), 53.24, 52.37, 49.41, 31.36, 14.21. 
FTIR (AT-IR) 3446.83, 2984.12, 2359.39, 2340.30, 1738.02, 1652.45, 1578.62, 1447.75, 























HRMS (TOF, ES+) calc’d for C18H17NO7 [M+H]+ 360.0078, found 360.0077 (ppm=0.22) 
 
Recovery of bis-epoxy ketone through Stahl oxidation 
 
Dissolve substrate (41.6 mg, 0.115 mmol, 1.0 equiv) in wet MeCN (1.15 mL). Add 
Cu(MeCN)4OTf (4.4 mg, 0.0115 mmol, 0.10 equiv), 4,4’-methoxybipyridine (2.5 mg, 0.0115 
mmol 0.10 equiv), ABNO (0.3mg, 0.0022 mmol 0.020 equiv) and NMI (1.9mg, 1.9 µL, 0.0229 
mmol, 0.20 equiv). Stir in air 40 minutes. Dilute in pH=7 buffer, and extract crude mixture three 
times with EtOAc. Dry organic phase over Na2SO4, filter, and concentrate. Take up residue in 
PhMe and filter through celite to remove insoluble material. Concentrate to yield 379 (41.3 mg, 
0.114 mmol, >95% yield) as a pale yellow tacky oil. 
 
Schwartz reduction of N-benzoylated western fragment tetrahydro-1,2-oxazine 
 
To a stirred suspension of Cp2Zr(H)Cl (12.4 mg, 0.0320 mmol, 1.5 equiv) in THF(0.15 mL) add 
substrate 380 (14.7 mg, 0.0320 mmol, 1.0 equiv) in a steady stream as a solution in THF (1.75 
mL). Rinse substrate syringe with THF (3×0.15mL) Stir at ambient temperature for 10 minutes. 


















Cu(MeCN)4OTf (10 mol %)
MeObpy (10 mol %)






















four times with EtOAc. Dry organics over Na2SO4. Filter and concentrate, purify crude product by 
flash chromatography (florisil 1.50 g, 10–60% EtOAc/Hexanes, +10% EtOAc/10 mL eluent). 
Concentrate and re–concentrate from dry toluene to yield 382 as a white solid (9.0 mg, 0.0253 
mmol, 79% yield). 
1H NMR (400 MHz, CDCl3) δ 6.41 (s, 1H), 6.06 (d, J = 3.8 Hz, 1H), 5.82 (dddd, J = 10.0, 5.0, 
1.3, 0.7 Hz, 1H), 4.34 – 4.16 (m, 2H), 4.15 (dt, J = 1.7, 0.8 Hz, 1H), 4.13 (ddd, J = 5.0, 1.9, 0.8 
Hz, 1H), 3.90 (ddd, J = 6.0, 2.8, 1.0 Hz, 1H), 3.21 (dt, J = 4.0, 1.2 Hz, 1H), 2.57 (dd, J = 13.4, 5.9 
Hz, 1H), 2.12 (dt, J = 13.4, 2.3 Hz, 1H), 1.29 (t, J = 7.1 Hz, 3H), 0.89 (s, 9H), 0.09 (d, J = 8.4 Hz, 
6H). 
13C NMR (126 MHz, CDCl3) δ 171.70, 133.48, 125.45, 81.96, 67.70, 61.78, 59.88, 59.68, 53.79, 
31.59, 26.08, 18.43, 14.41, -4.34. 
FTIR (AT-IR) 2928.00, 2855.59, 2361.23, 2339.00, 1734.81, 1472.07, 1462.93, 1388.10, 
1251.36, 1225.94, 1180.11, 1082.99, 1026.99, 1005.17, 931.05, 859.36, 836.96, 776.80, 739.28, 
667.95 cm-1 
HRMS (TOF, ES+) calc’d for C17H29NO5Si [M+H]+ 356.1888, found 356.1891 (ppm=-0.91) 
 
Ortho-iodonation of MOM-protected phenol 
 
Cool a solution of S2-10116 (2.51g, 12.64 mmol, 1.00 equiv ) and TMEDA (1.84 g, 2.36 mL, 15.80 
mmol, 1.25 equiv) in THF (45 mL) to –78 °C. Add freshly titrated n-BuLi (2.24 M in Hexanes, 




1. n-BuLi (1.20 equiv),
    TMEDA (1.25 equiv)







THF, º–78 to 0°C; 
then –78 °C to 0°C
Cool once more to –78 °C and cannulate I2 (4.65g, 18.33 mmol, 1.45 equiv) as a solution in THF 
(65 mL) dropwise into the reaction mixture. After addition is complete, continue stirring at  –78 
°C for 2h. Raise temperature to 0 °C and stir 30 minutes. Quench mixture with NaHCO3(aq) (13 
mL), stirring vigorously. Dilute with EtOAc (80 mL) wash organic layer with DI H2O (50 mL) 
and twice with Na2S2O3(sat) (2×50 mL) then brine (40 mL). Dry organics over Na2SO4. Filter and 
concentrate, purify crude product by flash chromatography (silica, 125 g, 15% EtOAc/Hexanes) 
to yield pure 385b (2.63g, 8.11 mmol, 64% yield) as a pale-yellow oil.  
1H NMR (500 MHz, CDCl3) δ 7.41 (d, J = 8.8 Hz, 1H), 6.47 (d, J = 8.8 Hz, 1H), 5.17 (s, 2H), 
3.82 (s, 3H), 3.80 (s, 3H), 3.64 (s, 3H). 
13C NMR (126 MHz, CDCl3) δ 154.47, 150.39, 142.32, 133.11, 109.91, 99.29, 81.39, 60.87, 
58.37, 56.16. 
FTIR (AT-IR) 2935.62, 2833.84, 2361.14, 1571.01, 1474.8, 1447.25, 1434.1, 1421.14, 1389.3, 
1288.37, 1218.22, 1156.21, 1083.61, 1063.49, 1002.39, 966.15, 905.55, 833.64, 792.64, 768.38, 
694.05 cm-1 
HRMS (TOF, ES+) calc’d for C10H13IO4 [M+H]+ 324.9931, found 324.9924 (ppm=2.24) 
 
Negishi cross-coupling of 384 with 2,3,4-trimethoxyiodobenzene 
 
Suspend Zn0 (596 mg, 9.12 mmol, 3.0 equiv) in DMF (3.0 mL) and add I2 (116 mg, 0.46 mmol, 





















(1.00 g, 3.04 mmol, 1.0 equiv) followed by an additional portion of I2 (116 mg, 0.46 mmol, 0.015 
equiv). An exotherm is observed, stir 15 minutes or until cooled. Add Pd2(dba)3 (69.6 mg, 0.076 
mmol, 0.025 equiv) and SPhos (62.4 mg, 0.15 mmol, 0.05 equiv) followed by 385a (1.16g. 3.95 
mmol, 1.3 equiv). Seal and stir at ambient temperature 48h. Purify by flash chromatography (silica, 
5→50% EtOAc/PhMe) by directly applying the crude mixture to column to provide 386a (589.5 
mg, 1.60 mmol, 52% yield) as an orange viscous oil.   
1H NMR (400 MHz, CDCl3) δ 6.77 (d, J = 8.5 Hz, 1H), 6.58 (d, J = 8.5 Hz, 1H), 5.25 (d, J = 7.9 
Hz, 1H), 4.41 (td, J = 7.8, 5.6 Hz, 1H), 3.87 (s, 3H), 3.83 (s, 3H), 3.82 (s, 3H), 3.69 (s, 3H), 2.96 
(qd, J = 13.7, 6.7 Hz, 2H), 1.36 (s, 9H). 
13C NMR (101 MHz, CDCl3) δ 172.85, 155.33, 153.04, 152.23, 142.10, 125.04, 122.13, 107.26, 
79.62, 60.89, 60.75, 56.02, 54.60, 52.20, 32.52, 28.35. 
FTIR (AT-IR)	 3365.29, 2936.72, 1744.06, 1712.45, 1602.02, 1494.22, 1467.17, 1435.51, 
1417.74, 1391.30, 1365.18, 1276.05, 1199.34, 1162.53, 1096.71, 1045.69, 1014.85, 906.91, 
855.78, 795.36, 730.34 cm-1 
HRMS (TOF, ES+) calc’d for C10H13IO4 [M+H]+ 370.1860, found 370.1862 (ppm=-0.46) 
[a]D
23 +21.5° (c = 1.0, CHCl3).  
 






















Suspend Zn0 (1.396 mg, 21.36 mmol, 3.0 equiv) in DMF (5.9 mL) and add I2 (271 mg, 1.07 mmol, 
0.015 equiv) as a single portion. Stir at ambient temperature until solution is colorless. Add 384 
(2.34 g, 7.12 mmol, 1.0 equiv) followed by an additional portion of I2 (271 mg, 1.07 mmol, 0.015 
equiv). An exotherm is observed, stir 15 minutes or until cooled. Add Pd2(dba)3 (163 mg, 0.178 
mmol, 0.025 equiv) and SPhos (146 mg, 0.356 mmol, 0.05 equiv) followed by 385b (3.00 g. 9.26 
mmol, 1.3 equiv). Seal and stir at ambient temperature 24h. Purify by flash chromatography (silica, 
10→15%EtOAc/20%CH2Cl2/Hexanes) by directly applying the crude mixture to column to 
provide impure product. Second purification with silica plug. Flush plug with 0→5%EtOAc/ 
CH2Cl2 to remove color impurities before flushing off the product with EtOAc. Provides 386b 
(2.44g (6 wt% biaryl), 5.74 mmol, 81% yield) as a thick oil with trace biaryl Wurtz coupling 
impurity (6 wt%). 
1H NMR (400 MHz, CDCl3) δ 6.79 (d, J = 8.5 Hz, 1H), 6.58 (d, J = 8.6 Hz, 1H), 5.48 (d, J = 8.1 
Hz, 1H), 5.10 (d, J = 1.0 Hz, 2H), 4.44 (td, J = 8.0, 5.9 Hz, 1H), 3.78 (s, 3H), 3.76 (s, 3H), 3.67 (s, 
3H), 3.53 (s, 3H), 3.08 – 2.81 (m, 2H), 1.31 (s, 9H). 
13C NMR (101 MHz, CDCl3) δ 172.94, 155.44, 152.90, 150.02, 141.58, 125.48, 125.04, 122.62, 
107.81, 99.72, 79.51, 60.67, 57.53, 56.03, 54.60, 52.22, 32.29, 28.35. 
FTIR (AT-IR) 3365.74, 2935.22, 2838.00, 1744.76, 1714.13, 1602.67, 1496.11, 1459.01, 
1437.74, 1392.02, 1365.56, 1278.40, 1212.16, 1161.19, 1100.05, 1067.79, 983.03, 924.74, 795.66 
cm-1 
HRMS (TOF, ES+) calc’d for C10H13IO4 [M+H]+ 400.1966, found 400.1972 (ppm=-1.52) 
 [a]D
23 +25.1° (c = 1.0, CHCl3).  
 
Saponification of 2,3,4-trimethoxyphenylalanine 386a 
 
Chill 386a (200 mg, 0.541 mmol, 1.0 equiv) in THF (3 mL) and H2O (1.5 mL) to 0 °C. Add 
LiOH•H2O (113.3mg, 2.70 mmol. 5 equiv) stir for 4h50m allowing the reaction to warm to ambient 
temperature. Add NaH2PO4 (373 mg) dissolved in DI H2O (3 mL). Extract crude mixture twice 
with CHCl3. Acidify aqueous layer to pH=5 with 1M HCl(aq) extract with CHCl3 once. Further 
acidify the aqueous solution to pH=3 and extract twice with 10% i-PrOH/CHCl3. Dry organics 
over Na2SO4, filter and concentrate to yield pure 387a (137.7mg, 0.387 mmol, 72% yield) as a 
clear oil. 
1H NMR	(400 MHz, CDCl3) δ 6.85 (d, J = 8.5 Hz, 1H), 6.62 (d, J = 8.5 Hz, 1H), 5.44 (d, J = 7.1 
Hz, 1H), 4.38 (d, J = 6.8 Hz, 1H), 3.90 (s, 3H), 3.86 (s, 3H), 3.84 (s, 3H), 3.23 – 2.79 (m, 2H), 
1.38 (s, 9H). 
13C NMR (101 MHz, CDCl3) δ 176.32, 156.23, 153.21, 152.15, 142.13, 125.25, 122.06, 107.48, 
80.36, 61.04, 60.88, 56.12, 55.04, 31.90, 28.42. 
FTIR (AT-IR)	 3342.19, 2976.23, 2932.13, 2361.42, 2340.28, 1716.10, 1602.88, 1495.73, 
1468.39, 1435.89, 1418.07, 1393.78, 1367.62, 1276.94, 1260.45, 1234.79, 1165.23, 1098.96, 
1049.02, 1017.44, 903.85, 851.00, 797.75, 764.67, 750.62, 684.65, 667.91, 643.91 cm-1 
HRMS (TOF, ES+) calc’d for C18H29NO8 [M+H]+ 400.1966, found 400.1960 (ppm=1.48) 
[a]D
23 +8.2° (c = 0.5, CHCl3).  
 














Cool 386b (132.7 mg, 0.332 mmol, 1.0 equiv) to 0°C stirring in THF (11 mL). Add solution of 
LiOH•H2O (70.0 mg, 1.661 mmol, 5.0 equiv) as a solution in DI H2O (2.0 mL). Allow reaction to 
warm to ambient temperature and stir 20h. Add DI H2O (5.0 mL) and extract mixture with 2:1 
Hexanes: CH2Cl2 (15 mL) and set aside. Lower of aqueous layer to pH=4 and extract twice with 
10% i-PrOH/CHCl3 (~30 mL). Concentrate crude and azeotrope with PhMe. Dissolve in minimal 
Et2O and crash out with Hexanes, remove solvent. Purify by flash chromatography (silica, 4.0 g, 
0.75%AcOH/19.25%Hexanes in EtOAc) 387b (105mg, 82% yield) was recovered as a tacky oil.   
1H NMR (400 MHz, CDCl3) δ 6.90 (d, J = 8.5 Hz, 1H), 6.66 (d, J = 8.6 Hz, 1H), 5.76 (s, 1H), 
5.19 (s, 2H), 4.42 (d, J = 7.2 Hz, 1H), 3.85 (s, 3H), 3.82 (s, 3H), 3.58 (s, 3H), 3.12 (d, J = 7.1 Hz, 
2H), 1.38 (s, 9H). 
13C NMR (101 MHz, CDCl3) δ 176.72, 156.17, 153.01, 150.04, 141.57, 125.15, 122.54, 108.00, 
99.79, 80.11, 60.75, 57.63, 56.11, 54.94, 31.66, 28.40. 
FTIR (AT-IR)	 3330.56, 2975.53, 2935.51, 2837.19, 1713.56, 1603.46, 1496.44, 1458.64, 
1426.45, 1394.22, 1367.28, 1278.34, 1211.14, 1160.04, 1100.99, 1067.90, 983.76, 925.03. 902.54, 
852, 799.42, 667.97, 623.01l, 613.00, 605.77, 602.38 cm-1 
HRMS (TOF, ES+) calc’d for C18H27NO8 [M+H]+ 386.1809, found 386.1806 (ppm=0.89) 
[a]D
23 +23.5° (c = 1.0, CHCl3).  
 















Bubble dried HCl(g), generated from NaCl(s) and H2SO4(conc), through a solution of 387b (166 mg, 
0.431 mmol, 1.0 equiv) in CH2Cl2 (17.3 mL) stirring vigorously at ambient temperature for 55 
minutes, reactions became cloudy. Concentrate mixture to a white powder in vacuo before diluting 
the crude intermediate in water (1.7 mL) and 1,4-dioxane (1.7 mL). Add NaHCO3 (145mg, 1.723 
mmol, 4.0 equiv) followed by Fmoc-OSu (145.4 mg, 0.431 mmol, 1.0 equiv). Stir at ambient 
temperature for 17h. Acidify with 1M HCl(aq) and extract the crude aqueous mixture three times 
CHCl3. Dry organic layer over Na2SO4. Filter and concentrate. Flushing crude intermediate 
through a silica plug (50% EtOAc/1% AcOH/Hexanes) provided as a white solid (154 mg, 0.333 
mmol). The intermediate was split, dissolve (76 mg, 0.164 mmol, 1.0 equiv) in DMF (0.5 mL). 
Add imidazole (67mg, 0.984 mmol, 6.0 equiv) and TBSCl (74 mg, 0.492 mmol, 3.0 equiv); wash 
down solids with additional DMF (0.6 mL) and stir at ambient temperature. Dilute with DI H2O 
(4.0 mL) extract with three times CH2Cl2 (3×10 mL). Wash combined organics with DI H2O and 
brine. Dry organic layer over Na2SO4. Filter, concentrate, azeotrope from PhMe then purify crude 
product by flash chromatography (silica, 1% AcOH/50% EtOAc/Hexanes) to yield impure 389. 
Take up in CHCl3 wash with DI H2O:brine (2:1) as a white solid. Dry organic layer over Na2SO4, 
filter, concentrate to yield a pure 389 (58 mg, 0.100 mmol, 47% yield, 3 steps) 
1H NMR (400 MHz, CDCl3) δ 7.73 (d, J = 7.5 Hz, 2H), 7.56 – 7.47 (m, 2H), 7.36 (tdd, J = 7.5, 
2.2, 1.1 Hz, 2H), 7.26 – 7.20 (m, 2H), 6.85 (d, J = 8.5 Hz, 1H), 6.49 (d, J = 8.5 Hz, 1H), 6.03 (d, 
J = 6.6 Hz, 1H), 4.45 – 4.36 (m, 1H), 4.36 – 4.22 (m, 2H), 4.12 (t, J = 7.0 Hz, 1H), 3.78 (s, 3H), 










   NaHCO3 (4 equiv)
(47%, 3 steps)394b 396
2.TBSCl (3 equiv)
   imidazole (6 equiv)
13C NMR (101 MHz, CDCl3) δ 176.72, 156.61, 152.96, 147.72, 143.97, 143.90, 141.35, 141.33, 
140.13, 127.74, 127.09, 125.19, 125.14, 121.15, 120.03, 105.79, 67.09, 60.49, 56.37, 55.90, 
47.21, 31.91, 26.28, 18.84, -3.82, -4.02. 
FTIR (AT-IR)	2929.71, 2857.1, 1716.2, 1604.17, 1518.77, 1493.02, 1462.32, 1425.95, 1251.58, 
1101.83, 1042.85, 983.26, 908.33, 833.54, 782.87, 757.89, 731.04, 646.98, 634.01, 621.45, 610.72 
cm-1 
HRMS (TOF, ES+) calc’d for C32H39NO7Si [M+H]+ 578.2569, found 578.2560 (ppm=-1.56) 
[a]D
23 –9.7° (c = 1.0, CHCl3).  
 
C-H oxidation of western fragment to form a dihydro-1,2-oxazine 
 
Add Pb(OAc)4 (1.4 mg, 0.00309 mmol, 1.10 equiv) to solution of 382 (1.0mg, 0.0028 mmol, 1.0 
equiv) cooled in an ice bath. Remove ice bath and stir at ambient temperature for 5 minutes. Add 
ethylene glycol (10 µL) and stir 1 minute. Dilute with DI H2O (1 mL) and extract with CH2Cl2 
twice. Dry over Na2SO4, filter, and concentrate. Azeotrope from toluene to yield 395 (1.0mg, 
0.0028 mmol,  >90% yield) 
1H NMR (400 MHz, CDCl3)  δ 6.08 (dd, J = 10.2, 3.6 Hz, 1H), 5.92 (dd, J = 9.9, 4.5 Hz, 1H), 4.46 
(t, J = 3.7 Hz, 1H), 4.36 (q, J = 7.1 Hz, 2H), 4.04 (d, J = 3.0 Hz, 1H), 3.29 (d, J = 3.7 Hz, 1H), 
2.99 (d, J = 18.7 Hz, 1H), 2.59 (d, J = 18.7 Hz, 1H), 1.38 (t, J = 7.1 Hz, 3H), 0.90 (s, 9H), 0.13 (d, 



















13C NMR (101 MHz, CDCl3) δ 162.46, 152.79, 134.39, 124.80, 78.55, 67.03, 62.63, 58.50, 53.39, 
29.85, 28.78, 25.99, 14.26, -4.42, -4.46. 
FTIR (AT-IR)	 2927.27, 2855.36, 1722.27, 1598.14, 1463.24, 1375.48, 1285.23, 1250.16, 
1177.33, 1100.85, 1005.97, 980.91, 915.69, 837.45, 777.06, 750.28, 695.41, 667.18 cm-1 
HRMS (TOF, ES+) calc’d for C17H27NO5Si [M+H]+ 354.1731, found 354.1733 (ppm=-0.49) 
 
Selective copper-mediated formation of chlorohydrin  
 
To a solution of substrate (1.0 mg, 0.00282 mmol, 1 equiv) in THF(0.2 mL) add solution Li2CuCl4 
[composed of LiCl (0.36mg, 0.00846 mmol, 3.0 equiv) and CuCl2 (0.57mg, 0.00423 mmol, 1.5 
equiv)] in THF (0.1mL). Stir mixture at ambient temperature for 70 minutes. Add pH=7 phosphate 
buffer (0.5 mL). Extract three times with EtOAc. Dry organic layer over Na2SO4, filter and 
concentrate in vacuo to yield 396 (1.0 mg, 0.00256 mmol, 91%) as a white solid.  
 1H NMR (600 MHz, CDCl3) δ 5.71 (ddd, J = 10.3, 2.5, 1.8 Hz, 1H), 5.59 (dt, J = 10.4, 2.5 Hz, 
1H), 4.80 (q, J = 2.4 Hz, 1H), 4.37 (qd, J = 7.1, 4.0 Hz, 2H), 4.19 (dq, J = 6.9, 2.5 Hz, 1H), 4.15 
(dd, J = 6.7, 2.2 Hz, 1H), 2.76 – 2.71 (m, 2H), 2.51 (d, J = 19.5 Hz, 1H), 1.38 (t, J = 7.1 Hz, 3H), 
0.90 (s, 9H), 0.15 (s, 3H), 0.08 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ 160.28, 129.35, 127.32, 82.82, 68.01, 67.17, 63.02, 62.54, 29.85, 



















FTIR (AT-IR) 3428.5, 2948.98, 2881.42, 2361.23 ,2339.97, 1720.97, 1472.4, 1386.18, 1282.69, 
1250.2, 1114.29, 1071.89, 1015.57, 905.99, 876.79, 838.12, 801.94, 779.67, 667.89, 654.80, 
623.98, 617.77, 609.26 cm-1 
HRMS (TOF, ES+) calc’d for C17H28ClNO5Si [M+H]+ 390.1498, found 390.1509 (ppm=-2.81) 
 
2.17.4 CRYSTALLOGRAPHIC DATA OF 369b (a16027_a) 
 
X-ray quality crystals of 396b obtained layer diffusion between 1:1 CHCl3/Hexanes and 
Hexanes. 
 
Table 1.  Crystal data and structure refinement for a16027_a.cif. 
Identification code    a16027_a 
Empirical formula    C18 H19 N O6 
Formula weight     345.34 
Temperature     99.99 K 
Wavelength     0.71073 Å 
Crystal system     Triclinic 
Space group     P-1 
Unit cell dimensions   a = 9.4539(6) Å   a= 114.437(3)°. 
     b = 9.8703(7) Å   b= 105.326(3)°. 
     c = 10.6887(7) Å   g = 102.469(3)°. 
Volume     813.45(10) Å3 
Z     2 
Density (calculated)   1.410 Mg/m3 
Absorption coefficient   0.107 mm-1 
F(000)     364 
Crystal size    0.8 x 0.45 x 0.35 mm3 
Theta range for data collection  2.281 to 37.744°. 
Index ranges    -15<=h<=16, -16<=k<=16, -18<=l<=18 
Reflections collected   65383 
Independent reflections   8412 [R(int) = 0.0252] 
Completeness to theta = 26.000°  99.9 %  
Absorption correction   Semi-empirical from equivalents 
Max. and min. transmissio n  0.7474 and 0.7156 
Refinement method   Full-matrix least-squares on F2 
Data / restraints / parameters  8412 / 0 / 228 
Goodness-of-fit on F2   1.043 
Final R indices [I>2sigma(I)]  R1 = 0.0343, wR2 = 0.1005 
R indices (all data)   R1 = 0.0395, wR2 = 0.1046 
Extinction coefficient   n/a 
Largest diff. peak and hole  0.555 and -0.205 e.Å-3 
 
 Table 2.  Atomic coordinates  ( x 104) and equivalent  isotropic displacement parameters (Å2x 
103) for a16027_a.  U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
______________________________________________________________________________ 
  x   y   z   U(eq) 
_____________________________________________________________________________________________  
O(1)  6873(1)   5237(1)   993(1)   23(1) 
O(2)  4078(1)   7342(1)   4849(1)   21(1) 
O(3)  1513(1)   4450(1)   837(1)   21(1) 
O(4)  6198(1)   8195(1)   2623(1)   12(1) 
O(5)  10068(1)  8470(1)   3357(1)   20(1) 
O(6)  5780(1)   4128(1)   2137(1)   17(1) 
N(1)  7672(1)   8243(1)   3435(1)   13(1) 
C(1)  6678(1)   5329(1)   2092(1)   14(1) 
C(2)  7469(1)   6856(1)   3630(1)   14(1) 
C(3)  6542(1)   6982(1)   4627(1)   17(1) 
C(4)  5059(1)   7241(1)   4009(1)   14(1) 
C(5)  3483(1)   6000(1)   3339(1)   17(1) 
C(6)  2082(1)   5930(1)   2205(1)   18(1) 
C(7)  2411(1)   7354(1)   1984(1)   18(1) 
C(8)  3827(1)   8515(1)   2614(1)   17(1) 
C(9)  5306(1)   8516(1)   3564(1)   14(1) 
C(10)  8946(1)   8903(1)   3200(1)   14(1) 
C(11)  8956(1)   10245(1)  2885(1)   15(1) 
C(12)  9779(1)   10449(1)  2025(1)   20(1) 
C(13)  9905(1)   11734(1)  1767(1)   26(1) 
C(14)  9229(1)   12823(1)  2380(1)   27(1) 
C(15)  8441(1)   12645(1)  3270(1)   23(1) 
C(16)  8295(1)   11352(1)  3517(1)   17(1) 
C(17)  4949(1)   2613(1)   725(1)   22(1) 
C(18)  4116(1)   1415(1)   1064(1)   27(1) 
 
Table 3.   Bond lengths [Å] and angles [°] for  a16027_a 
_____________________________________________________  
O(1)-C(1)   1.2069(7) 
O(2)-C(4)   1.4424(7) 
O(2)-C(5)   1.4510(7) 
O(3)-H(3)   0.8400 
O(3)-C(6)   1.4277(8) 
O(4)-N(1)   1.4127(6) 
O(4)-C(9)   1.4561(6) 
O(5)-C(10)   1.2234(7) 
O(6)-C(1)   1.3270(7) 
O(6)-C(17)   1.4591(7) 
N(1)-C(2)   1.4480(7) 
N(1)-C(10)   1.3767(7) 
C(1)-C(2)   1.5316(7) 
C(2)-H(2)   1.0000 
C(2)-C(3)   1.5339(8) 
C(3)-H(3A)   0.9900 
C(3)-H(3B)   0.9900 
C(3)-C(4)   1.5075(8) 
C(4)-C(5)   1.4682(8) 
C(4)-C(9)   1.5140(8) 
C(5)-H(5)   1.0000 
C(5)-C(6)   1.5068(9) 
C(6)-H(6)   1.0000 
C(6)-C(7)   1.5011(8) 
C(7)-H(7)   0.9500 
C(7)-C(8)   1.3347(8) 
C(8)-H(8)   0.9500 
C(8)-C(9)   1.4944(8) 
C(9)-H(9)   1.0000 
C(10)-C(11)   1.4945(8) 
C(11)-C(12)   1.3977(8) 
C(11)-C(16)   1.3956(8) 
C(12)-H(12)   0.9500 
C(12)-C(13)   1.3932(10) 
C(13)-H(13)   0.9500 
C(13)-C(14)   1.3882(12) 
C(14)-H(14)   0.9500 
C(14)-C(15)   1.3950(10) 
C(15)-H(15)   0.9500 
C(15)-C(16)   1.3928(8) 
C(16)-H(16)   0.9500 
C(17)-H(17A)   0.9900 
C(17)-H(17B)   0.9900 
C(17)-C(18)   1.5017(10) 
C(18)-H(18A)   0.9800 
C(18)-H(18B)   0.9800 
C(18)-H(18C)   0.9800 
 
C(4)-O(2)-C(5)  60.99(3) 
C(6)-O(3)-H(3)  109.5 
N(1)-O(4)-C(9)  109.45(4) 
C(1)-O(6)-C(17)  116.14(5) 
O(4)-N(1)-C(2)  110.53(4) 
C(10)-N(1)-O(4)  116.60(4) 
C(10)-N(1)-C(2)  122.41(4) 
O(1)-C(1)-O(6)  124.83(5) 
O(1)-C(1)-C(2)  123.79(5) 
O(6)-C(1)-C(2)  111.38(4) 
N(1)-C(2)-C(1)  109.45(4) 
N(1)-C(2)-H(2)  108.5 
N(1)-C(2)-C(3)  107.27(4) 
C(1)-C(2)-H(2)  108.5 
C(1)-C(2)-C(3)  114.37(4) 
C(3)-C(2)-H(2)  108.5 
C(2)-C(3)-H(3A)  109.6 
C(2)-C(3)-H(3B)  109.6 
H(3A)-C(3)-H(3B) 108.1 
C(4)-C(3)-C(2)  110.42(4) 
C(4)-C(3)-H(3A)  109.6 
C(4)-C(3)-H(3B)  109.6 
O(2)-C(4)-C(3)  114.92(4) 
O(2)-C(4)-C(5)  59.80(4) 
O(2)-C(4)-C(9)  114.11(5) 
C(3)-C(4)-C(9)  114.18(4) 
C(5)-C(4)-C(3)  122.07(5) 
C(5)-C(4)-C(9)  119.51(5) 
O(2)-C(5)-C(4)  59.22(3) 
O(2)-C(5)-H(5)  115.7 
O(2)-C(5)-C(6)  115.76(5) 
C(4)-C(5)-H(5)  115.7 
C(4)-C(5)-C(6)  122.52(5) 
C(6)-C(5)-H(5)  115.7 
O(3)-C(6)-C(5)  109.05(5) 
O(3)-C(6)-H(6)  107.2 
O(3)-C(6)-C(7)  112.48(5) 
C(5)-C(6)-H(6)  107.2 
C(7)-C(6)-C(5)  113.46(5) 
C(7)-C(6)-H(6)  107.2 
C(6)-C(7)-H(7)  117.8 
C(8)-C(7)-C(6)  124.41(5) 
C(8)-C(7)-H(7)  117.8 
C(7)-C(8)-H(8)  117.9 
C(7)-C(8)-C(9)  124.22(5) 
C(9)-C(8)-H(8)  117.9 
O(4)-C(9)-C(4)  108.30(4) 
O(4)-C(9)-C(8)  104.16(4) 
O(4)-C(9)-H(9)  109.8 
C(4)-C(9)-H(9)  109.8 
C(8)-C(9)-C(4)  114.81(4) 
C(8)-C(9)-H(9)  109.8 


































Symmetry transformations used to generate equivalent atoms:  
  
Table 4.   Anisotropic displacement parameters  (Å2x 103) for a16027_a.  The anisotropic 
displacement factor exponent takes the form:  -2p2[ h2 a*2U11 + ...  + 2 h k a* b* U12 ] 
______________________________________________________________________________  
  U11  U22   U33  U23  U13  U12 
_____________________________________________________________________________________________  
O(1)  34(1)   20(1)  18(1)   9(1)  16(1)   9(1) 
O(2)  23(1)   22(1)  17(1)   6(1)  14(1)   4(1) 
O(3)  19(1)   17(1)  21(1)   8(1)  7(1)   0(1) 
O(4)  9(1)   14(1)  14(1)   6(1)  6(1)   5(1) 
O(5)  15(1)   29(1)  24(1)   15(1)  10(1)   13(1)  
O(6)  23(1)   12(1)  15(1)   7(1)  6(1)   5(1) 
N(1)  10(1)   14(1)  16(1)   8(1)  5(1)   4(1) 
C(1)  18(1)   13(1)  15(1)   8(1)  7(1)   8(1) 
C(2)  14(1)   15(1)  13(1)   7(1)  5(1)   5(1) 
C(3)  18(1)   19(1)  11(1)   7(1)  5(1)   5(1) 
C(4)  16(1)   14(1)  12(1)   5(1)  8(1)   4(1)  
C(5)  18(1)   15(1)  16(1)   8(1)  10(1)   3(1) 
C(6)  14(1)   16(1)  22(1)   9(1)  10(1)   3(1) 
C(7)  13(1)   18(1)  27(1)   12(1)  11(1)   7(1) 
C(8)  14(1)   14(1)  26(1)   11(1)  11(1)   7(1) 
C(9)  13(1)   12(1)  16(1)   5(1)  9(1)   4(1) 
C(10)  11(1)   17(1)  13(1)   7(1)  6(1)   5(1) 
C(11)  10(1)   18(1)  15(1)   9(1)  5(1)   3(1) 
C(12)  14(1)   28(1)  20(1)   13(1)  8(1)   4(1) 
C(13)  17(1)   34(1)  27(1)   21(1)  8(1)   2(1) 
C(14)  19(1)   27(1)  34(1)   23(1)  6(1)   1(1) 
C(15)  17(1)   19(1)  31(1)   16(1)  7(1)   4(1) 
C(16)  13(1)   17(1)  21(1)   10(1)  7(1)   4(1)  
C(17)  30(1)   13(1)  17(1)   5(1)  6(1)   6(1)  
C(18)  23(1)   18(1)  28(1)   11(1)  3(1)   0(1) 
_____________________________________________________________________________________________  
 
Table 5.   Hydrogen coordinates ( x 104) and isotropic  displacement parameters (Å2x 103) 
for a16027_a. 
_________________________________________________________________  
  x   y   z   U(eq) 
_________________________________________________________________  
  
H(3)  2000  4558  310  31 
H(2)  8535  6899  4164  17 
H(3A)  6262  5987  4680  20 
H(3B)  7208  7887  5655  20 
H(5)  3460  4949  3261  20 
H(6)  1229  5920  2593  21 
H(7)  1553  7434  1352  22 
H(8)  3900  9397  2448  20 
H(9)  5908  9597  4480  17 
H(12)  10252  9711  1616  24 
H(13)  10453  11866  1172  31 
H(14)  9304  13692  2194  32 
H(15)  8003  13407  3708  27 
H(16)  7748  11224  4113  20 
H(17A)  5707  2261  308  27 
H(17B)  4178  2734  -14  27 
H(18A)  3545  373  142  40 
H(18B)  3366  1775  1470  40 
H(18C)  4892  1313  1801  40 
________________________________________________________________  
 
Table 6.  Torsion angles [°] for a16027_a. 
________________________________________________________________  
O(1)-C(1)-C(2)-N(1)  32.43(7) 
O(1)-C(1)-C(2)-C(3)  152.80(6) 
O(2)-C(4)-C(5)-C(6)  102.72(6) 
O(2)-C(4)-C(9)-O(4)  -175.31(4) 
O(2)-C(4)-C(9)-C(8)  -59.41(6) 
O(2)-C(5)-C(6)-O(3)  -172.59(4) 
O(2)-C(5)-C(6)-C(7)  61.20(6) 
O(3)-C(6)-C(7)-C(8)  -118.76(6) 
O(4)-N(1)-C(2)-C(1)  59.09(5) 
O(4)-N(1)-C(2)-C(3)  -65.52(5) 
O(4)-N(1)-C(10)-O(5)  -151.78(5) 
O(4)-N(1)-C(10)-C(11)  33.40(6) 
O(5)-C(10)-C(11)-C(12)  33.04(8) 
O(5)-C(10)-C(11)-C(16)  -141.58(6) 
O(6)-C(1)-C(2)-N(1)  -148.56(4) 
O(6)-C(1)-C(2)-C(3)  -28.19(6) 
N(1)-O(4)-C(9)-C(4)  -60.15(5) 
N(1)-O(4)-C(9)-C(8)  177.21(4) 
N(1)-C(2)-C(3)-C(4)  52.05(5) 
N(1)-C(10)-C(11)-C(12)  -152.25(5) 
N(1)-C(10)-C(11)-C(16)  33.14(7) 
C(1)-O(6)-C(17)-C(18)  175.96(5) 
C(1)-C(2)-C(3)-C(4)  -69.52(6) 
C(2)-N(1)-C(10)-O(5)  -10.28(8) 
C(2)-N(1)-C(10)-C(11)  174.90(4) 
C(2)-C(3)-C(4)-O(2)  178.71(4) 
C(2)-C(3)-C(4)-C(5)  110.02(5) 
C(2)-C(3)-C(4)-C(9)  -46.69(6) 
C(3)-C(4)-C(5)-O(2)  102.16(5) 
C(3)-C(4)-C(5)-C(6)  -155.13(5) 
C(3)-C(4)-C(9)-O(4)  49.71(6) 
C(3)-C(4)-C(9)-C(8)  165.61(4) 
C(4)-O(2)-C(5)-C(6)  -114.03(5) 
C(4)-C(5)-C(6)-O(3)  118.90(5) 
C(4)-C(5)-C(6)-C(7)  -7.31(8) 
C(5)-O(2)-C(4)-C(3)  -114.02(5) 
C(5)-O(2)-C(4)-C(9)  111.34(5) 
C(5)-C(4)-C(9)-O(4)  -107.64(5) 
C(5)-C(4)-C(9)-C(8)  8.26(7) 
C(5)-C(6)-C(7)-C(8)  5.62(8) 
C(6)-C(7)-C(8)-C(9)  3.49(9) 
C(7)-C(8)-C(9)-O(4)  107.72(6) 
C(7)-C(8)-C(9)-C(4)  -10.54(8) 
C(9)-O(4)-N(1)-C(2)  71.68(5) 
C(9)-O(4)-N(1)-C(10)  -142.45(4) 
C(9)-C(4)-C(5)-O(2)  -102.33(5) 
C(9)-C(4)-C(5)-C(6)  0.39(8) 
C(10)-N(1)-C(2)-C(1)  -84.44(6) 
C(10)-N(1)-C(2)-C(3)  150.94(5) 
C(10)-C(11)-C(12)-C(13)  -176.34(5) 
C(10)-C(11)-C(16)-C(15)  175.33(5) 
C(11)-C(12)-C(13)-C(14)  0.77(9) 
C(12)-C(11)-C(16)-C(15)  0.83(8) 
C(12)-C(13)-C(14)-C(15)  0.80(10) 
C(13)-C(14)-C(15)-C(16)  -1.55(10) 
C(14)-C(15)-C(16)-C(11)  0.73(9) 
C(16)-C(11)-C(12)-C(13)  -1.59(8) 
C(17)-O(6)-C(1)-O(1)  -1.75(8) 
C(17)-O(6)-C(1)-C(2)  179.25(5) 
________________________________________________________________  
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Spectra Relevant to Chapter 2: 






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Development of the First Catalytic Asymmetric Alkylation of an Oxime and its Application to the 
Synthesis of Enantioenriched Amines 
 
 
3.1 INTRODUCTION  
Amino acids and chiral amines are of great utility in the synthetic chemistry. They find application in 
many areas including building blocks for fine synthesis, as catalysts, ligands for transition metals, or as 
chemical probes in biological systems.1–3 Prominent examples of chiral amines in catalysis are the 
cinchona alkaloids and proline; however, these enantioenriched nitrogenous compounds are isolated from 
the chiral pool. Despite their great utility, nature favors the generation of a single enantiomer of these 
compounds; therefore, if the unnatural enantiomer is required it must be derived through synthetic means.4 
Chiral amines can be generated synthetically through a variety of tactics: chiral auxiliaries bound at 
nitrogen or otherwise appended to the substrate can undergo highly diastereoselective addition of 
organometallic nucleophiles (Scheme 3.1ab). In a similar vein, the use of stoichiometric chiral 
nucleophiles can generate similarly enantioenriched products with the added advantage that auxiliary no  
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Scheme 3.1. Examples of Strategies for the asymmetric synthesis of chiral amines 
 
longer needs to be cleaved. Alternatively, chiral amines can be generated through enantioselective 
catalysis of the imine, or tautomeric enamine, through hydrogenation (Scheme 3.1c).5 An enticing 
approach to the synthesis of non-canonical amino acids and other chiral amines is an asymmetric 1,2-
addition to an imine with a chiral catalyst or nucleophile.6 In the case of metal-based catalysis, it is critical 
to prevent irreversible coordination of the metal center and concurrent catalyst poisoning due to the highly 
Lewis basic products. The variety of applications for unnatural amino acids in organic chemistry have led 
to a focus upon their synthesis commonly achieved through a multi-step Strecker synthesis.7,8  Another 
common approach for their production is alkylation of benzophenone–derived Schiff bases in conjugation 
with a chiral phase transfer catalysts or chiral glycine–derived Schiff bases.9,10 Asymmetric addition to 
imines to form enantioenriched amines has been successfully realized with several nucleophiles.11–13 
Despite this work examples of asymmetric homopropargylation of imine electrophiles has been limited.  
The first example of an asymmetric homopropargylation of an imine was achieved through copper 
catalysis with a single example XX (Scheme3.2a); N-tosyl imines were later revisited as electrophiles in 
conjunction with silver catalysis establishing improved substrate scope and enantioselectivities (Scheme 
3.2d).14,15 The use of a stoichiometric chiral moiety has been found to be effective either through the attack 
of a chiral allenyl borane on a protected imine (Scheme 3.2b);16 or the 1,2–addition of propargylic 
nucleophiles to a chiral tert-butyl sulfinyl imine (Scheme 3.2c).17–21 Alkylation of a glycine–derived 
Schiff base, as previously alluded to can provide propargyl glycine derivatives either through the 
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Scheme 3.2. Known examples of the asymmetric homopropargylation of imines 
 
Copper catalysis has been effectively engaged in the catalytic asymmetric homopropargylation of N- 
phosphinoyl imines23 as well as cyclic aldimines (Scheme 3.2ef).24 Most examples of asymmetric 
alkylation of imines demonstrate limited substrate scope with variable yields and rely on N-deprotection 
conditions that are strongly acidic or reducing. These restrictions limit their application to more sensitive 
substrates and lead to poor recovery of the desired free amine. 
Providing new catalytic systems to deliver alkynylated derivatives are of particular interest as they 
are highly derivatizable.25 Furthermore, amino acid derivatives such as propargyl glycine can be 
incorporated into proteins to later undergo click chemistry to either enrich a synthesized protein or tag it 
with a labelling reagent.26 Alkynylation has several challenges, over the related allylations and 





b) chiral nucleophile – Sonderquist, 2007
H R
NH2































PhMe:THF, –25 to 0 °C;
then diethanolamine(aq)






















































































3.2 PREVIOUS WORK IN OXIME ALKYLATION  
Oximes are an intriguing substrate for an analogous asymmetric 1,2-addition. Not only could 
chiral amines be accessed from the alkylated products through the cleavage of the weak N-O bond (~35 
kcal•mol-1)28 but an a-hydroxylamine ester product could be used directly in a-ketoacid–hydroxylamine 
(KAHA) peptide coupling, pioneered by Bode and coworkers.29  
Previous examples of 1,2-additions to oximes are limited in both the racemic and asymmetric 
sense. Addition via alkyl radical30,31, boronate allylation32,33 and organometallic addition34 have been 
observed. To date, however, a stoichiometric amount of chiral information integrated into the nucleophile 
(Scheme 3.3a) or as an auxiliary appended to the substrate (Scheme 3.3b-e) are required in synthesis of 
enantioenriched hydroxylamines through alkylation. To the best of our knowledge, there are no current 
examples of asymmetric catalysis to generate an enantioenriched hydroxylamine. This challenging 
reactivity is not unanticipated as the mixing of the oxygen lone pair with p* of the C-N double bond 
lowers the electrophilicity of the substrate. Furthermore, once the product is formed, due to the alpha 
effect, the nitrogen lone pair can form a strong interaction with Lewis acids leading to catalyst poisoning 
or decomposition.35 
Scheme 3.3. Known methods to generate enantioenriched hydroxylamines 
 
R1O2C
d) chiral auxilary – Moody, 2003





e) chiral auxilary – Kibayashi, 2004
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3.3 THE DEVELOPMENT AN ENANTIOSELECTIVE PROPARGYLATION OF AN OXIME 
The racemic propargylation of oxime ester proceed with the use of an allenyl zinc nucleophile as 
has been previously observed by in additions to N-alkyl imines (See Chaper 2.3).36 To develop the first 
example of a catalytic asymmetric addition to an oxime electrophile both Lewis acidic and 
transmetallative reaction manifolds were explored. A high–throughput screening procedure was devised 
using a phenethyl glyoxalate-derived oxime, filtration work-up, quantitative NMR to provide expedient 
analysis of enantioselectivity and yield. Initial studies using of chiral Lewis acids to activate the 
electrophile in conjunction with allenyl organometallic nucleophiles, such as stannanes and organozincs, 
can gave no appreciable enantioinduction. Transiently generating a chiral nucleophile through boronate 
ligand exchange, on the other hand, product 445a with appreciable enantioinduction albeit in trace yield 
(Table 3.1, entry 1).37 Further screens of chiral diols and additives were unable to improve reactivity but 
reflection upon the more extensively explored asymmetric addition of carbonyl-containing compounds 
suggested that copper catalysis could provide the turnover desired.24,38,39  
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Encouragingly, a screen of copper–phosphine complexes with an allenyl boronate gave moderate 
enantioduction, albeit in trace yield (Table 3.1, entry 2). An extensive ligand screening effort identified
two families of ligands with contrasting reactivity: bis-phosphines (entry 3), which gave no turnover but 
higher enantioinduction, and phosphoramidates (entry 4), which gave higher turnover but low ee. 
Postulating that greater p-acidity of phosphoramidates imparted greater reactivity, electron-poor 
bisphosphines were screened.40 Gratifyingly, both commercially available electron-poor phosphines 
Difluorphos (entry 5) and BTFM-Garphos (entry 6) generated product with elevated ee. Significantly, 
BTFM-Garphos was the first bisphosphine ligand to achieve a turnover. In contrast to conventional metal-
catalyzed, boronate-mediated alkylations a series of control experiments demonstrated that catalytic base 
was not required to activate the boronate for transmetallation to the copper center. Indeed, upon exclusion 
of catalytic base both a slight improvement to yield was observed as well as strong enantioinduction 
(Table 3.1, entry 7). 
Figure 3.1. Catalyst decomplexation after ligand-metal prestir by 31P NMR, t=0, 2h, 4h, then 4h intervals 
 
At this point, the transformation was highly enantioselective but turnover remained low and efforts 
to further improve the yield through additive and ligand screening were stymied. In an effort to gain 
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greater insight into the alkylation it was monitored by NMR. The pre–catalyst is generated by pre–stirring 
the ligand and metal source for 10 minutes prior to the addition of the oxime electrophile and the boronate. 
When monitored by 31P NMR observed rapid decomplexation of the ligand from copper with 50% 
dissociation observed after eight hours and only trace catalyst present after 24 hours (Figure 3.1). 
Correspondent to this, 1H NMR showed a small induction time followed by a period of rapid product 
formation which slowed in rate as time progressed and active catalyst decreased in concentration. To 
improve the yield and eliminate the observed induction time, an isolated pre-complexed catalyst was used 
in place of a ligand–metal pre–stir and improved yield was observed with negligible erosion of ee (Table 
3.1, entry 8). 
Figure 3.2. Monitoring oxime alkylation by 1H NMR varying boronate linker with pre-complexed catalyst 
 
Finally, attention turned to the optimization of the boronate ester. The allenyl boronate was not 
completely consumed during the reaction; however, an excess of boronate provided improved robustness. 
The bulk of the boronate ester could affect both the rate of transmetallation as well as the rate of catalyst 
poisoning by limiting coordination of the Lewis basic hydroxylamine nitrogen to the copper center. To 
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probe this hypothesis, bulkier boronate esters were employed: while the pinacol ester demonstrated 
diminished reactivity and enantioinduction (entry 9, Table 3.1); gratifyingly, the neopentyl ester not only 
dramatically improved turnover but also provided a highly enantioenriched product (entry 10, Table 3.1). 
A comparison of the allenyl dioxaboralane and dioxaborinanes showed that the neopentyl ester improves 
both the initial rate of the reaction (Pgly, Pneo, Figure 3.2) as well as limiting off-pathway decomposition 
of the starting material (Sgly, Sneo). The half-life of active catalyst also lengthened from eight hours to 
14 hours when the neopentyl ester was employed (Cneo). 
The nature of this excellent reactivity was quite sensitive to the nature of the ester on the substrate, 
while linear alkyl esters gave excellent results, even moderate perturbations to more hindered esters, 
including benzyl, gave substantially poorer yields and selectivities. Subjection of amide substrates to the 
optimized conditions similarly led to depressed reactivity. Despite these limitations, the simplicity of the 
conditions employed in the homopropargylation of oxime ester 444a lend to easy scalability; the 
alkylation of 444b was scaled up to gram scale, retaining the desired reactivity and 88% of the electron 
poor phosphine ligand was recovered cleanly. 
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Seeking to gain an understanding of the limitations of the system we found that the glyoxalate 
derived oxime 444 is a special substrate. The presence and proximity of a carbonyl in the oxime 
electrophile was critical to good reactivity. Both benzaldoxime 447 and 3-oximinopropanoate 448 (Table 
3.2) were completely unreactive to the optimized conditions. Furthermore, the addition of catalytic base 
to encourage the transfer of the allenyl fragment onto the copper center were ineffective at rescuing 
reactivity. Other glyoxalate–derived electrophiles were reactive as replacing the oxime moiety with an N-
aryl imine which reacted with good efficiency but a depressed enantioselectivity at room temperature 
(449, Table 3.2). Cooling the homopropargylation of imine 449 restored enantioselectivity comparable to 
the successful oxime electrophiles. Under the optimized conditions, substrates which lacked a Lewis basic 
moiety, such as N-aryl benzaldimine 450, showed non-trivial reactivity in contrast to less electrophilic 
benzaldoxime 447 yet with far lower enantioselectivity. To further establish the importance of further 
justified pre-coordination of the substrate was required for good reactivity. To this end we surveyed N-
boc imines as a possible alternative substrate class for propargylation as complementary method 
Hoveyda’s allenylation.41 While reactivity was restored for these substrates the enantioselectivities 
observed were not exceptional, however a solvent swap to toluene did provide a small improvement in 
that respect with little detriment to yield.  
During these studies, Cu(PPh3)2(acac) proved an effective catalyst for the racemic 
homopropargylation of these electrophiles. This achiral catalyst also reacted well when an allyl boronate 
456 was used in place of the allenyl boronate 424b to form 457 in high yield (entry 1, Scheme 3.4a). 
Unfortunately, this reactivity was not reflected when the newly developed asymmetric catalyst was used. 
Both dioxaborolane and dioxaborinane generated a low yield of the allylated product; however, in line 
with the homopropargylation, the neopentyl ester rescued reactivity to a degree albeit with negligible 
enantioselectivity (entry 3, Scheme 3.4a). This massive erosion in selectivity between the propargylation 
and allylation is likely due to differences bond angles in a transition states.  
	 260	
When a substituted allenyl boronate 458 was engaged under the optimized reaction conditions both the 
allene and propargylated products were observed in low yield, both with non-trivial enantioinduction 
(Condition B, Scheme3.4b). It is notable that the ratio of between alkyne and allene appears tied to the 
nature of the ligand. While triphenylphosphine favors formation of the alkyne 459a the electron–poor 
bisphosphine BTFM-Garphos favors formation of the allene 459b. This shift in product distribution is 
suggestive that an isomerization event generating these two products is dependent on the nature of the 
copper center.  
Scheme 3.4. Attempts to use other boronate esters in copper-catalyzed alkylations 
 
The patterns of reactivity along with combined with the NMR studies, informed a mechanistic 
hypothesis of this transformation. Initial loss of a labile nitrile ligand from the precatalyst 460 (Scheme 
3.5) would provide a site for transmetallation. NMR monitoring of the reaction suggests the formation of 
a reactive boron-ate complex, control experiments demonstrated that this was not a result of phosphine 
coordination to boron. Therefore, the Lewis basic oxime nitrogen is proposed to activate the boronate 
ester to form an activated complex 462 to facilitate transmetallation of the allenyl fragment onto the 





















b) Alkylation of an oxime with a substituted allenyl boronate














































A: 54%, –– 
B: 16%, 44% ee
A: 31%, ––
B: 27%, 54% ee
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with the allenyl isomer 465. Given the necessity of a Lewis basic moiety in close proximity the 
electrophilic carbon, it is therefore thought that exchange of the ancillary nitrile ligand with the carbonyl 
of the ester of the electrophile not only brings the allenyl fragment into close proximity with electrophilic 
carbon in a pre-organized fashion but also would inductive activates the substrate for alkylation. It is 
proposed, therefore, that the delivery of the nucleophilic fragment proceeds through a cyclic transition 
state to yield a propargylated B-N adduct that is hydrolyzed readily upon work-up. 
Scheme 3.5. Mechanistic hypothesis of the copper-catalyzed alkylation of an oxime 
              
 
3.4 ELABORATION OF ENANTIOENRICH N-SILOXY AMINO ESTERS 
While glyoxylate–derived oximes appear uniquely reactive to the conditions disclosed herein, 
enantioenriched hydroxylamines are useful intermediates for chemical synthesis. Particularly as a means 
to access enantioencriched propargyl glycine. Heterogeneous methods to cleave N-O bonds including as 
Raney-Ni, palladium or activated zinc lead to competitive alkyne reduction. Thankfully, acylation of the 
nitrogen followed by reduction with SmI2 did provide the desired protected amino ester 469 in low yield; 
however, simply exposing of 445b to pyruvic acid in wet DMSO formed the enantioenriched N-acetyl 





















































biological studies to tag proteins we were delighted to find that 470 was formed in high yield under typical 
Cu-catalyzed “click” reaction conditions. To further improves access other unnatural N-hydroxyamino 
ester we also found that 445b could undergo high-yielding Sonagashira couplings after N-acylation. 
Scheme 3.5. Elaboration of hydroxyamino esters 
 
 
3.5 CONCLUSIONS AND OUTLOOK 
In conclusion, the use of an electron–poor chiral bisphosphine resulted in the development of the 
first catalytic asymmetric alkylation of an oxime. While this reactivity was highly specialized to 
glyoxalate–derived oximes these simple conditions could also be applied to the homopropagylation of 
imines electrophiles with moderate enantioinduction. Furthermore, it is established that the propargylated 
products of the reactions can be elaborated both at the alkyne and at the nitrogen orthogonally.   
While other boronates were not amenable to the reaction conditions they demonstrated good 
reactivity when an achiral catalyst was used. This suggests that Cu-bisphosphine catalysis could be a 
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(57%,  2 steps)




















2. p-MePhI, NEt3, 
    CuI, Pd(PPh3)4
a) selective N-O cleavage via KAHA coupling
b) Elaboration of alkyne via  Cu-catalyzed “click” chemistry
b) Terminal subistitution alkyne via  Sonagashira coupling
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3.6 EXPERIMENTAL SECTION 
3.6.1 MATERIALS AND METHODS 
Unless otherwise stated, reactions were performed under a nitrogen atmosphere using 
freshly dried solvents. Tetrahydrofuran (THF), methylene chloride CH2Cl2), acetonitrile (MeCN), 
dimethylformamide (DMF), benzene (PhH), diethyl ether (Et2O) and toluene (PhMe) were dried 
by passing through activated alumina columns. Unless otherwise stated, chemicals and reagents 
were used as received. Triethylamine (Et3N) was distilled over calcium hydride prior to use. All 
reactions were monitored by thin-layer chromatography using EMD/Merck silica gel 60 F254 pre-
coated plates (0.25 mm) and were visualized by UV, p-anisaldehyde, vanillian, CAM or KMnO4 
staining. Flash column chromatography was performed either as described by Still et al.31 using 
silica gel (partical size 0.032-0.063) purchased from Silicycle. Optical rotations were measured on 
a Jasco P-2000 polarimeter using a 100 mm path-length cell at 589 nm. 1H and 13C NMR spectra 
were recorded on a Varian 400 MR (at 400 MHz and 101 MHz, respectively), or a Varian Inova 
500 (at 500 MHz and 126 MHz, respectively), and are reported relative to internal CHCl3 (1H, d = 
7.26), or DMSO (1H, d	= 2.50), and CDCl3 (13C, d = 77.0), or DMSO (13C, d =40.0). Data for 1H 
NMR spectra are reported as follows: chemical shift (d	ppm) (multiplicity, coupling constant (Hz), 
integration). Multiplicity and qualifier abbreviations are as follows: s =singlet, d = doublet, t = 
triplet, q = quartet, m = multiplet, br = broad, app = apparent. IR spectra were recorded on a Perkin 
Elmer Paragon 1000 spectrometer and are reported in frequency of absorption (cm.–1). HRMS 
were acquired using an Agilent 6200 Series TOF with an Agilent G1978A Multimode source in 
electrospray ionization (ESI), atmospheric pressure chemical ionization (APCI), or mixed (MM) 
ionization mode. Analytical chiral HPLC was performed with an Agilent 1100 Series HPLC 
utilizing Chiralpak AD or Chiralcel OD-H columns (4.6 mm x 25 S7 cm) obtained from Daicel 
	 264	
Chemical Industries, Ltd with visualization at 254 nm. 
 
3.4.2 PREPERATIVE PROCEDURES AND SPECTROSCOPIC DATA 
 
Adapted from: OL, 2011, p.4020; Org Syn. 1981, 60,41. 
To freshly activated Mg0 (6.11g, 251.3mmol, 1.01 equiv), add HgCl2 (115mg, 0.425 mmol, 
0.2 mol%) and suspend in Et2O (50 mL). Propargyl bromide(29.79g, 250 mmol, 1.0 equiv) in 
PhMe (80 wt%, 27.8mL) was further diluted with additional Et2O (170 mL). A small amount of 
the propargyl bromide solution (10 mL) was added to the suspension of Mg0. Initiation was 
achieved through gentle heating of the resulting mixture. Cool in a salt/ice bath and add the 
remaining propargyl bromide solution as a slow, steady stream. After addition is complete, stir at 
ambient temperature for 1h. Cannulate the resulting Grignard solution, over 45 minute period, into 
a solution of freshly distilled trimethyl borate (26.0g, 27.9mL, 250 mmol, 1.0 equiv) in Et2O (250 
mL) cooled to –78 °C. After completion of Grignard addition, allow mixture to warm to ambient 
temperature. Cool the suspension once more to 0 °C and cannulate 3M HCl(aq) (250 mL, 3 equiv) 
dropwise into over 3h. Stir mixture until solids disappear, approximately 1h, and a further 20 
minutes at ambient temperature. Separate the organic layer and wash the aqueous layer with Et2O 
(3×150 mL); dry the combined organics over MgSO4. Decant dried organics into a 2L round 
bottom flask and wash the remaining solids with dry Et2O (100 mL). Concentrate solution under 
reduced pressure until the 500mL remain and backfill with argon. Add anhydrous MgSO4 (250g, 
3. neopentyl glycol (1 equiv), 
    MgSO4 (8.3 equiv)
•
BneoBr
(32% yield, 3 steps)
1. Mg0 (1.01 equiv),
    HgCl2 (0.2 mol%), 0 °C
2. B(OMe)3 (1 equiv), –78 °C;
    HCl (3 equiv), 0 °C
424bSI3-1
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2.08 mol, 8.31 equiv) and neopentyl glycol (26.04g, 250 mmol, 1.0 equiv). Rinse down solids with 
Et2O (50 mL) and stir under argon with an overhead stirrer for 40h. Filter off solids using a large 
swivel frit. Take the caked solids and rinse with Et2O (4×100 mL) through a packed sand filter. 
Recombine organic and remove solvent through a vacuum transfer. Add pentanes (400mL) to the 
remaining residue and cool to 0 °C. Filter off precipitated solids with a large swivel frit and remove 
pentane through a vacuum transfer. The remaining yellow oil is purified by kugelrohr distillation 
(90 °C/ 5.0 Torr → 110 °C/1.0 Torr) to yield a clear oil (12.61g, 83.0 mmol, 32% yield) 
1H NMR (400 MHz, CDCl3) δ 4.82 (t, J = 7.0 Hz, 1H), 4.61 (d, J = 7.0 Hz, 2H), 3.66 (s, 4H), 
0.98 (s, 6H). 
13C NMR (126 MHz, CDCl3) δ 217.90, 72.47, 69.77, 31.84, 21.82. 
11B NMR (128 MHz, CDCl3) δ 26.48. 
FTIR (AT-IR) 2961.46, 2886.72, 1934.21, 1477.56, 1414.40, 1377.85, 1327.80, 1256.69, 
1224.66, 1181.98, 1129.78, 812.31, 681.34, 667.05 cm-1 
 
Flame dry freshly activated Mg0 (802mg, 33.0 mmol, 1.10 equiv) and HgCl2 (81.4 mg, 0.30 mmol, 
1.0 mol %) under argon. Cool to 0 °C and add Et2O (3 mL) and stir 5 minutes. Add 1-bromo-2-
butyne (665mg, 0.44 mL, 5.0 mmol, 0.16 equiv) dropwise maintaining an internal temperature at 
5 °C. Stir vigorously to initiate Grignard formation. Cannulate the remainder of 1-bromo-2-butyne 
(3.33 g, 2.19 mL, 25.0 mmol, 0.84 equiv) dropwise as a solution in Et2O (20 mL) into the reaction. 
Remove cooling bath after addition of bromide is complete and stir mixture at ambient temperature 
3. neopentyl glycol (1 equiv), 
    MgSO4 (0.22 equiv)
•
BneoBr
(5.3% yield, 3 steps)
1. Mg0 (1.10 equiv),
    HgCl2 (1 mol%), 0 °C
2. B(OMe)3 (1 equiv), –78 °C;





for 4h30m. Cool mixture to –78 °C and add B(OMe)3 (3.12g, 3.35 mL, 30.0 mmol, 1.00 equiv). 
Stirred solution for 1h at –78 °C then raise the temperature to 0 °C for an additional 1h. Add 2M 
HCl (30 mL, 2.0 equiv) stir for 30 minutes. Separate organic layer and extract aqueous layer three 
times with Et2O (3×20 mL). Wash combined organic layer with brine and dry over Na2SO4. 
Concentrate crude mixture to ~30 mL under argon. Add anhydrous MgSO4 (800 mg, 6.6 mol, 0.22 
equiv) and neopentyl glycol (3.13 g, 30.0 mmol, 1.0 equiv) as a solution in Et2O (20 mL). Stir 
mixture at ambient temperature for 24h. Filter off solids and concentrate in vacuo to yield crude 
product. Purify by flash chromatography (silica, 5→50% Et2O/Hexanes) to yield a XX (265mg, 
1.60 mmol, 5.3 % yield) as a clear oil.   
1H NMR (500 MHz, CDCl3) δ 4.55 (d, J = 3.2 Hz, 2H), 3.66 (d, J = 0.7 Hz, 4H), 1.67 (t, J = 3.2 
Hz, 3H), 0.97 (d, J = 0.7 Hz, 6H). 
13C NMR (126 MHz, CDCl3) δ 214.88, 72.65, 69.94, 31.87, 21.95, 15.20. 
11B NMR (128 MHz, CDCl3) δ 26.97. 
FTIR (AT-IR) 2961.08, 2888.58, 1932.18, 1476.92, 1414.06, 1377.28, 1368.34, 1339.46, 
1304.51, 1252.74, 1221.90, 1204.31, 1130.36, 812.52, 703.27, 681.75, 624.42 cm-1 
 
3.4.3. Synthesis of Electrophile Substrates	
 
Combine glyoxylic acid monohydrate (3.00g, 32.59mmol, 1.0 equiv), hydroxylamine•HCl (2.29g, 
32.92, 1.01 equiv), p-toluenesulfonic acid monohydrate(930.2mg, 4.89mmol 0.15 equiv) and 



























trap to 50 °C and ramp to 120 °C over 80 min. Reflux overnight. Cool to ambient temperature, add 
EtOAc (100 mL). Wash organics layers with NaHCO3(aq) (100mL), then NH4Cl (20 mL), then 
pH=7 buffer (20 mL) and finally brine (40mL). Dry organics over Na2SO4. Purify by flash 
chromatography (silica, 300 g, 20→40% EtOAc/Hexanes) to yield S1 (2.92g, 15.1 mmol, 46% 
yield) as a pale liquid.  
1H NMR (400 MHz, CDCl3) δ 10.88 (s, 1H), 7.55 (d, J = 1.7 Hz, 1H), 7.35 – 7.27 (m, 2H), 7.27 
– 7.17 (m, 3H), 4.45 (td, J = 7.2, 1.6 Hz, 2H), 3.06 – 2.94 (m, 2H). 
13C NMR (101 MHz, CDCl3) δ 162.44, 141.47, 137.10, 128.87, 128.59, 126.75, 66.15, 34.77. 
FTIR (AT-IR) 3322.11, 3028.17, 2359.63, 1721.19, 1622.35, 1497.30, 1453.99, 1306.73, 
1257.07, 1193.59, 1009.49, 917.54, 744.20, 697.56, 667.93 cm-1 
HRMS (TOF, ES+) calc’d for C10H11NO3 [M+H]+ 194.0812, found 194.0819(ppm=-3.76) 
 
Take up S1 (566.5 mg, 2.93 mmol, 1.0 equiv) in DMF (5 mL). Add imidazole (618.2 mg, 9.08 
mmol, 1.5 equiv) and TBSCl (663.2 mg, 4.40 mmol, 3.1 equiv) and stir at ambient temperature for 
24h. Dilute in 6:1 DI H2O:brine (26 mL) and extract with Et2O (19 mL). Wash organic layer with 
brine (3.5 mL). Dry over Na2SO4, filter, and concentrate to yield the crude product. Purify by flash 
chromatography (silica, 3→5% EtOAc/Hexanes) to yield pure 1a (795.1 mg, 2.59 mmol, 88% 
yield) 
1H NMR (400 MHz, CDCl3) δ 7.60 (d, J = 1.2 Hz, 1H), 7.33 – 7.26 (m, 2H), 7.26 – 7.19 (m, 
3H), 4.42 (td, J = 6.9, 1.3 Hz, 2H), 2.98 (t, J = 6.9 Hz, 2H), 0.97 (d, J = 1.7 Hz, 9H), 0.25 (d, J = 
1.7 Hz, 6H). 
13C NMR (101 MHz, CDCl3) δ 162.24, 145.88, 137.57, 129.05, 128.52, 126.67, 65.78, 35.01, 
25.89, 18.14, -5.28. 
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FTIR (AT-IR) 2930.10, 2857.88, 1746.89, 1724.23, 1595.23, 1471.85, 1314.23, 1252.38, 
1182.26, 1012.32, 974.59, 834.85, 784.87, 748.45, 697.31 cm-1 
HRMS (TOF, ES+) calc’d for C16H25NO3Si [M+H]+ 308.1676, found 308.1676 (ppm=0.15) 
 
 
Charge a round bottom flask with glyoxylic acid monohydrate (20.0 g, 217 mmol 1.00 equiv), 
hydroxylamine hydrochloride (15.3 g, 220 mmol, 1.01 equiv), pTSA•H2O (3.12 g, 16 mmol, 7.6 
mol%) and ethanol (260 mL). Fit with a Socklett extractor charged with activated 4Å molecular 
sieves and a reflux condenser. Heat the mixture at 120°C for 9 hours. Cool reaction to 
room temperature. Concentrate in vacuo then dilute oil in Et2O (400 mL) and NaHCO3(sat) (240 
mL). Separate organic layer and wash organics with NH4Cl(sat) (100mL) followed by pH=7 buffer 
(100 mL). Test aqueous layer for product and re-extract with Et2O(150 mL), if necessary. Wash 
combined organics with brine(100 mL). Dry over Na2SO4, filter, and concentrate in vacuo to give 
clean S2 (20.9 g, 174 mmol, 82% yield) as a pale yellow oil. Physical and spectral properties were 
consistent with literature values.42  
 
 
Combine S2 (31.18g, 266 mmol), imidazole(55.76g, 819 mmol) and TBSCl (61.80g, 410 mmol) 
in DMF (210 mL). Stir at ambient temperature for 72h. Pour mixture into 6:1 DI:brine (2.1 L). 




OHNH2OH•HCl (1.01 equiv)     pTSA (7.6 mol %),

















concentrate in vacuo to yield crude product. Purify by flash chromatography (silica, 3.5-4.5% 
Et2O/Hexanes) to provide 1b (47.8 g, 207 mmol, 78% yield) as a clear oil. 
1H NMR (400 MHz, CDCl3) δ 7.59 (d, J = 1.5 Hz, 1H), 4.27 (qd, J = 7.1, 1.4 Hz, 2H), 1.31 (td, 
J = 7.1, 1.5 Hz, 3H), 0.92 (d, J = 1.9 Hz, 9H), 0.21 (d, J = 1.7 Hz, 6H). 
13C NMR (101 MHz, CDCl3) δ 162.41, 146.20, 61.42, 25.91, 18.18, 14.22, -5.23. 
FTIR (AT-IR) 2930.90, 2858.64, 2359.72, 1748.16, 1724.8, 1596.93, 1472.39, 1370.20, 1315.32, 
1253.03, 1190.11, 1035.38, 968.41, 835.09, 785.05, 690.07, 667.95 cm-1 
HRMS (TOF, ES+) calc’d for C20H21NO3Si [M+H]+ 232.1363, found 232.1365 (ppm=-0.66) 
 
 
Combine trans-b-hydromuconic acid (1.39g, 9.92 mmol, 1.0 equiv), phenethyl alcohol (2.65g, 
2.60 mL, 21.71 mmol, 2.2 equiv) and sulfuric acid (50 µL, 92mg, 0.94 mmol, 0.10 equiv) in 
benzene (50 mL). Heat to 100 °C with a Dean–Stark trap for 16h. Cool to ambient temperature 
and dilute with Et2O and wash with NaHCO3(aq), and then brine. Dry organics over MgSO4, filter, 
and concentrate in vacuo to yield diphenethyl (E)-hex-3-enedioate with trace impurities (2.75g, 
mmol, 79% yield) as a beige solid which was used in the next reaction without any further 
purification. An analytically pure sample could be obtained by solvation of S2 in minimal CH2Cl2 
to partially remove a color impurity. Partial concentration followed by trituration with pentanes 
provides a white solid.  
1H NMR (500 MHz, CDCl3) δ 7.33 – 7.28 (m, 4H), 7.26 – 7.19 (m, 6H), 5.69 – 5.59 (m, 2H), 








H2SO4 (0.10 equiv)HO2C CO2H
(79% yield) SI3-8SI3-7
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13C NMR (126 MHz, CDCl3) δ 171.56, 137.82, 129.05, 128.62, 126.72, 126.03, 65.30, 37.99, 
35.19. 
FTIR (AT-IR)	3028.47, 1784.57, 1728.66, 1603.24, 1496.92, 1453.99, 1398.83, 1358.33, 
1154.71, 1086.89, 1030.78, 967.39, 921.34, 810.32, 749.84, 698.56 cm-1 
HRMS (TOF, ES+) calc’d for C22H24O4 [M+H]+ 353.1747, found 353.1739 (ppm=2.37) 
 
	
Sparge a solution of S2 (500mg, 1.42 mmol, 0.50 equiv) with O2 for five minutes. Cool to 
–78 °C. Sparge with O3, stirring at –78 °C for five minutes until a persisitent blue color is observed. 
Sparge with O2 for 10 minutes until the solution is colorless. Add dimethyl sulfide (1.00 mL, 0.84 
g, 13.5 mmol, 4.8 equiv) and sparge with argon for five minutes. Concentrate in vacuo to yield the 
crude aldehyde as a yellow oil (487 mg) which was immediately take up in CH2Cl2 (2 mL) before 
adding DI H2O (12 mL) followed by hydroxylamine hydrochloride (193.2mg, 2.78 mmol, 0.98 
equiv) and NaHCO3 (276 mg, 3.29, 1.15 equiv). Stir vigorously at ambient temperature 24h. 
Separate organic layer and wash aqueous with additional CH2Cl2 (5 mL). Wash combined organics 
with NaHCO3(sat) (2 mL) followed by brine (5 mL). Dry organics over Na2SO4, filter and 
concentrate in vacuo to yield crude oxime (386 mg) as a mixture of E/Z isomers. Dissolve the 
crude oxime in DMF (2.5 mL). Add imidazole (393 mg, 5.77 mmol, 2.0 equiv) and TBSCl (420 
mg, 2.79 mmol, 0.98 equiv). Stir at ambient temperature 16h. Add Et2O (40 mL) and 6:1 DI 
H2O/brine (30 mL) and separate organics. Extract aqueous layer with Et2O (5 mL). Wash combine 














     DMF
(20%, 3 steps)SI3-8 448
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siloxime (496 mg) as a mixture of E/Z isomers. Purify by flash chromatography (4-10% 
Et2O/Hexanes) to yield 1d (180 mg, 0.560 mmol, 20% yield over three steps).  
1H NMR (500 MHz, CDCl3; major isomer designated by *, minor isomer designated by §) δ 7.58 
(t, J = 6.2 Hz, 1H§), 7.35 – 7.28 (m, 2H*, 2H§), 7.25 – 7.19 (m, 3H*, 3H§), 7.14 (t, J = 4.8 Hz, 
1H*), 4.34 (td, J = 7.1, 4.1 Hz, 2H*, 2H§), 3.42 (d, J = 4.8 Hz, 2H*), 3.25 (d, J = 6.2 Hz, 2H§), 
2.96 (td, J = 7.0, 2.6 Hz, 2H*, 2H§), 0.94 (s, 9H§), 0.93 (s, 9H*), 0.18 (s, 6H*), 0.17 (s, 9H§). 
 13C NMR (126 MHz, CDCl3) δ 169.51, 169.40, 148.56, 147.84, 137.61, 137.59, 128.98, 128.67, 
126.78, 65.71, 65.62, 35.42, 35.12, 31.46, 26.14, 26.06, 18.19, -5.18, -5.20. 
FTIR (AT-IR) 677.62, 698.10, 748.18, 782.57, 834.98, 916.93, 1165.67, 1250.38, 1340.16, 
1389.87, 1471.86, 1738.81, 2856.77, 2928.98 cm-1 
HRMS (TOF, ES+) calc’d for C17H27NO3Si [M+H]+ 322.1833, found 322.1839 (ppm=1.87) 
 
 
Dissolve phenyl aldoxime43 (1.21g, 10.00 mmol, 1.00 equiv), imidazole (2.11g, 31.00 mmol, 3.10 
equiv), and TBSCl (2.26g, 15.00 mmol, 1.50 equiv) and in DMF (10 mL) . Stir at ambient 
temperature for 16h. Dilute with Et2O, wash with organics with DI H2O:brine (6:1). Dry over 
Na2SO4, filter and concentrate in vacuo to yield crude product. Purification by flash 
chromatography (silica, 0→100% Et2O/Hexanes) to yield pure 1e (438 mg, 19% yield) as a clear 
oil. Physical and spectral properties were consistent with literature values.44 
 
Note: Synthesis of 1c and known imines electrophiles (12c-f) were made by literature 














3.4.4. Copper Catalyzed Reactions and Product Characterization  
General procedure A for the racemic copper–catalyzed alkylation of oxime ester 
 
 Stir Cu(acac)2 (5.7mg, 0.216 mmol, 0.10 equiv) and PPh3 (0.12 equiv) in THF or PhMe 
(1.08 mL, 0.2 M)  for 10 minutes at ambient temperature. Add 2c (65.7 mg, 0.432mmol, 2.0 equiv) 
followed by electrophile (0.22 mmol, 1.0 equiv). Seal under N2 and continue to stir at ambient 
temperature for 24h. Dilute with EtOAc (1 mL) and diethanolamine (0.2 mL) and stir 15 minutes. 
Dilute with DI H2O and extract with EtOAc (3x2 mL). Dry organic layer over Na2SO4, filter, and 
concentrate to yield crude product. Purify crude mixture by flash chromatography.  
 
General Procedure B for the asymmetric copper–catalyzed alkylation  
 
 In a N2-filled glovebox, dilute Cu(S-BTFMGarphos)(MeCN)2BF4 (28 mg, 0.020 mmol, 
0.10 equiv) with THF –or– PhMe (0.5 mL). Add electrophile (0.20 mmol) followed by 2c (60.8 
mg, 0.40 mmol, 2.0 equiv, 2 equiv) directly to the solution. Seal solution under N2 and stir at 
ambient temperature for 16h. Dilute with EtOAc (2 mL) and diethanolamine (80 µL) and stir 15 





Cu(acac)2 (10 mol %),
PPh3 (20 mol %)





















Na2SO4, filter and concentrate in vacuo to yield crude product. 1H NMR yields with dimethyl 
terephthalate (10 mol%) as a standard. Purification by flash chromatography.  
 
Separatory Conditions and Characterization of Products 
445b: Prepared from 444a (61.5 mg, 0.200 mmol) using General 
Procedure B in THF. Yield by 1H NMR with internal standard (10 mol% 
dimethyl terephalate) Purification by flash chromatography (silica, 
2.5%Et2O/ 10%CH2Cl2/10%PhMe/Hexanes) to yield 444a (40.9 mg, 0.118 mmol, 59% yield) as 
a clear oil. The enantiomeric excess was determined to be 96% by chiral SFC analysis (AD, 2.5 
mL/min, 1% IPA in CO2, λ = 254 nm): tR(minor) = 6.148 min, tR(major) =5.116 min. 
1H NMR (400 MHz, CDCl3): δ 7.33 – 7.28 (m, 2H), 7.24 (ddt, J = 7.6, 1.2, 0.6 Hz, 4H), 4.47 – 
4.30 (m, 3H), 3.63 (t, J = 6.4 Hz, 1H), 2.98 (t, J = 7.1 Hz, 3H), 2.53 (tdd, J = 16.8, 6.4, 2.6 Hz, 
2H), 2.04 – 1.93 (m, 1H), 0.89 (d, J = 0.5 Hz, 11H), 0.11 (d, J = 3.2 Hz, 6H). 
13C NMR (101 MHz, CDCl3) δ 171.71, 137.73, 129.01, 128.64, 126.73, 79.34, 70.98, 65.68, 
63.94, 35.19, 26.28, 19.41, 18.07, -5.38, -5.43. 
FTIR (AT-IR) 3309.43, 2928.68, 2856.23, 1739.08, 1497.68, 1471.5, 1389, 1345.74, 1279.25, 
1248.5, 1178.39, 1055.21, 974.31, 900.14, 833.73, 780.66, 747.8, 698.5, 644.51 cm-1 
HRMS (TOF, ES+) calc’d for C19H29NO3Si [M+H]+ 348.1989, found 348.1998 (ppm=-2.45) 
[a]D
23 –16.3 (c = 1.0, CHCl3).  
 
445b: Prepared from 444b (1.00 g, 4.322 mmol, 1.0 equiv), 424b (295 mg, 
1.944 mmol, 2.0 equiv) and freshly prepared Cu(S-










0.432 mmol, 0.10 equiv) and S-BTFMGarphos (512.6 mg, 0.432 mmol, 0.10 equiv) in MeCN for 
10 minutes before concentrating in vacuo to a yield a white powder.  Using an appropriately scaled 
General Procedure 2 in THF (21.6 mL). Purification by flash chromatography (silica, 
2.5%Et2O/10%CH2Cl2/10%PhMe/Hexanes) provided  both product (1.01 g, 3.76 mmol, 87% 
yield) and recovered ligand (450 mg, 88% recovery) Note: Any product fractions contaminated 
with ligand were concentrated and triturated with cold pentanes, before an azeotrope with PhMe. 
The enantiomeric excess was determined after benzoylation to be 95% by chiral SFC analysis. 
1H NMR (400 MHz, CDCl3) δ 5.58 (s, 1H), 4.22 (q, J = 7.1 Hz, 2H), 3.60 (t, J = 6.4 Hz, 1H), 2.55 
(dt, J = 6.4, 3.0 Hz, 2H), 2.00 (t, J = 2.7 Hz, 1H), 1.27 (td, J = 7.1, 0.7 Hz, 3H), 0.86 (d, J = 1.0 
Hz, 9H), 0.08 (s, 6H). 
13C NMR (101 MHz, CDCl3) δ 171.77, 79.37, 70.86, 63.89, 61.25, 26.21, 19.37, 18.01, 14.34, -
5.43, -5.49. 
FTIR (AT-IR)	 3313.49, 2929.08, 2856.83, 2361.12, 2340.34, 1738.61, 1472.12, 1370.05, 
1342.99, 1248.41, 1215.41, 1186.14, 1054.34, 904.00, 834.61, 780.54, 667.96 cm–1 
HRMS (TOF, ES+) calc’d for C13H25NO3Si [M+H]+ 272.1676, found 272.1674 (ppm=0.91) 
[a]D
23 –18.0° (c = 1.0, CHCl3).  
 
SI3-9: Prepared from 449 (20.2 mg, 0.100 mmol) using a modified General 
Procedure 2 in THF at –78 °C for 36h using a 5mL Schlenk tube. Purification 
by flash chromatography (silica, 15%Et2O/10%CH2Cl2 /10%PhMe/Hexanes) to yield SI3-9 (11.3 
mg, 0.046 mmol, 46% yield) as a clear oil. The enantiomeric excess was determined to be 93% by 
chiral SFC analysis (AD-H, 2.5 mL/min, 8% IPA in CO2, λ = 254 nm): tR(minor) = 7.850 min, 




1H NMR (500 MHz, CDCl3) δ 6.82 – 6.70 (m, 2H), 6.71 – 6.56 (m, 2H), 4.28 – 4.18 (m, 2H), 4.16 
(t, J = 5.5 Hz, 1H), 3.74 (s, 3H), 2.75 (dd, J = 5.4, 2.7 Hz, 2H), 2.08 (t, J = 2.6 Hz, 1H), 1.27 (t, J 
= 7.1 Hz, 3H). 
13C NMR (126 MHz, CDCl3) δ 172.26, 153.20, 140.21, 115.85, 115.00, 78.99, 71.73, 61.64, 
56.46, 55.82, 23.07, 14.38. 
FTIR (AT-IR) 2878.46, 2359.83, 1734.61, 1512.59, 1214.47, 1035.14, 750.2, 667.76 cm-1 
HRMS (TOF, ES+) calc’d for C14H17NO3 [M+H]+ 248.1281, found 248.1280 (ppm=0.48) 
[a]D
23 +18.7° (c = 1.0, CHCl3). 
 
 SI3-10: Prepared from 450 (21.2 mg, 0.100 mmol) using General Procedure 2 in 
THF. Yield determined to be 38% by NMR (10 mol% dimethyl terephthalate). 
Physical and spectral properties were consistent with literature values.47 The enantiomeric excess 
was determined to be 56% by chiral SFC analysis (AS-H, 2.5 mL/min, 4% IPA in CO2, λ = 210 
nm): tR(minor) = 7.777 min, tR(major) = 8.391 min.  
 
SI3-11: Prepared from 450 (41.0 mg, 0.200 mmol) using General Procedure 2 in 
PhMe. Purification by flash chromatography (silica, 10%Et2O/10%CH2Cl2/ 
10%PhMe/ Hexanes) to yield SI3-11 (31.2 mg, 0.127 mmol, 64% yield) as a white solid. The 
enantiomeric excess was determined to be 85% by chiral SFC analysis (IC, 2.5 mL/min, 3% IPA 
in CO2, λ = 210 nm): tR(minor) = 8.278 min, tR(major) = 6.991 min.  
1H NMR (400 MHz, CDCl3) δ 7.39 – 7.23 (m, 5H), 5.16 (s, 1H), 5.00 – 4.50 (m, 1H), 2.85 – 2.55 






13C NMR (101 MHz, CDCl3) δ 155.18, 141.10, 128.62, 127.69, 126.44, 80.07, 79.89, 71.50, 
52.65, 28.47, 26.53. 
FTIR (AT-IR):	 3298.44, 2977.06, 1693.35, 1495.09, 1454.71, 1391.08, 1365.46, 1246.52, 
1162.62, 1078.25, 1050.37, 1017.56, 951.85, 859.79, 753.00, 698.10, 632.69 cm-1 
HRMS (TOF, ES+) calc’d for C15H19NO2 [M+H]+ 246.1489, found 246.1486 (ppm=1.04) 
[a]D
23  –33.4° (c = 1.0, CHCl3) 
 
SI3-12: Prepared from 12c (47.1 mg, 0.200 mmol) using General Procedure 2 in 
PhMe. Purification by flash chromatography (silica, 7→15%Et2O/10% 
CH2Cl2/10%PhMe/ Hexanes) to yield 13c (39.5 mg, 0.143 mmol, 72% yield) as a white solid. The 
enantiomeric excess was determined to be 73% by chiral SFC analysis (AD-H, 2.5 mL/min, 2% 
IPA in CO2, λ = 210 nm): tR(minor) = 7.440 min, tR(major) = 7.012 min.  
1H NMR (400 MHz, CDCl3) δ 7.32 – 7.20 (m, 2H), 6.94 – 6.82 (m, 2H), 5.11 (s, 1H), 4.83 (s, 
1H), 3.79 (s, 3H), 2.70 (pd, J = 14.7, 13.2, 8.6 Hz, 2H), 2.00 (t, J = 2.6 Hz, 1H), 1.43 (s, 9H). 
13C NMR (101 MHz, CDCl3) δ 159.05, 155.15, 133.27, 127.60, 113.96, 80.29, 79.80, 71.38, 
55.34, 52.15, 28.46, 26.50. 
FTIR (AT-IR) 3294.27, 2976.11, 2930.51, 1695.09, 1613.30, 1512.19, 1391.26, 1365.93, 
1296.78, 1244.83, 1163.94, 1110.88, 1033.71, 862.18, 831.44, 779.23, 640.34 cm-1 
HRMS (TOF, ES+) calc’d for C16H21NO3 [M+H]+ 276.1594, found 276.1592 (ppm=0.80) 
[a]D
23 –37.7 (c = 1.0, CHCl3).  
 
SI3-13: Prepared from 12X (54.6mg, 0.200 mmol) using General 






10%Et2O/ 10%CH2Cl2/10%PhMe/ Hexanes) to yield 13X (41.0mg mg, 0.130 mmol, 65% yield) 
as a white solid.  The enantiomeric excess was determined by chiral SFC analysis to be 71% (AD-
H, 2.5 mL/min, 2% IPA in CO2, λ = 210 nm): tR(minor) = 5.322 min, tR(major) = 6.650 min.  
1H NMR (400 MHz, CDCl3) δ 7.60 (d, J = 8.1 Hz, 2H), 7.46 (d, J = 8.1 Hz, 2H), 5.40 – 5.09 (m, 
1H), 5.08 – 4.79 (m, 1H), 2.86 – 2.53 (m, 2H), 2.04 (t, J = 2.6 Hz, 1H), 1.43 (s, 9H). 
13C NMR (101 MHz, CDCl3) δ 155.08, 145.26, 129.94 (q, J = 32.4 Hz), 126.81, 125.62 (q, J = 
3.7 Hz), 122.87, 80.32, 79.24, 72.21, 52.29, 28.45, 26.45. 
FTIR (AT-IR) 3312.68, 2979.57, 1694.52, 1620.25, 1498.22, 1422.19, 1367.11, 1323.46, 
1279.78, 1248.84, 1160.67, 1122.33, 1067.87, 1017.04, 840.57, 643.93 cm–1 
HRMS (TOF, ES+) calc’d for C16H18F3NO2 [M+H]+ 314.1362, found 314.1370 (ppm=–2.42) 
[a]D
23 –20.5° (c = 1.0, CHCl3).  
 
 SI3-14: Prepared from 12e (42.3 mg, 0.200 mmol) using General Procedure 2 
in PhMe. Purification by flash chromatography (silica, 10%Et2O/10%CH2Cl2/ 
10%PhMe/ Hexanes) to yield 13e (29.8mg mg, 0.119 mmol, 59% yield) as a white solid.  The 
enantiomeric excess was determined by chiral SFC analysis to be 76% (OD-H, 2.5 mL/min, 1% 
IPA in CO2, λ = 210 nm): tR(minor) = 11.423 min, tR(major) = 10.681 min.  
1H NMR (400 MHz, CDCl3) δ 7.33 (dd, J = 5.0, 3.0 Hz, 1H), 7.27 (dd, J = 2.8, 1.2 Hz, 1H), 7.12 
(dd, J = 5.0, 1.4 Hz, 1H), 5.11 (s, 1H), 5.03 (s, 1H), 2.78 (qdd, J = 16.8, 5.5, 2.7 Hz, 2H), 2.06 (t, 
J = 2.6 Hz, 1H), 1.49 (s, 9H). 
13C NMR (101 MHz, CDCl3) δ 155.14, 142.19, 126.42, 126.20, 121.46, 80.28, 79.94, 71.50, 




FTIR (AT-IR) 3299.32, 2977.13, 2360.00, 1694.07, 1496.67, 1391.64, 1365.96, 1328.22, 
1246.99, 1162.16, 1051.38, 1019.27, 849.62, 781.82, 636.53 cm-1 
HRMS (TOF, ES+) calc’d for C13H17NO2S [M+H]+ 252.1053, found 252.1045 (ppm=3.08) 
[a]D
23 –32.0 (c = 1.0, CHCl3).  
S3C2-3 
 
SI3-15: Prepared from 12f (39.0 mg, 0.200 mmol) using General Procedure 2 
in THF. Purification by flash chromatography (silica, 5% Et2O/10% 
CH2Cl2/10% PhMe/Hexanes) to yield 13f (28.4 mg, 60% yield) as a clear oil. The enantiomeric 
excess was determined to be 60% by chiral SFC analysis (AD-H, 2.5 mL/min, 2% IPA in CO2, λ 
= 210 nm): tR(minor) = 5.895 min, tR(major) = 6.192 min  
1H NMR (400 MHz, CDCl3) δ 7.36 (dd, J = 1.8, 0.9 Hz, 1H), 6.32 (dd, J = 3.3, 1.8 Hz, 1H), 6.27 
(dt, J = 3.3, 0.9 Hz, 1H), 5.07 (s, 1H), 4.98 (s, 1H), 2.75 (dt, J = 5.5, 1.8 Hz, 2H), 1.99 (t, J = 2.6 
Hz, 1H), 1.46 (s, 9H). 
13C NMR (101 MHz, CDCl3) δ 155.05, 153.40, 142.17, 110.36, 106.64, 80.12, 79.81, 71.14, 47.42, 
28.48, 24.44. 
FTIR (AT-IR)	 3299.51, 2977.82, 2930.12, 1698.08, 1498.78, 1456.01, 1428.43, 1391.91, 
1366.51, 1336.32, 1247.83, 1162.69, 1076.41, 1050.52, 1009.24, 941.43, 910.82, 884.51, 865.88, 
811.90, 736.07, 642.95, 597.65 cm-1 
HRMS (TOF, ES+) calc’d for C13H17NO3 [M+H]+ 236.1281, found 236.1276 (ppm=-2.20) 
[a]D
23 –22.6° (c = 1.0, CHCl3). 
 





To a solution of 444a (15.4mg, 0.20 mmol, 1.0 equiv) in THF (0.15 mL) add 2a (16.3, 0.100 mmol, 
2.0 equiv) followed by [Cu(S-BTFMGarphos)(MeCN)2]BF4 (7.1mg, 0.0050 mmol, 0.10 equiv) or 
with Cu (acac)2 (0.0050 mmol, 0.10 equiv)and PPh3 (0.20 equiv). Rinse down catalyst with 
additional THF (0.10 mL). Stir racemic alkylation for 5h, asymmetric alkylation for 12h, at 
ambient temperature.  Add diethanolamine (20 µL) as a solution in EtOAc (0.5 mL). Stir 10 
minutes at ambient temperature. Add DI H2O (1.0 mL). Extract with crude mixture with EtOAc 
four times. Dry over Na2SO4, filter and concentrate in vacuo to yield crude product. Purify by flash 
chromatography (silica, 2.5%Et2O/10%CH2Cl2/10%PhMe/Hexanes) to yield 457 as a clear oil 
(60.6 mg, 0.186 mmol, 87% yield). Enantiomers were separated by	chiral SFC analysis (AD-H, 
2.5 mL/min, 2% IPA in CO2, λ = 210 nm): tR(minor) = 2.724 min, tR(major) = 4.528 min 
1H NMR (500 MHz, CDCl3) δ 7.34 – 7.29 (m, 2H), 7.26 – 7.21 (m, 3H), 5.70 (ddt, J = 17.1, 10.1, 
7.1 Hz, 1H), 5.47 (d, J = 8.1 Hz, 1H), 5.09 – 5.00 (m, 2H), 4.38 (t, J = 7.0 Hz, 2H), 3.53 (q, J = 7.6 
Hz, 1H), 2.97 (t, J = 7.0 Hz, 2H), 2.32 – 2.22 (m, 2H), 0.90 (s, 9H), 0.10 (d, J = 4.3 Hz, 6H). 
13C NMR (126 MHz, CDCl3) δ 173.64, 137.82, 133.16, 129.02, 128.60, 126.69, 118.01, 65.61, 
65.31, 35.25, 33.97, 26.35, 18.10, -5.34, -5.39. 
FTIR (AT-IR) 2955.32. 2928.25, 2855.86, 1738.49, 1641.92, 1497.53, 1471.50, 1462.13, 
1388.74, 1344.25, 1246.95, 1181.89, 1051.22, 992.86, 917.49, 833.26, 779.87, 747.64, 698.04, 
667.31 cm-1 
HRMS (TOF, ES+) calc’d for C19H31NO3Si [M+H]+ 349.2146, found 349. 2147 (ppm=-0.29) 
 
 














Follow general Procedure A with substituted 458 on a 0.100 mmol scale. To a solution of XX 
(15.4mg, 0.050 mmol, 1.0 equiv) in THF (0.15 mL) add boronateXX (16.3, 0.100 mmol, 2.0 equiv) 
followed by [Cu(S-BTFMGarphos)(MeCN)2]BF4 (7.1mg, 0.0050 mmol, 0.10 equiv) or with Cu 
(acac)2 and PPh3. Rinse down catalyst with an additional THF (0.10 mL). Stir racemic alkylation 
5h, asymmetric 12h.  Dilute with 20 µL diethanolamine  in 0.5 mL EtOAc. Stir 10 minutes at 
ambient temperature. Add 1 mL H2O. Extract with EtOAc four times. Dry over Na2SO4, filter and 
concentrate in vacuo to yield crude product. Yields by 1H NMR with an internal standard (dimethyl 
terephthalate, 10 mol %): S-BTFM-Garphos: 16% 7a, 27% 7b; PPh3: 54% 7a, 31% 7b  
Purification by flash chromatography gave 7a and 7b as a mixture of isomers (12.2mg, 34% yield 
total). Preparatory TLC (7.5% Et2O/Hexanes) provides clean samples of 7a and 7b for 
characterization.    
459a: The enantiomeric excess was determined to be 44% by chiral 
SFC analysis (AD-H (Column 2, 2.5 mL/min, 1% IPA in CO2, λ = 
254 nm): tR(minor) = 6.780 min, tR(major) = 5.451 min. 
1H NMR (400 MHz, CDCl3) δ 7.34 – 7.28 (m, 2H), 7.25 – 7.20 (m, 3H), 5.57 (d, J = 9.7 Hz, 1H), 
4.39 (td, J = 7.1, 2.1 Hz, 2H), 3.58 (q, J = 7.8, 7.3 Hz, 1H), 2.97 (t, J = 7.1 Hz, 2H), 2.54 – 2.38 
(m, 2H), 1.74 (t, J = 2.6 Hz, 3H), 0.89 (s, 9H), 0.10 (s, 6H). 
13C NMR (101 MHz, CDCl3) δ 172.28, 137.83, 129.03, 128.65, 126.73, 78.52, 73.86, 65.54, 





























FTIR (AT-IR) 2954.61, 2926.83, 2855.19, 2359.46, 2340.28, 1739.39, 1471.67, 1455.85, 
1387.70, 1360.88, 1275.45, 1248.56, 1176.62, 1052.00, 1008.32, 936.64, 835.23, 780.98, 764.44, 
749.28, 698.52, 667.93 cm-1 
HRMS (TOF, ES+) calc’d for C20H31NO3Si [M+H]+ 362.2146, found 362.2147 (ppm=-0.28) 
[a]D
23: –3.82° (c = 0.10, CHCl3).  
459b: The enantiomeric excess was determined to be 44% by chiral 
SFC analysis (AD-H(C2), 2.5 mL/min, 1% IPA in CO2, λ = 254 nm): 
tR(minor) = 4.884 min, tR(major) = 3.733 min. 
1H NMR (400 MHz, CDCl3) δ 7.33 – 7.27 (m, 2H), 7.25 – 7.20 (m, 3H), 5.56 (d, J = 12.0 Hz, 1H), 
4.77 – 4.62 (m, 2H), 4.38 (td, J = 7.1, 3.3 Hz, 2H), 3.87 (dt, J = 11.9, 2.3 Hz, 1H), 2.97 (td, J = 7.0, 
2.0 Hz, 2H), 1.73 (td, J = 3.2, 0.4 Hz, 3H), 0.89 (s, 9H), 0.10 (d, J = 7.1 Hz, 6H). 
13C NMR (101 MHz, CDCl3) δ 206.62, 171.80, 137.88, 129.06, 128.62, 126.70, 94.32, 68.39, 
65.60, 35.27, 26.39, 18.16, 17.08, -5.32, -5.33. 
FTIR (AT-IR) 2954.34, 2927.61, 2855.65, 2359.52, 2340.26, 1957.65, 1742.48, 1497.43, 
1471.54, 1461.90, 1361.23, 1329.87, 1275.49, 1247.46, 1189.46, 1047.01, 999.42, 832.06, 780.37, 
764.60, 749.17, 698.20, 667.89 cm-1 
HRMS (TOF, ES+) calc’d for C20H31NO3Si [M+H]+ 362.2146, found 362.2146 (ppm=-0.01) 
[a]D














4. Synthesis of enantioenriched derivatives 
Formation of N-acetylpropargyl glycine by decarboxylative coupling  
 
To a solution of 3a (27.1 mg, 0.100 mmol, 1.0 equiv) in wet DMSO (1.0 mL) add oxalic acid 
(mg,  2.0 equiv) and pyruvic acid (mg, 4.0 equiv). Seal mixture under air and stir at 40 °C for 
18 hours. Cool to ambient temperature and dilute in pH=7 buffer (10 mL). Extract crude 
mixture with three times with EtOAc and twice with 10% i-PrOH/CH2Cl2. Dry organic layer 
over Na2SO4, filter and concentrate to yield crude product. Purification by flash 
chromatography (silica, 20→50% EtOAc/Hexanes) yields 9 (13.6mg, 0.741 mmol, 74% yield) 
as colorless crystals. 
1H NMR (400 MHz, CDCl3) δ 6.34 (d, J = 7.6 Hz, 1H), 4.72 (dt, J = 7.8, 4.6 Hz, 1H), 4.34 – 4.17 
(m, 2H), 2.83 – 2.71 (m, 2H), 2.06 (s, 3H), 2.02 (t, J = 2.6 Hz, 1H), 1.29 (t, J = 7.1 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 170.51, 169.97, 78.60, 71.65, 62.13, 50.73, 23.29, 22.63, 14.28. 
FTIR (AT-IR) 3309.21, 3286.98, 1727.34, 1645.05, 1544.92, 1422.68, 1369.94, 1345.49, 
1278.11, 1228.63, 1192.86, 1133.72, 1055.73, 1026.11, 943.06, 911.25, 857.89, 703.64, 655.55, 
598.75 cm-1	
HRMS (TOF, ES+) calc’d for C9H13NO3 [M+H]+ 184.0968, found 184.0966 (ppm=-1.09) 
[a]D
23 +97.5° (c = 1.0, CHCl3).  
 
Copper-catalyzed “Click” chemistry with N-siloxy amine 
EtO2C
NHAc
oxalic acid (2 equiv)









Stir CuI (38.1 mg, 0.020 mmol, 0.20 equiv) and DIPEA (0.300 mmol, 3.0 equiv) in MeCN (1.0 
mL) for five minutes. Add 1b (27.1 mg, 0.100 mmol, 1.0 equiv) followed by benzyl azide (13.8 
mg, 14.5 mL, 0.100 mmol, 1.0 equiv). Stir at ambient temperature for 2h30m. Dilute in pH=7 
buffer (3.5 mL) and extract crude mixture four times EtOAc (4×5mL) taking care to allow 
time for the emulsion to clear. Dry combined organic over Na2SO4, filter through celite and 
concentrate to yield the crude product. Purification by flash chromatography (30→40% 
EtOAc/Hexanes) provides 11 (31.8 mg, 0.078 mmol, 78% yield) as a pale-yellow oil. 
1H NMR (400 MHz, CDCl3) δ 7.37 – 7.29 (m, 3H), 7.25 – 7.18 (m, 2H), 5.57 (s, 1H), 5.45 (d, J 
= 2.9 Hz, 2H), 4.19 – 4.01 (m, 2H), 3.72 (d, J = 7.1 Hz, 1H), 3.01 (dd, J = 15.0, 6.2 Hz, 1H), 
2.88 (dd, J = 15.0, 7.8 Hz, 1H), 1.15 (t, J = 7.1 Hz, 3H), 0.80 (s, 9H), -0.06 (d, J = 6.5 Hz, 6H). 
13C NMR (101 MHz, CDCl3) δ 173.28, 144.06, 134.81, 129.21, 128.83, 128.20, 122.12, 65.26, 
61.06, 54.22, 26.21, 26.08, 18.00, 14.28, -5.41, -5.46. 
FTIR (AT-IR) 2928.52, 2855.45, 1734.08, 1461.97, 1361.75, 1335.81, 1247.76, 1216.08, 
1184.28, 1122.52, 1047.32, 939.38, 901.01, 833.97, 780.04, 721.51, 697.84, 666.92 cm-1 
HRMS (TOF, ES+) calc’d for C20H32N4O3Si [M+H]+ 405.2316, found 405.2318 (ppm=-0.39) 
[a]D
23 –12.5° (c = 1.0, CHCl3). 
 

















To a solution of 445b (534 mg, 1.97 mmol, 1.0 equiv) in MeCN (2.0 mL) add DIPEA (0.68 mL, 
508 mg, 3.93 mmol, 2 equiv) and benzoyl chloride (0.40 mL, 484mg, 3.44 mmol, 1.75 equiv) at 
ambient temperature. Heat mixture to 40 °C stirring vigorously 3h. Dilute in Et2O (25 mL) and 
wash organics with 2x with pH=7 phosphate buffer (20 mL), then brine (20 mL). Dry organic layer 
with Na2SO4. Filter and concentrate. Take up residue with in pentanes and cool solution to –20 °C 
and filter rapidly through celite. Concentrate crude material and purify on florisil (20% 
Et2O/Hexanes) to yield SI3-16 (492 mg, 1.31 mmol, 67% yield) as a colorless crystallizing oil.  
SFC analysis (IC, 5% i-PrOH in CO2) tR(major): 6.748 min; tR(minor): 8.324 min; 94% ee 
1H NMR (400 MHz, CDCl3) δ 7.76 – 7.65 (m, 2H), 7.53 – 7.35 (m, 3H), 4.65 (dd, J = 10.5, 4.5 
Hz, 1H), 4.21 (qdd, J = 10.7, 7.0, 3.6 Hz, 2H), 2.97 (ddd, J = 17.4, 10.6, 2.7 Hz, 1H), 2.89 – 2.70 
(m, 1H), 2.14 (t, J = 2.7 Hz, 1H), 1.30 (t, J = 7.1 Hz, 3H), 0.95 (s, 9H), 0.30 (s, 3H), 0.21 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ 173.13, 168.28, 134.61, 131.05, 128.59, 128.48, 80.35, 71.70, 
63.97, 62.11, 26.18, 18.58, 14.31, -4.31, -4.51. 
FTIR (AT-IR)	 3310.03, 2929.56, 2857.22, 2359.18, 1744.02, 1694.62, 1472.02, 1446.93, 
1390.26, 1362.25, 1289.85, 1250.00, 1226.16, 1186.10, 1072.43, 1017.66, 964.62, 920.36, 831.69, 
809.32, 783.13, 748.13, 703.47, 674.24, 654.39 cm–1 
HRMS (TOF, ES+)  calc’d for C20H30NO4Si [M+H]+ 376.1939, found 376.1934 
[a]D
23 –89.9° (c=1.0, CHCl3) 
 







BzCl (1.2 equiv), 







Add 4-iodotoluene (26.2 mg, 0.120 mmol, 1.20 equiv) to 3b (37.5 mg, 0.100 mmol, 1.00 equiv) 
in DMF (0.84 mL) followed by triethylamine (13 mg, 18 µL, 0.130 mmol, 1.30 equiv) and 
Pd(PPh3)4 (8.1 mg, 0.007 mmol, 0.07 equiv). Finally add CuI (2.6 mg, 0.014 mmol, 0.14 equiv). 
Seal and stir at ambient temperature 48h. Dilute with pH=7 buffer (8.5 mL) and filter off 
solids. Extract this mixture with EtOAc four times. Dry over Na2SO4, filter and concentrate 
in vacuo to yield crude 10. Purification by flash chromatography (silica, 10% 
EtOAc/Hexanes) yields 9 (39.4mg, 0.085 mmol, 85% yield) as a pale yellow oil.  
1H NMR (400 MHz, CDCl3) δ 7.77 – 7.68 (m, 2H), 7.47 – 7.40 (m, 1H), 7.39 – 7.31 (m, 4H), 7.17 
– 7.11 (m, 2H), 4.71 (dd, J = 11.0, 4.1 Hz, 1H), 4.34 – 4.11 (m, 2H), 3.19 (dd, J = 17.5, 11.1 Hz, 
1H), 2.96 (dd, J = 17.5, 4.1 Hz, 1H), 2.36 (s, 3H), 1.31 (t, J = 7.1 Hz, 3H), 0.98 (s, 8H), 0.34 (s, 
3H), 0.25 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ 173.23, 168.49, 138.33, 134.77, 131.53, 130.97, 129.29, 128.58, 
128.41, 120.32, 85.31, 83.72, 64.42, 62.05, 26.22, 21.61, 19.50, 18.88, 14.35, -4.31, -4.39. 
FTIR (AT-IR)	 2928.59, 2856.73, 1744.86, 1694.26, 1510.29, 1471.57, 1446.59, 1362.89, 
1250.43, 1183.24, 1021.70, 968.05, 919.34, 832.59, 814.99, 782.88, 749.82, 698.18, 677.26 cm-1 
HRMS (TOF, ES+) calc’d for C27H35NO4Si [M+H]+ 466.2408, found 466.2415 (ppm=-1.48) 
[a]D
23 +20.4°(c = 1.0, CHCl3).  
 
 








Me4-MePhI (1.20 equiv), 
NEt3 (1.3 equiv) 





3.6.4. SFC traces for racemic and enantioenriched products      





































































































































3.6.5. X-ray crystallographic data of desilylated hydroxylamine  (p16469_b)       
Crystal was obtained in analogy to 3b-Bz with 2-Br-benzoyl chloride. Recrystallized from 
CHCl3/Hexanes. Layer diffusion between 1:1 CHCl3/Hexanes and Hexanes yielded X-ray 
quality crystals of the desilylated hydroxylamine. 
 
Table 1. Crystal data and structure refinement for final p16469_b. 
 
Identification code  p16469_b  
Empirical formula  C14 H14 Br N O4  
Formula weight  340.17  
Temperature  100(2) K  









Crystal system  Monoclinic  
Space group  P1211  
Unit cell dimensions  a = 8.6346(7) Å α = 90°. 
 b = 5.6380(5) Å β = 103.728(3)° 
 c = 15.6510(13) Å γ  = 90° 
Volume  740.15(11) Å3  
 Z  2  
Density (calculated)  1.410 Mg/m3  
Absorption coefficient 0  2.788 mm-1  
F(000)  344  
Crystal size  0.23 × 0.15 × 0.07 mm3  
Theta range for data collection 2.428 to 45.369°  
Index ranges  -16<=h<=17, -11<=k<=11, -31<=l<=31  
Reflections collected  68030  
Independent reflections  12256 [R(int) = 0.0378]  
Completeness to theta = 25.000° 99.7 %  
Absorption correction  Semi-empirical from equivalents  
Max. and min. transmission 0.747 and 0.716  
Refinement method  Full-matrix least-squares on F2  
Data / restraints / parameters  12256/1/183  
Goodness-of-fit on F2 0.989  
Final R indices [I>2sigma(I)] R1 = 0.0241, wR2 = 0.0526  
R indices (all data) R1 = 0.0305, wR2 = 0.0541  
Extinction coefficient n/a  
Largest diff. peak and hole 0.526 and -0.838 e.Å-3  
   
 
Table 2. Atomic coordinates (×104) and equivalent isotropic displacement parameters (Å 2×103) 
for final p16469_b. U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
 
 x y z Ueq 
Br1 0.15673(2) 0.20544(3) 0.66433(2) 0.02070(3) 
O1 0.86808(9) 0.26712(16) 0.92479(6) 0.01991(14) 
O2 0.80569(9) 0.56641(15) 0.82777(6) 0.01865(13) 
O3 0.54192(7) 0.19604(14) 0.73103(4) 0.01256(9) 
O4 0.492 0.0738 0.7396 0.019 
N1 0.43360(9) 0.76829(12) 0.77810(5) 0.01514(11) 
C1 0.50418(9) 0.38290(13) 0.78093(5) 0.00968(10) 
C2 0.77148(10) 0.39468(16) 0.87841(6) 0.01261(12) 
C3 0.59223(10) 0.38553(15) 0.87231(5) 0.00991(11) 
C4 0.5623 0.5331 0.9 0.012 
C5 0.55204(9) 0.17365(15) 0.92407(5) 0.01207(13) 
C6 0.5754 0.025 0.8959 0.014 
C7 0.6205 0.1778 0.9845 0.014 
C8 0.38480(10) 0.17397(16) 0.92825(6) 0.01385(14) 
C9 0.24845(11) 0.1758(2) 0.93395(7) 0.01919(18) 
C10 0.1407 0.1773 0.9384 0.023 
C11 0.43888(10) 0.58063(14) 0.73832(5) 0.00977(11) 
C12 0.37367(10) 0.56879(15) 0.64074(5) 0.01081(11) 
C13 0.25012(11) 0.42021(17) 0.59858(6) 0.01398(13) 
C14 0.18903(13) 0.4296(2) 0.50811(7) 0.01944(17) 
 












O2–C1–C2   110.65(8) 
N1–C2–C1   110.34(7) 
N1–C2–H2 107.8 
N1–C2–C3  112.48(7) 
C1–C2–H2 107.8 





C4–C3–C2   111.95(7) 
Br1–C8 1.8892(9) 
O1–C1 1.2052(12) 
O2–C1  1.3282(11) 
O2–C13 1.4559(13) 
O3–H3   0.8400 
O3–N1 1.3953(10) 
O4–C6  1.2340(11) 
N1–C2 1.4518(11) 
N1–C6  1.3517(11) 





C3–C4  1.4610(11) 
C4–C5  1.2017(12) 
C5–H5  0.9500 
C6–C7  1.4986(11) 
C7–C8  1.3932(13) 
C7–C12  1.3987(12) 
C8–C9 1.3899(14) 
C9–H9  0.9500 
C9–C10  1.3905(15) 





C13–H13A  0.9900 
C13–H13B 0.9900 
C13–C14  1.5054(17) 
C14–H14A  0.9800 







O4–C6–N1   121.28(8) 
O4–C6–C7   120.17(8) 
N1–C6–C7   118.55(7) 
















C11–C12–C7   120.70(9) 
C11–C12–H12 119.6 
O2–C13–H13A 110.3  
O2–C13–H13B  110.3 
O2–C13–C14  107.04(9) 
H13A–C13–H13B  108.6 
C14–C13–H13A  110.3 
C14–C13–H13B  110.3 
C13–C14–H14A  109.5 
C13–C14–H14B  109.5 
C13–C14–H14C  109.5 
H14A–C14–H14B  109.5 
H14A–C14–H14C  109.5 
Symmetry transformations used to generate equivalent atoms:  
 
Table 4. Anisotropic displacement parameters (Å2) for final p16469_b. The anisotropic 
displacement factor exponent takes the form: -2p2[h2 a*2U11 + ... + 2 h k a* b*U12] 
 U11 U22 U33 U23 U13 U12 
Br1 0.01666(4) 0.02574(5) 0.01784(4) 0.00477(4) 0.00036(3) -0.01092(4) 
O1 0.0128(2) 0.0248(4) 0.0218(3) 0.0102(3) 0.0035(2) 0.0027(2) 
O2 0.0128(2) 0.0203(3) 0.0226(3) 0.0095(3) 0.0035(2) -0.0029(2) 
O3 0.0179(2) 0.0080(2) 0.0122(2) -0.0020(2) 0.00421(17) 0.0012(2) 
O4 0.0234(3) 0.0083(2) 0.0131(2) -0.00124(19) 0.0030(2) 0.0014(2) 
N1 0.0128(2) 0.0076(2) 0.0080(2) -0.00085(18) 0.00111(19) 0.00054(19) 
C1 0.0118(3) 0.0137(3) 0.0119(3) 0.0014(2) 0.0019(2) -0.0021(2) 
C2 0.0109(3) 0.0099(3) 0.0084(3) 0.0002(2) 0.0013(2) -0.0013(2) 
C3 0.0123(3) 0.0127(4) 0.0108(3) 0.0025(2) 0.0019(2) -0.0012(2) 
C4 0.0139(3) 0.0153(4) 0.0119(3) 0.0031(2) 0.0024(2) -0.0019(2) 
C5 0.0148(3) 0.0245(5) 0.0180(3) 0.0066(3) 0.0035(3) -0.0002(3) 
C6 0.0115(3) 0.0083(3) 0.0095(3) 0.0004(2) 0.0023(2) 0.0000(2) 
C7 0.0129(3) 0.0101(3) 0.0092(3) 0.0010(2) 0.0023(2) -0.0001(2) 
	 298	
C8 0.0126(3) 0.0166(3) 0.0114(3) 0.0020(3) 0.0003(2) -0.0022(3) 
C9 0.0164(4) 0.0268(5) 0.0123(3) 0.0014(3) -0.0022(3) -0.0031(3) 
C10 0.0211(4) 0.0267(5) 0.0104(3) 0.0041(3) 0.0004(3) 0.0014(3) 
C11 0.0262(4) 0.0187(5) 0.0120(3) 0.0044(3) 0.0058(3) -0.0009(3) 
C12 0.0216(3) 0.0122(4) 0.0122(3) 0.0016(2) 0.0048(2) -0.0025(3) 
C13 0.0139(4) 0.0264(5) 0.0263(5) 0.0092(4) 0.0048(3) -0.0038(3) 
C14 0.0238(5) 0.0323(6) 0.0394(7) 0.0178(5) 0.0113(5) -0.0040(4) 
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Spectra Relevant to Chapter 3: 
Development of the First Catalytic Asymmetric Alkylation of an Oxime and its Application to the 
Synthesis of Enantioenriched Amines 
 
 
 
•
B
O
O
M
eM
e
 
 
•
B
O
O
M
eM
e
 
 
•
B
O
O
M
eM
e
 
•
B
O
O
M
eM
e
M
e
 
 
•
B
O
O
M
eM
e
M
e
 
 
 
•
B
O
O
M
eM
e
M
e
  
 
N
H O
H
O
O
Ph
 
 
N
H O
H
O
O
Ph
 
H
N
TB
SO
O
O
Ph
 
 
H
N
TB
SO
O
O
Ph
 
 
C
O
2 Et
H
N
TB
SO
 
O
O
Ph
O
O
Ph
 
O
O
Ph
O
O
Ph
 
 
H
N
TB
SO
O
O
Ph
 
 
 
H
N
TB
SO
O
O
Ph
 
	
	
C
O
2 Et
H
N
O
TB
S
 
	
HN
O
TBS
O
O
Ph
 
HN
O
TBS
O
O
Ph
 
	
EtO
2 C
NHPM
P
 
	
EtO
2 C
NHPM
P
 
	
N
H
B
oc
 
N
H
B
oc
 
N
H
B
oc
M
eO
 
	
N
H
B
oc
M
eO
 
	
N
H
B
oc
F
3 C
 
N
H
B
oc
F
3 C
 
NHBoc
S
 
N
H
B
oc
S
 
	
NHBoc
O
 
NHBoc
O
 
HN
O
TBS
M
e
O
O
Ph
 
	
HN
O
TBS
M
e
O
O
Ph
 		
		
HN
O
TBS
M
e
•
O
O
Ph
 
	
HN
O
TBS
M
e
•
O
O
Ph
 
	
HN
O
TBS
O
O
Ph
 
HN
O
TBS
O
O
Ph
 
	
EtO
2 C
NHAc
 
	
EtO
2 C
NHAc
 
EtO
2 C
N
B
z
TB
SO
 
EtO
2 C
N
B
z
TB
SO
 
	
EtO
2 C
N
B
z
TB
SO
M
e
 
	
EtO
2 C
N
B
z
TB
SO
M
e
 
EtO
2 C
N
H
TB
SO
N
B
n
N
N
 
	
EtO
2 C
N
H
TB
SO
N
B
n
N
N
